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ABSTRACT 
 
Toxin–antitoxin (TA) systems are unique modules that effect plasmid stabilization via 
post-segregational killing of the bacterial host.  The genes encoding TA systems also exist on 
bacterial chromosomes, and it has been speculated that these are involved in a variety of cellular 
processes.  Interest in TA systems has increased dramatically over the past five years as the 
ubiquitous nature of TA genes on bacterial genomes has been revealed.  The exploitation of TA 
systems as an antibacterial strategy via artificial activation of the toxin has been proposed and has 
considerable potential; however, efforts in this area remain in the early stages and several major 
questions remain.  This thesis research investigated the tractability of targeting the TA systems 
RelBE and MazEF and these systems were found to be ubiquitous in clinical isolates of 
Pseudomonas aeruginosa and Staphylococcus aureus.  A high-throughput in vitro screen to 
identify small molecule disruptors of RelBE was developed using the photonic crystal biosensor 
technology.  Peptide activators of the toxin RelE were sought by screening phage-displayed 
peptide against the RelB antitoxin.  Additionally, a kinetic assay using a fluorogenic substrate 
was designed for the ribonuclease toxin MazFSa and applied in a screen for peptide enhancers of 
MazFSa enzymatic activity.  A highly sensitive radiometric gel-based assay allowed for the first 
detection of endogenous MazFSa activity in S. aureus lysate, which will enable further studies to 
identify both artificial and natural activators of the MazFSa toxin.  Further defining the prevalence 
of TA systems in clinical isolates and developing a variety of assays for assessment of MazFSa 
enzymatic activity have advanced our progress towards the goal of identifying TA system 
activators for use as an antibacterial therapy. 
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CHAPTER 1 
ARTIFICIAL ACTIVATION OF TOXIN-ANTITOXIN SYSTEMS AS AN 
ANTIBACTERIAL STRATEGY 
 
Sections from Chapter 1 have been published in “Artificial activation of toxin-antitoxin systems 
as an antibacterial strategy,” Williams JJ and Hergenrother PJ. (2012) Trends Microbiol, 20:291-
298. 
 
1.1 THE PROBLEM OF ANTIBIOTIC RESISTANCE 
The discovery of penicillin by Alexander Fleming in 1928 marked the beginning of an 
era that would see the reduction in deaths and sustained illness due to bacterial infections.  The 
“Golden Age” of antibiotics saw the discovery of various natural products and synthetic small 
molecules capable of curing once untreatable ailments.  The successful use of antibiotics was a 
breakthrough in medicine and saved many lives.  Unfortunately, application of antibiotics in the 
clinic had the adverse consequence of selecting for bacteria that evade their lethal effect, and 
introduction of each antibiotic was inevitably and eventually followed by identification of 
infections resistant to those that drug (Figure 1.1) [87, 177].  Nonetheless, the plentiful stockpile 
of new antibiotics ensured successful treatment of infections, so although the problem was 
recognized, it did not appear to pose a major threat to human health. 
Eventually the arsenal of antibiotics dwindled, no novel drugs were introduced into the 
clinic from 1970-2000 (Figure 1.1) and drug-resistant infections became increasingly common 
with limited treatment options.  The rise in antibiotic resistance continues to impede our ability to 
treat bacterial infections; the emergence of strains resistant to nearly all classes of antibiotics 
threatens a reversion to the “pre-antibiotic era” [54].  Resistance can be due to one or more of a 
variety of mechanisms, including inherent tolerance due to cell wall impenetrability, upregulation 
of efflux pumps, mutation in the cellular target, or drug modification.  Many of the new 
therapeutics are derivatives of existing drugs, thus bacterial resistance is observed sooner, 
especially if it is achieved by a general mechanism, such as efflux pumps.  Recently, novel 
classes of antibiotics have been introduced, including the oxazolidinones, lipopeptides, 
glycylcyclines and pleuromutilins, which are useful in treating some infections resistant to older 
drugs.  However, not surprisingly, bacteria have evolved resistance to these compounds as well.  
One limitation is that all antibiotics target one of five essential cell functions—DNA replication, 
transcription, translation, cell-wall biosynthesis and folic acid biosynthesis (Figure 1.1).  Thus, 
there is a need to identify novel drug scaffolds that hit new targets within the cell to keep pace 
with ever-evolving bacteria.   
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Figure 1.1  The introduction of the major classes of antibiotic into the clinic and the subsequent observed resistance.  
The “Golden Age” of antibiotics throughout 1940-1960 was followed by a 30-year gap in the discovery of a novel 
antibiotic.  Resistance to nearly every class of antibiotics has been observed in the clinic, severely limiting treatment 
options.   
 
In addition to identifying novel targets and drugs, development of narrow-spectrum 
antibiotics may result in prolonged efficacy.  Broad-spectrum drugs that kill commensal as well 
as pathogenic bacteria expand the effect of natural selection by orders of magnitude, providing a 
competitive advantage for bacteria to harbor genes that confer resistance, thereby increases the 
pool of drug-resistant genes that bacteria can trade via horizontal gene transfer [146].  
Furthermore, complications arise from prolonged use of antibiotics, such as increased 
susceptibility to chronic infections (e.g., Clostridium dificile-associated disease).  However, the 
success of narrow-spectrum drugs requires the concurrent implementation of improved diagnostic 
methods to facilitate proper prescription.   
History has proven that bacteria will develop resistance to any antibacterial compound, 
thus the concept of a “magic bullet,” as antibiotics were once perceived, is not realistic.  
However, staying one step ahead of bacterial evolution by replenishing the stockpile of antibiotics 
is a feasible goal.  With fewer large pharmaceutical companies investing in antibacterial 
discovery and development [87, 123], there is a great need for novel efforts to maintain a 
continued supply into the pipeline of antibacterial drugs and avoid increased morbidity and 
mortality associated with the looming or realized “post-antibiotic era [4, 8].”   
This document describes progress towards the development of toxin-antitoxin (TA) 
systems as an antibacterial target.  The efforts of this dissertation focused on validating TA 
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systems as a viable antibacterial target and identifying a compound that artificially activates the 
toxin TA systems for use as a therapeutic against drug-resistant infections.  Discussed in Chapter 
1 of this thesis is the biological role of TA systems, their prevalence in bacteria, our strategy for 
targeting them, other efforts in the field to target TA systems, and the precedence for the types of 
compounds we pursued, namely protein-protein interaction inhibitors and enzyme activators.  The 
inherent toxicity of TA systems makes them an attractive candidate for antibacterial development; 
however success has yet to be realized for this strategy.  One requirement for the success of this 
strategy is determining the prevalence of TA systems, and although bioinformatics studies have 
demonstrated their widespread nature across bacterial species, only a few studies have confirmed 
these data by detecting the presence of TA systems in clinical isolates.  Additionally, there are 
few examples targeting TA systems and the success of those efforts has been limited.  The 
background information discussed in Chapter 1 sets the stage for efforts towards investigating TA 
systems as an antibacterial target, including the epidemiological data on TA systems present in 
clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii, presented in Chapter 
2, work towards identifying a disruptor of the RelBE TA system in Chapter 3 and efforts towards 
the activation of the Staphylococcus aureus toxin MazFSa presented in Chapter 4. 
 
1.2 CLINICAL SIGNIFICANCE OF DRUG-RESISTANT BACTERIAL PATHOGENS 
The proportion of hospital-associated infections caused by resistant bacteria is rising [63].  
The most commonly encountered drug-resistant bacteria in the clinic have been called the 
“ESKAPE” pathogens and include Enterococcus faecium, S. aureus, Klebsiella pneumoniae, A. 
baumannii, P. aeruginosa and Enterobacter species [19, 128, 136].  These problematic pathogens 
are noteworthy because they are responsible for the majority of hospital-acquired infections and 
some strains are resistant to nearly every available antibiotic.  The work presented in this thesis 
focused primarily on S. aureus, P. aeruginosa and A. baumannii; the others will not be further 
discussed.   
 
1.2.1 Methicillin-resistant S. aureus 
S. aureus is an invasive Gram-positive bacterium that causes a range of acute and chronic 
infections, from boils and pneumonia to meningitis and septicemia [95].  Hospital-associated 
MRSA (HA-MRSA) is a major cause of nosocomial infections, and community-associated 
MRSA (CA-MRSA) has emerged as a leading cause of skin and soft tissue infections in 
otherwise healthy individuals who had no healthcare contact [23, 72].  HA-MRSA usually infects 
hospitalized elderly, immunocompromised patients who have a history of antibiotic therapy and 
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indwelling devices whereas CA-MRSA affects younger, healthy individuals [110].  Recently, 
hospital-associated outbreaks caused by the endemic CA-MRSA clone USA300, which produces 
the Panton-Valentine leukocidin virulence factor, have been reported [119].   
Methicillin resistance is conferred via acquisition of a genomic island called 
staphylococcal chromosome cassette mec.  SCCmec harbors mecA, which encodes the penicillin-
binding protein PBP2a, and due to its reduced affinity for β-lactam antibiotics allows cell wall 
synthesis to occur in the presence of methicillin [116].  Previously, vancomycin was the drug of 
choice to control MRSA infections, but now vancomycin non-susceptibility and vancomycin-
intermediate resistance is becoming increasingly common [47, 141, 153].  Fortunately, MRSA 
remains largely susceptible to newer antibiotics, such as daptomycin, linezolid, tigecycline, 
quinupristin-dalfopristin, and ceftaroline [11, 22, 68, 102, 166]; however, MRSA is notorious in 
its ability to acquire resistance to antibiotics [23] and some strains resistant to linezolid have been 
identified [56] 
 
1.2.2 Multi-drug resistant P. aeruginosa 
P. aeruginosa, a Gram-negative opportunistic pathogen, causes infections of the lungs, 
burn wounds and eyes and is a common nosocomial pathogen in the United States [49, 52].  
Acute P. aeruginosa infection occurs in immunocompromised, burned, or neutropenic patients or 
those undergoing mechanical respiration [99].  Chronic P. aeruginosa infection of the lung occurs 
in 80% of cystic fibrosis patients and is the leading cause of death associated with CF, despite 
intensive antibiotic treatment [40, 51].   
P. aeruginosa utilizes a variety of mechanism to evade antibacterials.  The 
impenetrability of many antibiotics due to the largely impassable Gram-negative cell membrane 
contributes to the difficulty in treatment [7, 154].  Additionally, the formation of hardy biofilms 
confers resistance to many antibiotics, including pencillins, carbapenems and aminoglycosides 
[39, 51, 107].  Intrinsic mechanisms impart resistance to β-lactam antibiotics [5].  P. aeruginosa 
can also acquire laterally-transferred resistance determinants; however, its ability to develop 
resistance during the course of treatment is most troubling.  This is achieved primarily by the 
production of cephalosporinase AmpC, the outer membrane porin OmpD and multidrug efflux 
pumps [92].  P. aeruginosa infections are somtimes treated with potentially synergistic 
combinations of antibiotics including fluoroquinolones, aminoglycosides and β-lactams, as well 
as colistin, sometimes supplemented with rifampicin [92, 115, 160]. 
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1.2.3 Multi-drug resistant A. baumannii 
A. baumannii, another Gram-negative opportunistic pathogen, primarily causes infections 
in patients in intensive care units [1, 71, 127].  Hospital- and community-acquired A. baumannii 
infections result in bacteremia, ventilator-associated pneumonia, surgical-site infections, urinary 
tract infections and skin and soft-tissue infections [64, 65, 104].  Wound infections are typically 
contracted by soldiers in Iraq and Afghanistan [149, 165].   
Pan-resistant strains refractory to all antimicrobial agents have been identified and 
resistance genes are typically clustered into large “resistance islands” [1, 46, 172].  Resistance is 
achieved by intrinsic mechanisms or by acquisition of mobile genetic elements carrying 
resistance determinants, including efflux pumps, porins, extended-spectrum β-lactamases, and 
other drug-inactivating enzymes [46, 71, 127].  Similar to P. aeruginosa, chromosomally-
encoded cephalosporinase AmpC and multidrug efflux pumps play a major role in resistance 
[112].  Carbapenems are the drug of choice for treating A. baumannii infections and tigecycline, 
aminoglycosides, polymyxins, sulbactam, and piperacillin/tazobactam and are also typically 
effective [104, 112] 
 
1.3 TOXIN-ANTITOXIN SYSTEMS 
Toxin-antitoxin (TA) systems are unique genetic modules that effect plasmid stabilization 
via post-segregational killing of the bacterial host.  The genes encoding TA systems also exist on 
bacterial chromosomes, where they are speculated to be involved in a variety of cellular 
processes.  Interest in TA systems has increased dramatically over the past five years as the 
ubiquitous nature of TA genes on bacterial genomes has been revealed.  The exploitation of TA 
systems as an antibacterial strategy via artificial activation of the toxin has been proposed and has 
considerable potential; however, efforts in this area remain in the early stages, and several major 
questions remain.  The following section will investigate the tractability of targeting TA systems 
to kill bacteria, including fundamental requirements for success, recent advances, and challenges 
associated with artificial toxin activation. 
 
1.3.1 Role of proteic TA systems on plasmids 
Type II toxin-antitoxin (TA) systems consist of an antitoxin protein that binds to and 
inactivates a toxin protein.  In relative terms, the toxin is considerably more stable (i.e., longer 
cellular half-life) than the antitoxin, as the less ordered structure of the antitoxin makes it more 
susceptible to proteolytic degradation.  The TA functionality capitalizes on this differential 
stability between the two proteins (Figure 1.2).  TA systems were discovered in 1983 to confer 
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plasmid stabilization via toxin-induced post-segregational killing (PSK) [117].  If the plasmid 
encoding the TA system is not inherited by a daughter cell, the antitoxin is degraded by cellular 
proteases and not replenished, liberating the latent toxin to kill the cell and thereby diminishing 
the population of plasmid-free cells [25, 50, 164].  Many such “addiction” modules stabilize 
plasmids that carry drug-resistance determinants in important pathogens, notably the axe-txe and 
ε-ζ TA systems commonly found on vanA plasmids in vancomycin-resistant enterococci (VRE) 
[105, 138].  
 
Figure 1.2  The role of toxin-antitoxin (TA) systems.  Plasmid-encoded TA systems (left panel) stabilize plasmids via a 
post-segregational killing mechanism.  The co-expressed antitoxin (A) binds to and inhibits the toxin (T), preventing its 
toxic effect on the cell.  Plasmid loss is concomitant with antitoxin degradation, releasing the toxin to kill the cell, 
removing plasmid-free cells from the population.  Chromosomally-encoded TA systems (right panel) have been 
implicated in a number of functions.  In one model, cell stress modulates the expression at the promoter as well as 
upregulating the activity of proteases.  The result is increased antitoxin degradation, freeing the toxin to inhibit growth 
or kill the cell.  
 
TA systems are found on both plasmids and chromosomes.  The role of plasmid-encoded 
TA systems is clear: they function as post-segregational killing systems (PSK) (Figure 1.2) [50, 
66, 117].  Proteic TA systems produce a stable toxic protein and a labile antitoxin protein and are 
used by plasmids to ensure that only those daughter cells that inherit the plasmid survive after cell 
division.  When both proteins are present, the antitoxin binds to the toxin, inhibiting its toxic 
activity.  However, if a plasmid-free daughter cell arises, the labile antitoxin is quickly degraded 
(and not replenished), freeing the toxin to induce cell death.  Because of this indelible link 
between plasmid maintenance and bacterial life, TA systems have been termed ‘plasmid 
addiction systems’ [83].   
 
1.3.2 Proposed role of TA systems on bacterial chromosomes 
 Although the role of plasmid-encoded TA systems is clear, there is no such consensus for 
chromosomal TA genes, and in fact there are at least ten proposed biological roles for such 
systems [78, 96, 169].  Once regarded as superfluous genetic material with ambiguous benefit to 
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the bacterial cell [163], chromosomal TA systems have recently been proposed to be involved in 
numerous cellular pathways including starvation-induced cell stasis [32, 125], stress response [41, 
61], genetic stabilization [181, 183], programmed cell death [111, 144], biofilm formation [75, 
175], quorum sensing [78], antiphage protection [45, 60], virulence [20], persistence [76, 97], and 
gene regulation [6].  
A straightforward model to understand chromosomally-encoded TA systems is based on 
data from several studies that indicate that these systems function to halt bacterial growth during 
times of stress (Figure 1.2) [32, 125].  For example, the relBE TA system modulates the stringent 
response induced by amino acid starvation [30, 32].  In this scenario, amino acid starvation 
triggers transcription of relBE as well as increased activity of Lon protease, which degrades the 
antitoxin RelB, freeing RelE [31, 89, 121].  RelE inhibits translation by cleaving mRNA in the 
ribosomal A site, resulting in a stalled ribosome [126].  Similarly, the mazEF TA system has been 
described as a suicide module that causes programmed cell death (PCD) in response to extreme 
amino acid starvation.  In this scenario, relA synthesizes the stringent response molecule 
guanosine 3’,5’-bispyrophosphate (ppGpp), inhibiting mazEF transcription, activating MazF, and 
ultimately leading to cell death [3, 33, 44].  Ultimately, the cell response to stress modulates 
transcription at the TA promoter which skews the ratio of toxin to antitoxin towards free toxin, 
which exerts its toxic effect and inhibits cell growth. 
 
1.3.3 Overview of classes of TA systems 
There are three known types of TA systems; this thesis work focuses exclusively on the 
Type II proteic modules.  The 10 toxin families within the Type II proteic systems are depicted in 
Figure 1.3, categorized by general toxin mode of action [59, 108, 169].  The toxins of the CcdAB 
[9, 14, 36] and ParDE [67] families inhibit DNA replication by locking gyrase and DNA in an 
inactive complex (Figure 1.3A).  The ζ toxin from the ω-ε-ζ TA system is the only known toxin 
to inhibit cell wall biosynthesis by blocking peptidoglycan synthesis [109] (Figure 1.3B).  The 
ribosome-independent ribonucleases MazF [185, 186] and HicA [69, 98] cleave free mRNA 
(Figure 1.3C).  There are two classes of ribosome-dependent toxins.  The RelE [29, 126] and 
HigB [21, 28] family of toxins cleave mRNA in a ribosome-dependent manner and thereby 
inhibit translation (Figure 1.3D).  The remaining toxins HipA [35, 80, 148], Doc [48, 93] and 
VapC [38, 180] inhibit translation by phosphorylating the elongation factor Ef-Tu, binding the 
30S ribosome and cleaving tRNAfMet, respectively (Figure 1.3E). 
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Figure 1.3  The 10 major classes of toxins, grouped by mode of action.  (A) The CcdB and ParE family toxins inhibit 
replication by locking DNA gyrase in an inactive complex on the DNA.  (B) The ζ toxin phospohorylates UDP-Glc-
Nac (uridine diphosphate-N-acetylglucosamine) resulting in inhibition of peptidoglycan biosynthesis.  (C) The MazF 
and HicA toxin families comprise the ribosome-independent ribonucleases that cleave free mRNA.  (D) RelE and HigB 
famillies cleave mRNA in a ribosome-dependent manner.  (E) The last group is characterized by ribosome inhibition 
mediated by a mechanism other than mRNA cleavage. HipA phosphorylates the elongation factor Ef-Tu, Doc binds the 
30S ribosomal subunit and VapC cleaves tRNAfmet. 
 
1.3.4 Regulation of TA systems 
The toxin and antitoxin are encoded in an operon and are co-transcribed in a polycistronic 
message, ensuring that toxin is produced only in the context of the antitoxin (Figure 1.4A).  
Transcriptional regulation is accomplished by the ability of the antitoxin to bind upstream 
operator sequences and inhibit transcription (Figure 1.4B).  Furthermore, the TA complex binds 
the operator with higher affinity and suppresses transcription to greater levels, enabling the cell to 
sense the level of toxin and fine-tune transcription to maintain manageable levels in the cell 
(Figure 1.4B).  Additionally, in many TA operons, the start codon of the toxin overlaps with the 
stop codon of the antitoxin (Figure 1.4A), achieving translational regulation that ensures higher 
levels of antitoxin compared to toxin.  Indeed, a quantitative Western blot showed that the RelB 
antitoxin exists in a 10-fold excess over the toxin RelE is actively growing cells (Figure 1.4C) 
[120].  The higher level of antitoxin is required however, to account for the constant turnover of 
the antitoxin in the TA complex due its increased susceptibility to proteolysis.  The half-life of 
the antitoxin alone is approximately 15-50 minutes [3, 24, 32, 42] (Figure 1.4D); however when 
bound to the toxin, the half-life increases by approximately 50% [26, 114, 170].  The toxin alone 
is stable on the order of hours and its stability is not affected the presence of the antitoxin [3, 32, 
42, 170]. 
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Figure 1.4  Regulation of TA systems.  (A) Co-transcription ensures production of the toxin only in the context of the 
antitoxin.  (B) Transcription is autoregulated by the antitoxin and to a further extent by the TA complex.  (C) 
translational coupling achieved by a single Shine-Dalgarno sequence and overlapping start and stop codons ensures 
excess of antitoxin over toxin to maintain inhibition of the toxin.  (D) The inherent instability of the antitoxin increases 
its susceptibility to proteases, resulting in turnover within the complex.  (E) Extensive electrostatic and hydrophobic 
interactions impart a low nanomolar affinity between the toxin and antitoxin.  
 
In addition to transcriptional and translational regulation, the toxin activity is harnessed 
by binding with high affinity to the antitoxin (Figure 1.4E).  The affinity of the TA complex has 
been measured by SPR and NMR experiments to be on the order of 0.1-10 nM [70, 90, 120] and 
separation of the toxin and antitoxin requires proteolytic degradation of the antitoxin or harsh 
denaturing conditions in vitro.  Although in vitro the two proteins exist as a stable complex with 
no apparent “off-rate,” in the cell, the proteolytic susceptibility of the antitoxin is central to the 
function of the TA systems.  The activity of the toxin is unleashed in conditions under which the 
antitoxin is degraded and not replenished, such as plasmid loss or environmental stress (Figure 
1.2).   
 
1.4 TA SYSTEMS AS AN ANTIBACTERIAL TARGET 
Inspired by their lethal effect in the plasmid-directed post-segregational killing 
mechanism, we set out to exploit the inherent toxicity of TA systems as a therapeutic strategy.  
TA genes have no human homologs and appear to be present in the most important bacterial 
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pathogens (as described below); thus, toxin proteins could serve as ideal targets for novel 
antibacterial drugs via one of the mechanisms depicted in Figure 1.5 and described below. 
 
1.4.1 Strategies for toxin activation 
Activation of the toxin could be achieved by either an indirect means of freeing the toxin 
from the antitoxin or directly interacting with the TA proteins.  The goal of indirect approach is 
expedited proteolytic degradation of the antitoxin (Figure 1.5).  A molecule that binds promoter 
DNA and inhibits transcription at the TA locus would prevent replenishment of the antitoxin; 
there is considerable precedent for such sequence-specific DNA binders [135].  Degradation of 
the existing antitoxin by Lon or Clp proteases would release the toxin, allowing it to kill the cell.  
It has also been suggested that toxin activation in response to cellular stress requires increased 
expression or activity of Lon or Clp, responsible for degrading the antitoxins [32].  Thus, 
activation of Lon or Clp could serve as an indirect mechanism for toxin activation within the cell, 
and there is recent precedent for the identification of such compounds in other systems [85, 143].  
Although this strategy may be generally toxic to the cell, there is evidence that Lon 
overproduction specifically activated the toxin YoeB from its complex with the YefM antitoxin, 
resulting in mRNA cleavage and cell lethality [31]. 
 Although the indirect approaches have promise, this thesis work focused on methods to 
directly activate the toxin.  In the most straightforward approach, a drug would directly target the 
TA system proteins and relieve antitoxin inhibition of the toxin.  This could be achieved by 
disruption of the TA complex or prevention of complex formation, as shown in Figure 1.5.  
Complete disruption may be required for activation of a toxin such as the ribosome-dependent 
ribonuclease RelE, as the RelB-RelE complex is likely too large to access the ribosomal A-site 
[158].  In contrast, activation of a toxin such as MazF, which cleaves free mRNA, may not 
require full disruption of the complex and instead may be achieved by vacating MazE from the 
MazF active site or by allosteric activation of MazF in complex with MazE.  Thus, direct toxin 
activation may be accomplished by targeting the complex, the antitoxin, or the toxin. 
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Figure 1.5  Introduction of a hypothetical toxin activator (orange fused ring) can activate the TA complex in either a 
direct or indirect manner. Direct activation (left) can be achieved by either disruption of the TA complex (top) or 
prevention of complex formation (bottom). Indirect activation (right) may occur either by modulating the expression of 
the TA complex at the promoter (top) or by activating cellular proteases (bottom) responsible for antitoxin degradation. 
Figure taken from [179].   
 
1.4.2 Which protein should be targeted? 
When designing experiments to identify a direct toxin activator, one must decide which 
protein to target:  the complex, the antitoxin or the toxin (Figure 1.6).  There are advantages and 
disadvantages to each approach.  Identification of a compound that activates the toxin by directly 
disrupting the interaction between the toxin and antitoxin would be the ultimate triumph, as the 
complex constitutes the most physiologically relevant form.  The limitation of this approach is 
overcoming the incredibly high affinity complex formed between the toxin and antitoxin.  As 
mentioned previously, the TA interaction is on the order of sub- to low double digit nanomolar 
affinity and has no apparent “off-rate” in vitro.  It is likely that the static nature of the in vitro 
complex does not accurately reflect the situation in the cell, where proteases are involved in 
constant turnover of the antitoxin in the complex.  However, faithfully recapitulating the 
conditions in the cell to take advantage of the turnover of the antitoxin in vitro presents its own 
challenges. 
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Binding the antitoxin to compete it away from the toxin and thus prevent complex 
formation is an intuitive strategy for toxin activation.  The major advantage of a molecule that 
targets the antitoxin is to remove its inhibition on the toxin.  Additionally, a compound that 
Figure 1.6  A molecule could achieve artificial toxin activation by one of three methods:  disruption of the TA complex 
(middle), binding the antitoxin (left) or binding the toxin (right).  Each strategy results in activation of the toxin, 
allowing it to bind its cellular target and kill the cell.  Figure adapted from [179].   
 
 
targets the antitoxin may interfere with the antitoxin binding to the operator DNA, alleviating the 
transcriptional repression and resulting in higher amounts of toxin available to mediate cell 
killing.  Of course, the levels of the antitoxin would increase as well, which highlights the major 
disadvantage of targeting the antitoxin:  the antitoxin exists in abundance over the toxin, so high 
concentrations of compound may be required for full effect.  One experimental limitation with 
targeting the antitoxin is its inherently unstructured nature, which makes it less suitable for in 
vitro binding assays. 
A compound that binds the toxin could act by either preventing the binding of the 
antitoxin to the toxin or by enhancing the enzymatic activity of the toxin, or both.  One potential 
limitation of this strategy is that since the antitoxin usually inhibits the toxin by occupying its 
active site, a molecule that competes for binding with the antitoxin may also inhibit the toxin.  
However, there are many points of contact between the toxin and antitoxin so it is possible that 
preventing any of these contacts would effectively preclude antitoxin inhibition of the toxin.  A 
compound that enhances the enzymatic activity may or may not modulate the interaction between 
the toxin and the antitoxin, but rather amplify the potency of the toxin by increasing its catalytic 
efficiency.  Although this strategy could potentially be applied to any enzymatic toxin, the 
feasibility of in vitro assays currently limits it to the ribosome-independent ribonucleases.  One 
physiologically relevant limitation of this strategy with ribosome-dependent ribonucleases is the 
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potential allosteric change or increase in size that might prevent the toxin from binding the 
ribosome due to steric hindrance. 
Each of these strategies was employed throughout efforts towards identifying TA systems 
activators described herein.  Disruption of the RelBE TA system by targeting either the complex 
or the antitoxin, as discussed in Chapter 3, were tenable strategies as RelE is a ribosome-
dependent ribonuclease that may require complete disruption from RelB to gain access to the 
ribosome.  Furthermore, analysis of RelE activity requires actively translating ribosomes, which 
is not amenable for high throughput experiments.  After discovering that the antitoxin is a poor 
target for in vitro studies, the focus switched to the MazEF TA system.  The advantage of 
working with the ribosome-independent ribonuclease MazF toxin was that its robust in vitro 
activity enabled a meaningful assessment of the compound’s effect on the toxin activity, as 
presented in Chapter 4 and Appendix 2.   
 
1.4.3 Which TA systems should be targeted? 
Although the strategies described above are mechanistically distinct, their common goal 
is to artificially activate the toxin from the inert TA complex to kill the bacterial cell.  There are 
two main requirements for successful application of this target-based strategy; the first is an 
understanding of which TA pairs would serve as ideal targets of an artificial activator.  Once that 
is achieved, the search for molecules that activate the toxin and lead to toxin-mediated cell death 
can commence.  Considerations for an ideal target include prevalence, toxicity, and potential for 
resistance. 
 
1.4.3.1 Bioinformatics studies reveal widespread nature of TA systems 
 Recent genome sequencing and bioinformatic studies have revealed a plethora of TA 
systems across bacterial species.  In 2005, Pandey and Gerdes performed an exhaustive search of 
126 sequenced prokaryotic genomes and reported that genes predicted to encode TA systems are 
highly abundant in free-living bacteria but are absent from the genomes of host-associated 
bacteria [122].  Shao and co-workers expanded on existing datasets to identify 10,753 putative 
TA pairs in 1240 sequenced genomes representing 962 bacterial and archaeal strains [152].  More 
recently, Leplae and co-workers revealed 7034 toxins and 10,829 antitoxins in a search for Type 
II TA systems in 2181 prokaryotic genomes [57, 84].  From this work novel toxins and antitoxins 
were discovered, some of which were experimentally validated using a host killing and rescue 
assay in E. coli [84].  In addition to discovering a multitude of TA systems and advancing our 
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understanding of the evolutionary relationships between them, these bioinformatics studies serve 
as a starting point for more detailed analyses of TA systems within their respective hosts. 
Genes for TA systems have been identified in nearly all bacterial pathogens, contributing 
to their attractiveness as potential antibacterial targets, but which ones will make the best targets?  
Since many TA systems exist on plasmids or are closely linked with mobile genetic elements, 
their presence within a given bacterial species is likely to be heterogeneous.  Thus, studying TA 
systems within actual clinical isolates is a necessary and complementary approach to 
bioinformatics studies. The crucial steps in investigating the tractability of TA systems as 
antibacterial targets are to determine (i) if TA systems are present in drug-resistant bacterial 
pathogens, (ii) which TA system are most prevalent, and (iii) whether the TA systems are 
functional. 
 
1.4.3.2 Epidemiology in enterococci 
In 2007, an examination of TA genes within total genomic DNA from clinical isolates of 
VRE was reported.  Using a PCR-based screen with gene-specific primers for individual TA 
systems, certain TA genes were found to be widespread across the collection of 75 VRE isolates, 
namely mazEF (100%), axe-txe (75%), relBE (47%), and ω-ε-ζ (44%) [105] (Table 1.1).  Many 
of these TA systems were present on plasmids carrying the vanA gene cassette.  Reverse 
transcription PCR (RT-PCR) analysis showed that the ubiquitous TA system, mazEF, was 
transcribed in VRE.  Furthermore, the mazEF genes, cloned with their native promoter from a 
VRE isolate, stabilized the unstable enterococcal plasmid pAM401, demonstrating the 
functionality of this TA system [105].  This epidemiological survey was the first to define which 
TA systems are most prevalent in clinical isolates of pathogenic bacteria, suggesting these as a 
viable target for exploitation.  Further examination of six axe-txe-positive VRE strains from this 
study revealed that axe-txe was transcribed in all cases, and physical linkage to the VanA 
resistance determinant was confirmed by DNA sequencing [58].  Another survey of plasmid 
DNA isolated from a collection of 93 geographically and epidemiologically diverse Enterococcus 
faecium strains revealed that 42 (45%) and 18 (19%) harbor genes for axe-txe and ω-ε-ζ, 
respectively [138] (Table 1.1).  A smaller study of VRE strains carrying VanB-type vancomycin 
resistance genes, each from different pulse-field gel electrophoresis (PFGE) types, showed that 
axe-txe was physically linked to the plasmid encoding vanB in eight of nine strains [15].   
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Table 1.1  Prevalence of TA systems determined by PCR screen and BLASTN homology search  
Epidemiological Data Bioinformatics Data 
TA system Organism Location PCR resultsa Referenceb 
presence on published sequence 
from specific organism (blastn)c 
mazEF enterococci plasmid 75/75 [105] 0 genomes 
axe-txe enterococci plasmid 56/75 [105] 6 plasmids 
  E. faecium plasmid 42/75 [138]   
relBE enterococci plasmid 35/75 [105] 0 genomes 
ω-ε-ζ enterococci plasmid 33/75 [105] 7 plasmids w/ ≥90% identity 
  E. faecium plasmid 18/93 [138] 
mazEFSa  S. aureus chromosome 78/78 [178] 44 chromosomes 
parDEPa  P. aeruginosa chromosome 13/42 [178] 2 chromosomes 
relBEPa  P. aeruginosa chromosome 42/42 [178] 9 chromosomes 
higBAPa  P. aeruginosa chromosome 42/42 [178] 9 chromosomes 
relBESpn  S. pneumoniae chromosome 70/70 [113] 30 chromosomes [113] 
aPCR using gene-specific primers to screen for presence of TA systems in collections of pathogenic bacteria 
bReference refers to manuscript in which PCR result was published 
cNumber of hits in blastn search and location (plasmid or chromosome) of TA genes.  Blast searches were performed as 
part of this study unless otherwise indicated. 
 
1.4.3.3 Further defining prevalence and functionality in clinically significant bacteria 
Additionally, the prevalence of TA systems was studied in methicillin-resistant 
Staphylococcus aureus (MRSA) and P. aeruginosa.  This survey demonstrated the ubiquity of 
mazEFSa in 78 MRSA clinical isolates, and higBAPa and relBEPa in 42 P. aeruginosa clinical 
isolates [178] (Table 1.1).  It was also shown that these TA systems are transcribed by their 
respective hosts, suggesting that they are functional units.  Importantly, the PCR-based screen 
revealed that the parDEPa TA system was present in only 30% of the clinical isolates.  Inspection 
of the three sequenced genomes of P. aeruginosa clinical isolates shows that parDEPa is present 
in PAO1 and PA7, but not PA14.  Furthermore, genotyping of P. aeruginosa isolates using multi-
locus variable number tandem repeat analysis (MLVA) revealed that the presence of parDEpa did 
not correlate with genome relatedness.  Thus, the inconsistent presence of parDEPa suggests that 
activation of ParDEPa would not be a good candidate for a TA-based therapeutic strategy versus 
P. aeruginosa.  Some of these results, along with a survey of A. baumannii, are presented in more 
detail in Chapter 2 of this thesis.  A similar study revealed the conservation of relBE2Spn in 70 
clinical isolates and 30 sequenced strains of Streptococcus pneumoniae [113] (Table 1.1). 
A combination of factors will determine whether a given TA system is a good 
antibacterial target.  Prevalence and functionality within clinical isolates are absolutely required.  
The aforementioned epidemiological studies showed that the genes for TA systems were present 
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and transcribed; however, Western blot analysis using antibodies raised to the specific TA 
systems would lend further support for these protein targets.  While more data must be collected, 
based on prevalence, functionality, and mode-of-action, MazEF, RelBE, and HigBA appear to be 
reasonable targets for artificial toxin activation that could lead to bacterial cell death [105, 178].  
Additional points to consider revolve around the activity of the toxin itself and will be discussed 
below.   
 
1.4.3.4 Toxin mode of action/Potential for resistance 
The toxin mode of action could influence both the toxicity of the toxin and the propensity 
for resistance to toxin-activating molecules to arise, leading to reduced efficacy of the strategy.  
For example, resistance to the toxin CcdB is conferred by a single point mutation within its target, 
DNA gyrase [13], suggesting limitations with CcdB activation strategy.  However, it is more 
difficult to envision how resistance would arise to a toxin like MazF, which cleaves single-
stranded mRNA [186].  Mutational inactivation of the toxin could occur, but presumably the cell 
would incur a fitness cost associated with such a mutation.   
 
1.4.3.5 TA system involvement in persistence 
Persister cells are defined as a small fraction of a bacterial population that tolerate 
antibiotics not by mutation or acquisition of resistance determinants but by entering a state of 
dormancy [86].  Further culturing of these dormant cells restores normal growth, and subsequent 
application of antibiotic selects for a new sub-population of persister cells [74].  One model 
proposes that persisters arise when a small fraction of cells in a mid-exponential phase experience 
stochastic changes in gene expression, producing individual dormant cells that are recalcitrant to 
subsequent antibiotic treatment [10, 150].  This phenotypic switch has been shown to be induced 
by activation of chromosomally-encoded toxin genes [97].  Additionally, upregulation of the 
transcripts for TA genes have been observed in persister cells [150], and the occurrence of 
persister cells progressively diminished with successive deletion of the ten ribonuclease-encoding 
toxin genes in E. coli [97].  A separate model proposes that the SOS response induces persister 
cell formation via the Type I TA system tisAB/istR.  Treatment with fluoroquinolones induces the 
SOS response, causing transcription of the LexA-controlled tisB, which encodes a membrane 
acting toxin [43].  TisB decreases the proton motive force, which leads to decreased ATP levels 
and a state of dormancy [167].  Although additional work is required to describe the exact 
mechanism of persister cell formation and resuscitation, it will be important to determine whether 
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artificial toxin activators induce persister cell formation as this may contribute to chronic 
infections [86].   
 
1.4.4 Previous work toward discovering toxin activators 
The exploitation of TA systems as an antibacterial strategy has been proposed by many 
groups as a viable tactic, however success remains elusive.  There have been efforts towards 
identification of peptides that modulate the activity of TA systems; these peptides have been 
shown to enhance the toxin enzymatic activity, preclude the inhibition of the toxin by the 
antitoxin, reduce the degree of complex formation or disrupt the TA complex.  Although these 
works have advanced our understanding of TA systems and how to target them, they are not 
without issues, limitations or drawbacks, which are discussed below.   
 
1.4.4.1 Extracellular death factor and MazEFEc 
E. coli mazEF is one of the best characterized TA systems and has been implicated in cell 
stress responses and programmed cell death.  A variety of stressors cause MazF-induced cell 
death, including short-term exposure to antibiotics that target transcription or translation [144], 
DNA damage due to thymine starvation [145], overproduction of ppGpp [3], and exposure to 
DNA damaging agents such as mitomycin C or nalidixic acid [61].  
The Engelberg-Kulka group has published a series of papers in which they claim to have 
identified an endogenous peptidic activator of the MazF [12, 77-79].  If confirmed, this would be 
a significant discovery and would lend considerable support to the notion that TA systems are 
exploitable antibacterial targets.  However, as described below, this work is controversial and 
awaits independent validation.  These studies began with the observation that the ability of 
mazEF to mediate cell death in response to stress was dependent on population size.  Brief 
treatment of cells with rifampicin triggered mazEF-mediated cell death at densities of 3 x 108 or 3 
x 107 cells/mL, but not when the same culture was diluted to 3 x 105 or 3 x 104 cells/mL [78].  
Furthermore, transfer of supernatant from a dense culture to a dilute culture followed by a short 
treatment with rifampicin, chloramphenicol, or trimethoprim resulted in mazEF-dependent cell 
death.  These results suggest that mazEF-dependent cell death requires an “extracellular death 
factor” (EDF).  Subsequent isolation experiments identified EDF as a linear pentapeptide 
quorum-sensing molecule with the sequence NNWNN.  Synthetic NNWNN also induced mazEF-
mediated cell death in response to antibiotic stress [78].   
 The effect of EDF on MazF activity in vitro was assessed using a continuous fluorometric 
assay for MazF, and in this experiment EDF significantly enhanced the endoribonucleotlytic 
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activity of MazF in both a concentration- and sequence-dependent manner [12].  The derivatives 
NNGNN and NWN gave no enhancement of MazF activity, whereas other residue substitutions, 
additions, and deletions were well-tolerated.  Furthermore, when increasing concentrations of 
EDF were mixed with MazE and then added to MazF and fluorogenic substrate, the ability of 
MazE to inhibit MazF activity was diminished, indicating that EDF prevented the inhibition of 
MazF by MazE in vitro.  A structural model suggests that EDF directly competes with the 
MazE71-75 sequence IDWGE by placing the EDF Trp3 in the hydrophobic MazF pocket that is 
typically occupied by MazE Trp73.    
Figure 1.7  A possible model for mazEF-dependent cell death induced by extracellular death factor (EDF). EDF 
production requires primarily the protein Zwf and the protease ClpXP.  Preliminary investigation suggests that EDF 
freely diffuses in and out of the cell.  Treatment with an antibiotic triggers the stress response, which inhibits 
transcription of mazEF.  EDF binds to and enhances MazF ribounuclease activity in vitro, although it is not known 
whether EDF binds to free MazF or to the MazEF complex (as it is depicted here).  MazF cleaves single-stranded 
mRNA in a sequence-specific manner, leading to cell death.  It should be noted that there is controversy about EDF, 
and the role of EDF has not been independently confirmed by multiple laboratories. Figure taken from [179].   
 
Given the experimental results, the authors proposed that the endoribonuclease MazF 
serves as a cytoplasmic sensor of EDF [12, 77, 78] and that EDF is required for mazEF-
dependent cell death.  A possible model for this phenomenon is shown in Figure 1.7 and 
summarized in Table 1.2.  It is important to note that several laboratories have tried to replicate 
critical elements of the EDF experiments, but have been unsuccessful [57, 59, 169].  As such, it is 
too early to classify EDF as a bona fide TA system activator; a rigorous validation of the 
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NNWNN peptide in various bacterial strains by multiple research groups will be required for the 
EDF phenomena to be widely accepted.  
 
1.4.4.2 Inhibitors of the PemI-PemK/MoxX-MoxT interaction 
PemK, of the B. anthracis PemIK TA module, cleaves single-stranded RNAs and is 
inhibited by the binding of antitoxin PemI [2].  Analysis of PemI deletion variants indicated that 
the C-terminus is required to bind to PemK.  Based on this information, six hepta- and octa-
peptides, representing fragments of the antitoxin located in a predicted helical region within the 
TA binding interface, were analyzed for their ability to inhibit the PemI-PemK interaction [2].  
ELISA results revealed that each designed peptide was capable of preventing the PemI-PemK 
interaction to a certain extent (Table 1.2), whereas nonspecific 15- and 9-residue peptides based 
on the N-terminus of PemI did not affect the PemI-PemK interaction [2].     
The authors then examined the effect of the peptides on PemK ribonuclease activity using 
a fluorogenic chimeric DNA-RNA substrate or a fluorogenic rC substrate [2].  The two peptides 
that prevented the PemI-PemK interaction to the greatest extent, LLFQHLTE (35% prevention) 
and RRGYIEMG (30% prevention), inhibited the PemK ribonuclease activity in vitro (Table 
1.2), while the remaining four peptides did not inhibit PemK ribonuclease activity.  This result is 
not surprising, as one might expect a peptide fragment of the antitoxin to reduce the activity of 
the toxin.  Recently, this B. anthracis TA system was re-named MoxXT [27].  A rationally 
designed octapeptide, SKIGAWAS, which has potential to form an α-helix and is predicted to 
occupy the binding interface between MoxX and MoxT, was shown to prevent the MoxXT 
complex formation in vitro by 42% (Table 1.2).  However, this peptide also partially inhibited the 
ribonuclease activity of MoxT [27].  These experiments are encouraging in that they demonstrate 
that TA interactions can be prevented by peptides; the next step is to design and identify peptides 
that prevent the protein-protein interaction without inhibiting the toxin enzymatic activity.   
 
1.4.4.3 Disruptors of ε-ζ 
A publication disclosed the results from a screen of peptides for disruption of the 
Streptococcus pyogenes plasmid-derived TA system called ε-ζ [91].  This screen utilized Luc-ε 
and ζ-GFP fusion proteins in a bioluminescence resonance energy transfer (BRET) assay.  An 
extensive collection of various peptide libraries, including over 4.95 x 107 6-residue peptides, 
2.74 x 104 14-residue β-sheet peptides, and 2.74 x 104 17-residue α-helix peptides were evaluated 
for their ability to disrupt the interaction between Luc-ε and ζK46A-GFP in a cell-free extract.  
Peptides were tested at both 0.6 µM and 7 µM.  Hits were selected based on their ability to 
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decrease the BRET signal relative to untreated controls.  No hits were observed at either 
concentration with the 6- and 14-residue peptide libraries; however, two wells containing 
members of the 17-residue library decreased the BRET signal [91] (Table 1.2).  These peptide 
mixtures were not tested for their ability to activate or inhibit the ζ toxin.  When the number of 
peptides from the sub-libraries that contained the positives tested was reduced, the decrease in 
BRET signal was lost [91].  Thus, the disruption of the Luc-ε–ζK46A-GFP complex was possibly 
due to more than one peptide with weak activity.  While this could mean that the ε-ζ interaction 
can be disrupted, more investigation is required to confirm this finding and to determine whether 
the peptide(s) binds to the antitoxin or to the toxin and if toxin activity is affected in the process. 
 
Table 1.2  Peptide modulators of toxin-antitoxin systems 
Target     Peptide Notes Reference 
MazEFEc NNWNN 
Isolated from E. coli supernatant; referred to as Extracelluar Death Factor 
[78] Induces MazF-dependent death in response to rifampicin treatment 
Increases MazF activity in the presence of MazE by ~60% 
[12] Enhances enzymatic activity of MazF by ~60% 
Model suggests direct competition with MazE71-75 sequence IDWGE 
MoxXT 
LLFQHLTE 
Represents fragment of antitoxin within TA binding interface 
[2] 
prevents MoxX-MoxT complex formation by 35% 
inhibits MoxT ribonuclease activity by ~30% 
RRGYIEMG 
Represents fragment of antitoxin within TA binding interface 
prevents MoxX-MoxT complex formation by 30% 
inhibits MoxT ribonuclease activity by ~30% 
SKIGAWAS 
Designed based on modeled structure of MoxXT complex 
[27] prevents MoxX-MoxT complex formation by 42% 
inhibits MoxT ribonuclease activity by ~38% 
ε-ζ 
17-residue α-helix 
library 
2 wells containing mixtures of peptide library appeared to disrupt ε-ζ interaction 
[91] Reduction in number of peptides caused a loss in disruption effect 
 
1.5 STRATEGIES TO TARGET TA SYSTEM PROTEINS 
 The strategies employed to target TA system proteins are disruption of the protein-protein 
interaction, as noted in each case discussed above, and enhancement of the enzymatic activity of 
the toxin.  There have been considerable efforts towards both of these strategies in other drug 
discovery endeavors, which will be discussed now. 
 
1.5.1 Protein-protein interaction inhibition 
Interactions between some globular proteins are mediated by relatively large, flat and 
featureless interfaces, which are typically more challenging to target.  The interaction between the 
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toxin and the antitoxin is typically mediated by extensive electrostatic and hydrophobic interacts 
and the contact surface between the two proteins is significant.  In MazEFEc, the C-terminus of 
the antitoxin MazE resembles a long, relatively unstructured polypeptide that binds between 
within the toxin MazF dimer to occupy its active site [70].  In RelBEEc, antitoxin RelBEc appears 
to wrap around the toxin RelEEc to inactivate it [17, 90].  The limited amount of crystallographic 
data for TA proteins impedes our ability to understand the intricate interactions between the two 
proteins.  Furthermore, although we understand that the protein-protein interface is extensive, 
there is limited information on residues important for binding between the two proteins or if 
binding “hot spots” exist.  “Hot spots,” are short interfaces that facilitate high affinity binding 
[16, 34].  Alanine-scanning mutagenesis is typically used to reveal such hot-spots [37], which 
may help guide the development of protein-protein interaction (PPI) inhibitors.   
Site-directed mutagenesis of MazEEc revealed that residues L55 and L58 were required 
for binding to MazFEc [184].  Additionally, a RelBEc A39T mutant exhibited decreased stability 
and was degraded faster than WT RelBEc, leading to hyperactivity of RelEEc [30].  Unfortunately, 
it was never fully elucidated if the increased proteolytic susceptibility of RelBEc A39T was due to 
improved recognition or cleavage by Lon or because its affinity for RelEEc was lower thus 
reducing the protection gained by being in the TA complex, so the contribution of this residue to 
the interaction remains to be determined.  Crystallographic or NMR structural data are invaluable 
to the design of PPIs; indeed, such data exist for nearly all PPIs that have been successfully 
disrupted [168].   
Targeting the interfaces between protein binding partners is an attractive therapeutic 
strategy and considerable progress has been made in identification of PPI antagonists for 
antiviral, antibacterial and anticancer targets [176].  The peptide-based HIV gp41 fusion inhibitor 
T20, sold as enfuvirtide or Fuzeon, was approved for the treatment of resistant HIV infections in 
2003 [82, 137]; however, limited potency and poor pharmacokinetic properties motivate 
continuous searches for improved HIV fusion inhibitors [182].  The most extensive target studied 
for antibacterial application is the ZipA-FtsZ interaction.  Inhibitors of ZipA-FtsZ have been 
identified by a variety of methods, including a fluorescence-polarization assay to screen 250,000 
small molecules, [73], structure-based design combining two weak fragments to form a more 
potent inhibitor [157], NMR screening of 825 fragments, the hits of which were evaluated in a co-
crystal structure [161], and a shape-directed lead-hopping approach facilitated by Rapid Overlay 
of Chemical Structures [140].  Although hits have been evaluated, a PPI with sufficient potency 
remains to be identified [161].   
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The widely studied p53-MDM2 system has become the model system for the inhibition 
of PPIs, and identification of such inhibitors has been tackled by a variety of approaches.  The 
crystal structure MDM2-p53 revealed a deep hydrophobic p53-binding pocket on MDM2; p53 
binds with a KD of 420nM [81].  Inhibition of MDM2-p53 has been accomplished using both 
peptides and small molecules.  Isothermal titration calorimetry revealed a 10-mer peptide based 
on the p53 sequence with a KD value of 46 nM [147].  Additionally, a peptide with a KD value of 
3.3 nM for MDM2 was selected from a phage displayed peptide library [124] and structure-based 
design guided modifications which improved the potency 5-fold [133].  The potent small 
molecule antagonist discovered by a screening method, Nutlin-3, has been extensively studied 
and optimized to yield a Ki value of 36 nM [151, 171].  All peptides and small molecules able to 
disrupt MDM2-p53 bind in the hydrophobic cleft of MDM2 [124, 147, 151, 171].   
Other notable drug targets for which potent PPI inhibitors have been identified include 
two anti-apoptotic proteins, Bcl-XL and XIAP.  A 25-mer peptide that binds Bcl-XL and prevents 
its interaction with pro-apoptotic molecule, BAD, was shown to have a KD of 0.2nM [132].  
Additionally, a potent small molecule inhibitor with a Ki value of 0.6 nM was developed using 
NMR to carry out fragment-based design [131].  A high throughput “SAR by NMR” strategy was 
employed to discover ABT-737, a potent inhibitor of the Bcl-Xl-BAD interaction with a Ki ≤ 1 
nM [118].  Poor bioavailability prompted the development of a similarly potent derivative, ABT-
263 [162].  It functions as a single-agent therapeutic to cause regression of tumor growth by 
activating pro-apoptotic proteins and has undergone evaluation in Phase II clinical trials [139].   
The anti-apoptotic protein XIAP directly inhibits caspase-3 and -7; inhibition is relieved 
by binding of Smac to XIAP, mediated by the four N-terminal amino acids, AVPI [155].  
Fluorescence polarization was used to identify a potent non-peptide mimetic of Smac, SM-164, 
which showed an IC50 value of 1.39 nM [94, 155].  A number of molecules targeting inhibitors of 
apoptosis proteins (IAP inhibitors) have been tested in clinical trials [53, 156]   
Strategies employed to identify PPI inhibitors include peptide fragment analysis, 
chemical library screening, phage display of peptide libraries and alanine screening mutagenesis 
[106, 176].  Peptide fragment analysis provides useful information regarding the key regions for 
binding and the minimal sequence required to disrupt, which can then be guide the design of 
peptidomimetic or small molecule disruptors.  Screening libraries of diverse chemical structures 
has also successfully identified small molecule PPI inhibitors.   
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1.5.2 Enzyme activators 
RNase L is an endoribonuclease that is involved in antiviral innate immunity of higher 
vertebrates to viral infections.  Its activity is stimulated by 2’-5’oligoadenyslate (2-5A), which 
induces self-association of RNase L, driving formation of the catalytically-active high-order 
homo-oligomers that cleave dsRNA and prevent expression of viral proteins [173].  Two lead 
compounds that activate RNase L were identified from a high throughput screen of 32,000 
compounds [159].  Unfortunately, although it was shown that these 2 hits activate by the same 
mechanism as the natural activator, the activators exhibited an EC50 of ~20 µM, approximately 5 
orders of magnitude higher concentration than 2-5A, which has an EC50 of 0.5 nM.   
Restoration of a function apoptotic pathway by activation of the precursor to executioner 
caspase-3, procaspase-3, has been developed as a targeted anticancer strategy.  A high throughput 
screen of 20,500 compounds revealed the procaspase-activating compound PAC-1 which 
promotes maturation of the zymogen procaspase-3 to active caspase-3 with an EC50 of 0.22 µM 
[134].  PAC-1 functions by chelating inhibitory zinc from procaspase-3, enhancing autocleavage 
to form active caspase-3 [129].  The non-neurotoxic derivative sulfonamide-PAC-1 also displays 
potent anticancer activity and has shown success in a phase I pet dog clinical trial [130]. 
The activation of glucokinase is a promising antidiabetic strategy [100].  The role of 
glucokinase (GK) as a glucose sensor in pancreatic cells stimulates glucose-dependent insulin 
production and release; it also directs the ability of the liver to convert glucose to glycogen.  
Evaluation of 120,000 small molecules revealed one GK activator, which led to the development 
of RO0281575 [55].  This compound enhances the enzymatic activity of GK by increasing both 
its affinity for glucose and its maximal catalytic rate and in mice it was shown to increase insulin 
release from the pancreas and stimulate glucose usage in the liver [55].  However, toxicity in 
preclinical trials prompted the development of safer derivatives, including the compound 
RO4389620 or Piragliatin [142], which was shown to lower glucose levels in Type II Diabetes 
patients in a Phase II clinical trial [18].  
 
1.6 CHALLENGES FOR THE DISCOVERY OF TOXIN ACTIVATORS 
Artificial activation of TA systems is a potentially powerful antibacterial strategy.  
However, the three examples discussed in 1.4.4 are the state-of-the art for TA activation with a 
drug-like compound, thus as of yet there is no molecule convincingly capable of modulating the 
TA interaction.  Such compounds are needed to fully explore the potential of TA disruption and 
toxin activation as an antibacterial strategy.  Five key questions regarding the discovery of an 
artificial toxin activator are discussed below. 
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First, will the strength of the TA interaction preclude disruption with a peptide or small 
molecule?  Most toxin-antitoxin pairs have strong affinities, mediated by extensive electrostatic 
and hydrophobic interactions [70], resulting in KD values on the order of 1 nM [88, 120].  In most 
cases, the antitoxin wraps around the toxin to form the inactive complex.  In contrast, interactions 
between other protein-protein pairs that have been successfully inhibited are characterized by 
long, shallow pockets that are accessible to small molecules [62, 176].  Perhaps not surprisingly, 
in all the three examples presented above, peptides were evaluated as toxin-antitoxin disruptors; a 
small molecule TA modulator has yet to be discovered. 
 Confounding this issue is the relatively limited information on the specifics governing the 
TA interaction.  Crystal structures have been solved for some TA systems including S. pyogenes 
ε2-ζ2 [101], and E. coli MazEF [70], and there is a solution structure of E. coli RelBE [90].  
However, although there is considerable homology between toxins of the same family and even 
of different families, the sequence and secondary structure of antitoxins are much more divergent; 
thus, more structural data is needed.  Additionally, minimal data is available regarding the amino 
acid residues that define the ‘hotspots’ between toxin and antitoxin.  Defining these hotspots and 
minimal TA binding regions through mutational analysis will facilitate the design of molecules 
specifically targeting these interactions  
 Second, can the limitations in current assays for toxin activity be overcome?  The process 
of searching for toxin activators is hindered by significant limitations in current in vitro 
enzymatic assays for toxin activity.  Efficient screening of potential activators requires a robust 
assay, such as the continuous fluorometric assay developed to monitor MazF ribonuclease 
activity [174].  This assay, utilized in two separate examples presented above, allows for high-
throughput analysis of molecules that modulate the enzymatic activity of toxins that cleave free 
mRNA, such as MazF and PemK.  In contrast, toxins such as the ribosome-dependent 
ribonuclease RelE must be evaluated by reconstituting actively translating ribosomes, which 
requires a fairly complicated in vitro assay not easily amenable to high-throughput screening.  
The development of high-throughput methods of assessing ribosome-dependent ribonuclease 
activity would facilitate the discovery of activators of RelE and HigB. 
Additionally, in vitro assays lack key components that exist within the cell, namely the 
proteases that naturally relieve antitoxin inhibition of the toxin.  Thus, current in vitro assays are 
unable to discover compounds that work through an indirect mechanism.  For example, a 
molecule could increase the proteolytic susceptibility of the antitoxin or modulate TA expression.  
Discovery of a molecule that acts by one of these mechanisms would best be achieved using cell-
based assays. 
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Third, should the toxin or the antitoxin serve as the target?  The examples presented 
above do not give a unified answer.  On one hand, EDF (suggested to bind MazF by mimicking a 
region of the MazE antitoxin) is claimed to both enhance MazF activity and prevent MazE 
inhibition by directly binding to MazF [12].  On the other hand, peptide fragments of the antitoxin 
MoxX bind to and inhibit the ribonuclease activity of the toxin MoxT [2, 27].  Different antitoxin 
fragments can have varying effects on the toxin; obviously, if binders to the toxin are developed, 
they should activate, rather than inhibit.  Conceptually, a molecule that binds the antitoxin and 
modulates its interaction with the toxin is desirable; however, the intrinsically disordered 
structure of the antitoxin makes it a difficult target for in vitro screens.  Nevertheless, a promising 
new class of molecules that specifically target intrinsically disordered peptides is being developed 
[103].  A number of small molecules that target the oncoprotein c-Myc have been discovered via 
high throughput screening efforts [103].  Many of these compounds bind to highly unstructured c-
Myc monomers, precluding their dimerization as well as complex formation with its binding 
partner, Max [103]. 
On a related note, is full TA disruption is necessary, or is activation of the toxin sufficient 
for an antibacterial effect?  EDF is purported to prevent TA complex formation, but was not 
shown to activate MazF from the pre-formed MazE-MazF complex [12].  Similarly, the peptide 
fragments of MoxX prevented complex formation between MoxX and MoxT but were not shown 
to disrupt the interaction between MoxX and MoxT in a pre-formed complex [2, 27].  Is this 
significant in the cell where the antitoxin is subject to metabolic turnover?   
Fourth, will a toxin-activating compound kill bacteria as a single-entity agent?  Toxin-
mediated cell death is typically studied in response to some outside stimulus, such as amino acid 
starvation or treatment with an antibiotic.  Despite the ability of EDF to enhance MazF activity in 
vitro, it is unable to induce MazF-dependent cell death on its own, and requires prior activation of 
the mazEF module via an antibiotic such as rifampicin or chloramphenicol [77, 78].   
 Finally, how does the location of the TA genes (plasmid or chromosomal) influence the 
TA-targeting strategy?  It seems clear that artificial activation of TA proteins encoded on 
plasmids would kill the cell in a manner analogous to antitoxin degradation, toxin activation, and 
cell death in post-segregational killing though TA plasmid stabilization mechanisms.  When the 
TA genes are chromosomally-encoded, however, the copy number of resulting TA proteins may 
not be high enough to induce death after toxin activation.  Furthermore, chromosomal TA 
systems have been implicated in the formation of persister cells, which some believe may 
contribute to chronic infection.  There is concern that artificial activation of chromosomally-
encoded toxins could potentially induce persister cell formation, an obviously undesirable effect. 
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TA systems present exciting opportunities for the development of novel antibacterial 
agents.  The first requirement, demonstration of the ubiquity and functionality of TA systems in 
clinical isolates, has been satisfied for key pathogens, including VRE, MRSA and P. aeruginosa 
and S. pneumoniae.  Additional epidemiological surveys and biochemical analyses of toxins will 
add to the catalog of potential TA systems to target.  Although potentially significant, the 
Extracellular Death Factor story needs further clarification and independent validation.  
Preliminary work on the disruption of the ε-ζ complex and prevention of the MoxXT complex 
suggests that peptides can indeed be used to modulate the TA system interaction.  Development 
of a toxin activator and extension of the TA activation strategy to in vivo studies are required to 
fully assess the potential of this strategy. 
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CHAPTER 2 
PREVALENCE AND TRANSCRIPTION OF TOXIN-ANTITOXIN SYSTEMS IN 
CLINICAL ISOLATES OF PSEUDOMONAS AERUGINOSA AND ACINETOBACTER 
BAUMANNII 
 
Sections from Chapter 2 have been published in “Toxin-Antitoxin (TA) Systems are Prevalent 
and Transcribed in Clinical Isolates of Pseudomonas aeruginosa and Methicillin-Resistant 
Staphylococcus aureus,” Williams JJ, Halvorsen EM, Dwyer EM, DiFazio RM and Hergenrother 
PJ. (2011) FEMS Microbiol Lett, 322:41-50. 
 
2.1 INTRODUCTION 
Genes encoding toxin-antitoxin (TA) systems were found to be widespread in 
Enterococcus [9, 15, 20, 22], Staphylococcus aureus [25] and Streptococcus pneumoniae [18], 
however information regarding the prevalence of TA systems in Gram-negative bacteria is 
lacking.  As discussed in Chapter 1, infections caused by the Gram-negative pathogens 
Pseudomonas aeruginosa and Acinetobacter baumannii are difficult to treat due to their intrinsic 
resistance and ability to acquire resistance to nearly all available antibiotics.  Novel treatment 
strategies, such as TA system activation, are required to combat these hardy pathogens.  Thus, we 
sought to define the prevalence of TA systems in a collection of clinical isolates of P. aeruginosa 
(PA) and A. baumannii (AB).   
Previously, a bioinformatics survey of 126 prokaryotic genomes identified three TA loci, 
relBE, parDE, and higBA, on PA strain PAO1 [19].  Although no additional work has been 
published on the TA systems in PA, functional homologs have been described in other pathogenic 
bacteria, including RelBE in Streptococcus pneumoniae [17], Yersinia pestis [8] and 
Mycobacterium tuberculosis [27]; ParDE in Vibrio cholerae [28]; and HigBA in V. cholerae [3, 
4], Proteus vulgaris [10] and Y. pestis [8].  Five TA loci belonging to the relBE gene family and 
one solitary toxin belonging to the ζ gene family were identified in the published sequences of 
one AB chromosome and five AB plasmids [11, 23].  Until recently, no information regarding TA 
systems in AB was available; however, a bioinformatics study of AB genomes identified at least 
15 TA pairs, five of which were shown to be functional ribonucleases [12]. 
While the analysis of sequenced genomes has been informative, defining the presence 
and identity of TA loci in collections of clinical isolates is a preliminary requirement for the 
success of the TA targeting strategy.  Thus, we surveyed 42 PA and 39 AB clinical isolates for 
the existence of the specific TA systems identified by bioinformatics analysis on PA [19] and on 
the sequenced genomes of AB [11, 23].  We found that relBE and higBA are ubiquitous in PA 
42 
clinical isolates and that relBE-1Ab and the lone ζ toxin were present in approximately half of the 
AB clinical isolates.  Establishing the prevalence of specific TA systems in important pathogens 
dictates their potential for success as an antibacterial target. 
 
2.2 INVESTIGATION OF TOXIN-ANTITOXIN SYSTEMS IN PSEUDOMONAS 
AERUGINOSA 
 
2.2.1 Assessment of P. aeruginosa clinical isolate diversity 
Twenty PA clinical isolates from cystic fibrosis patients were obtained from Carle 
Foundation Hospital (Urbana, IL) [16] and an additional twenty-two PA strains isolated from 
various acute infections were a gracious gift from Cubist Pharmaceuticals, Inc (Lexington, MA); 
these strains were collected from eight geographically distinct locations.  These isolates were 
analyzed by the DNA-based typing method multi-locus variable number tandem repeat analysis 
(MLVA) to assess intra-species relatedness.  The experimental variation between duplicate 
experiments was determined for the MLVA profile using five PA isolates and applied to establish 
a cutoff value of 97% for typing strains with identical DNA banding patterns.  For PA, using the 
97% cutoff value, 43 MLVA banding patterns were formed out of the 44 strains.  When a cutoff 
value of 75% was applied, 10 clusters were generated comprising 28 strains, and 26 MLVA 
banding patterns were discerned (Figure 2.1).  Strains that group according to these two cutoff 
values are in a variety of clusters, demonstrating that the isolates studied were not clonal. 
 
2.2.2 Presence of TA systems in P. aeruginosa genomic DNA 
Armed with the knowledge that the collection of PA clinical isolates were sufficiently 
diverse, an effort was made to define the prevalence of TA genes in the strains.  The PA isolates 
were probed for homologs of the higBA, parDE and relBE systems identified in PA strain PAO1 
[19].  The oligonucleotide sequences of all PCR primers used to amplify TA genes are listed in 
Table 2.1 and the homologous regions are represented in Figure 2.2. 
Total DNA preparations from each of the 42 PA strains were analyzed by PCR, and 
results were designated positive if a distinct band was observed at the expected size on an agarose 
gel.  For the 42 PA isolates, relBEPa (42/42, 100%) and higBAPa (42/42, 100%) were ubiquitous, 
whereas parDEPa (13/42, 30%) was less prevalent (Figure 2.3).  Table 2.2 contains a complete 
list of all PA isolates and the TA genes detected by PCR.  Comparison of the MLVA genotypes 
of PA strains that carry parDEPa showed that these strains are dispersed throughout the 
43 
dendrogram, indicating that there is no correlation between genome relatedness and carriage of 
parDEPa. 
 
Figure 2.1  Multi-locus variable number tandem repeat analysis of P. aeruginosa clinical isolates.  The 97% clonal 
cutoff value and 75% similarity cutoff value are indicated by solid and dashed vertical lines, respectively.  The clusters 
generated are shown in corresponding solid and dashed brackets alongside the dendrogram.  
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Figure 2.2  Locations of primary homology for primers used in PCR screen, RT-PCR and flanking region 
PCR.  (A-C) Primer sequences were based off the P. aeruginosa PAO1 genome.  (A) The same internal 
primers were used to amplify a region of parDEPa for both the PCR-based screen and RT-PCR.  Flanking 
parDEPa are genes encoding an integrase, a tRNA and a transferase.  Primers were designed to amplify the 
sequence between the integrase gene and parDPa and between parEPa and the transferase gene.  (B) 
Separate sets of internal primers were used to amplify regions of relBEPa for the PCR-based screen and for 
RT-PCR.  Flanking relBEPa are genes encoding a transcriptional regulator and a hypothetical protein.  
Primers were designed to amplify the sequence from the transcriptional regulator gene to relBPa and from 
relEPa to the hypothetical protein gene.  (C) Separate sets of internal primers were used to amplify regions 
of higBAPa for the PCR-based screen and for RT-PCR.  Flanking higBAPa are genes encoding a hypothetical 
protein and a Ton-B dependent receptor.  Primers were designed to amplify the sequence from the 
hypothetical protein gene to higAPa and from higBPa to the Ton-B dependent receptor gene.  (D) In P. 
aeruginosa PA7, higBAPa is flanked by genes encoding a restriction endonuclease and a hypothetical 
protein.  Primers were designed to amplify the sequence from the restriction endonuclease gene to higAPa 
and from higBPa to the hypothetical protein gene.  
 
 
 
higAPa higBPa
803 bp product 655 bp product
(d) Restriction endonuclease Hypothetical protein
Integrase TransferaseparDPa parEPa
679 bp product 676 bp product
tRNA-Gly(a)
556 bp product
Hypothetical proteinrelBPa relEPa
548 bp product 646 bp product
(b) Transcriptional regulator
505 bp product
349 bp product
higAPa higBPa
823 bp product 712 bp product
tRNA-Met(c) Hypothetical protein Ton-B dependent receptor
469 bp product
305 bp product
PCR screen, RT-PCR
Flanking region PCR
PCR screen
RT-PCR
Flanking region PCR
PCR screen
RT-PCR
Flanking region PCR
Flanking region PCR
45 
Figure 2.3  PCR analysis of PA isolates.  The prevalence of genes encoding TA systems as assessed by PCR from the 
total genomic DNA of 42 clinical P. aeruginosa isolates.   
 
 The identity of approximately 10% of the positive PCR products was confirmed by 
sequencing.  Sequenced PCR products revealed strong sequence identity (97.8 – 100%) to the 
reference TA system sequences (higBAPa, 99.4% average identity; parDEPa, 99.6% average 
identity; and relBEPa, 98.7% average identity); alignments are shown in Figures 2.7-2.9).   
 
2.2.3 TA gene location assessment 
It was next investigated whether the TA genes were located on a plasmid or the 
chromosome of the PA isolates.  The sequences directly upstream and downstream of the relBEPa 
TA genes are highly conserved among the P. aeruginosa genomes in the National Center for 
Biotechnology Information (NCBI) Genome database, whereas the flanking regions of parDEPa 
and higBAPa are conserved in P. aeruginosa PAO1, LESB85 and UCBPP-PA14, but are different 
in strain PA7.  Primers were designed (Table 2.1 and Figure 2.2) to amplify the sequences 
flanking the TA genes based on the conserved sequence in P. aeruginosa strains PAO1 and PA7.  
In this experiment the presence of a PCR product would suggest chromosomal location of the TA 
systems. 
PCR analysis revealed that in the PA isolates, both flanking regions of the parDEPa genes 
in all isolates (13/13, 100%) were amplified using primers homologous to the PAO1 reference 
sequence.  The flanking regions of nearly all relBEPa genes (41/42, 97%) were amplified, except 
for strain 1284, for which no flanking region could be amplified.  Amplification was observed for 
the downstream sequence of every higBAPa loci (42/42, 100%) as well as for the region upstream 
of higBAPa except for in 10 strains (32/42, 76%).  For these 10 strains, PCR was performed with 
various primers designed based on the PAO1 reference sequence, as well as primers designed to 
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probe the upstream sequence of higBAPa observed in P. aeruginosa PA7; however, no product 
was amplified in any of these cases.  All results from the flanking region PCR are listed in Table 
2.3.   
DNA sequencing was performed on >10% of the PCR products to confirm the identity of 
the amplified sequence.  The flanking region PCR products of parDEPa (92.6 – 98.2%), relBEPa 
(96.2 – 99.4%) and higBAPa (91.8 – 99.4%) also showed strong sequence identity to the reference 
P. aeruginosa PAO1 sequence (Figures 2.10-2.12).   
 
2.2.4 Detection of TA transcripts 
To determine if the TA systems were transcribed by the clinical isolates, RT-PCR was 
performed with total RNA isolated from >10% of strains shown by PCR to contain the genes for 
each TA system.  The oligonucleotide sequences of all primers used for RT-PCR are listed in 
Table 2.1 and Figure 2.2 depicts the regions of homology.  The transcripts for relBEPa (6/6), 
higBAPa (5/5) and parDEPa (3/3) transcripts were detected in all PA strains probed by RT-PCR 
(Figure 2.4).  For all samples, no amplification products were observed in the absence of reverse 
transcriptase, confirming that the products seen by RT-PCR were due to the presence of the TA 
transcript in the clinical isolates and not DNA contamination (Figures 2.4).   
 
Figure 2.4  Detection of TA system transcripts. RT-PCR with primers complementary to the genes encoding each TA 
system indicates that transcripts are produced in the clinical isolates of P. aeruginosa, (+) RT row.  Controls for DNA 
contamination, in which the reverse transcriptase is omitted from the reaction mix, yield no product, (-) RT row.  
Clinical isolates analyzed are indicated by the strain number above each column.  
CI0412841174996
higBAPa
(+) RT
(-) RT
CI19CI13
parDEPa
(+) RT
(-) RT
relBEPa
(+) RT
(-) RT
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2.3 INVESTIGATION OF TA GENES IN ACINETOBACTER BAUMANNII 
 
2.3.1 Presence of TA genes in A. baumannii genomic DNA 
Thirty-nine A. baumannii (AB) clinical isolates obtained from Prof. John Quale were 
gathered from citywide surveillance studies in Brooklyn, NY from 2001 to 2006 [2].  The 
following homologs identified in the specified AB chromosomes or plasmids were probed:  
relBE-1Ab from strain ACICU [11], relBE-2Ab from plasmid pACICU [11], a solitary ζAb toxin 
from plasmid pACICU2 [11, 23], relBE-3Ab, from p1ABAYE [23], relBE-4Ab from p3ABAYE 
[23], relBE-5Ab from p2ABSDF [23].  The oligonucleotide sequences of all PCR primers used to 
amplify TA genes are listed in Table 2.1.  For AB, relBE-1Ab (21/39, 53%) and the solitary ζAb 
toxin (18/39, 46%) were each observed in approximately half of the 39 AB strains (Figure 2.5).  
For those AB strains that harbored no detectable TA systems, PCR performed with primers to 
amplify recA [13] confirmed the presence of DNA (data not shown).  Sequence analysis 
confirmed the identity of approximately 10% of the positive PCR products (relBE-1Ab, 100% 
identity, ζAb, 100% identity; alignments are shown in Figures 2.13 and 2.14).   
 
Figure 2.5  PCR analysis of A. baumannii (AB) isolates.  The prevalence of genes encoding TA systems as assessed by 
PCR from the total genomic DNA of 39 clinical AB isolates.   
 
2.3.2 RT-PCR analysis 
To determine if the TA systems were transcribed by the clinical isolates, RT-PCR was 
performed with total RNA isolated from >10% of strains shown by PCR to contain the genes for 
each TA system.  In contrast, the transcripts for relBE-1Ab (0/3) and ζAb (0/2) were not observed in 
any of the AB isolates tested (Figure 2.6).  However, transcripts were detected for recA in the 
same AB RNA samples, confirming the presence of RNA (data not shown).  Although the genes 
encoding relBE-1Ab and solitary ζAb toxin were present in approximately half of the AB isolates, 
the transcripts were unable to be detected in the isolates probed. 
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Figure 2.6  RT-PCR analysis. Detection of recA transcripts by RT-PCR indicates that intact mRNA is present in the 
samples.  No TA transcripts were detected in the clinical isolates of A. baumannii tested.   
 
2.4 CONCLUSIONS 
Bioinformatics analyses of published prokaryotic genomes have demonstrated the 
pervasive nature of TA loci [14]; however, little effort has been made to survey large collections 
of clinical bacterial strains for the presence and functionality of TA systems.  Herein we used 
PCR to determine that higBAPa and relBEPa are ubiquitous in a collection of P. aeruginosa 
clinical isolates, whereas parDEPa is less commonly observed.  The genes encoding relBE-1Ab and 
a lone ζAb toxin were found in approximately half of the A. baumanii clinical isolates.  This PCR 
method is complementary to the whole genome sequencing that has previously been used to 
examine the presence of TA systems in PA and AB, and the results reveal the value of inspecting 
large numbers of clinical isolates in this manner.  For example, of the three sequenced PA clinical 
isolates that have been analyzed, PA14 does not have the genes for parDEPa, whereas PAO1 and 
PA7 do [14].  However, the results presented herein show that PA clinical isolates that cluster 
with PA14 (via MLVA) are just as likely to have the genes for parDEPa as those PA strains that 
do not cluster with PA14.  The results with AB demonstrate the heterogeneous nature of the 
distribution of TA systems in this important pathogen.  One recent study has identified at least 
five functional TA systems in AB, belonging to the relBE, higBA, hicAB, splTA and cheTA 
families [12].   
Assessment of the flanking sequence of the TA systems in PA revealed that the 
chromosomal location was conserved across all strains carrying parDEPa, in nearly all strains for 
relBEPa and in the majority of strains for higBAPa.  The inability to amplify the upstream sequence 
of higBAPa in 10 strains suggests that the upstream sequence has diverged or that the higBA loci 
of these 10 strains is located elsewhere; however, the conservation of the downstream sequence 
implies that higBAPa is chromosomally encoded.   
ζAb (+) RT
relBE-1Ab (+) RT
KB357 LI311MA541
recA (+) RT
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Defining the identity of TA systems in clinical isolates satisfies the first requirement in 
validating TA systems as a viable antibacterial target.  However, it is imperative to establish 
which TA systems are transcribed in clinical isolates.  Thus RT-PCR analysis was performed to 
determine if the TA systems were transcribed.  Importantly, it was shown by RT-PCR that 
higBAPa, relBEPa and parDEPa were transcribed in strains that carried the genes.  In AB, despite a 
positive RT-PCR result for recA, no TA transcript was detected, suggesting that the TA systems 
are not functional in AB or that the TA systems are not expressed under the specific laboratory 
conditions used.  Collectively, the results presented herein indicate that the TA genes detected in 
PA strains reside on the chromosome and are active TA modules, whereas further investigation 
will be required to fully characterize the TA systems in AB.  
It has been suggested that activation of TA systems could be an attractive antimicrobial 
strategy, as the freed toxin would kill the host bacterial cell [1, 5-7, 26].  While the presence of 
TA systems in sequenced prokaryotic genomes has been established, prior to this work the 
prevalence of TA systems in clinical isolates PA and AB was unknown.  In addition, this is the 
first time that the higBAPa, parDEPa, and relBEPa transcripts have been shown to be produced in 
these bacteria, and one of the few examples of demonstrated transcription of any TA genes from a 
clinical isolate.  Given the results of a previous study showing that TA systems are ubiquitous and 
transcribed in VRE [9, 15] and MRSA [25], and the current survey showing that TA systems are 
also highly prevalent and transcribed in PA, it appears that these problematic bacterial pathogens 
would indeed be susceptible to TA-based antibacterial strategies.  Specifically, activation of 
RelEPa or HigBAPa appear to be attractive strategies against Pseudomonus aeruginosa. 
 
2.5 EXPERIMENTAL PROCEDURES 
 
2.5.1 Sources of clinical isolates 
The clinical isolates of PA designated CI01-CI20 were obtained from the sputum of 20 
different cystic fibrosis patients at Carle Foundation Hospital, as described previously [16]. The 
remaining 22 PA clinical isolates were a kind gift from Cubist Pharmaceuticals, Inc. (Lexington, 
MA) and had been obtained from various acute infections over eight geographically diverse 
clinical sites in the US.  Thirty-nine A. baumannii clinical isolates were a generous gift from Prof. 
John Quale and were gathered from citywide surveillance studies in Brooklyn, NY from 2001 to 
2006 [2].   
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2.5.2 MLVA 
To assess the clonality of the clinical PA isolates, basic molecular typing was performed 
by PCR-based multiple-locus variable number of tandem repeats analysis (MLVA) previously 
described [21, 24].  For PA, 10 of the 15 minisatellites described by Vu-Thien and co-workers 
were analyzed (ms142, ms211, ms 212, ms213, ms214, ms215, ms216, ms217, ms222, ms223) 
and 1 µL of PCR products was electrophoresed in 2.0% Molecular Biology Grade agarose 
(Fisher) at 10 V/cm.  JPEG files of the MLVA gel images were visually evaluated with 
BioNumerics software (Applied Maths) and a dendrogram of banding patterns was constructed 
using the Dice or Pearson coefficients, respectively, and the unweighted-pair group method using 
average linkages (UPGMA).   
 
2.5.3 DNA isolation 
Total DNA from PA and AB strains was prepared using a modified genomic DNA 
extraction method from Qiagen (Valencia, CA).  Cells were resuspended in 1 mL Buffer B1 
containing 40 µg/mL RNase A, 20 mg/mL lysozyme and 50 µg/mL pronase and incubated at 
37°C for 30 minutes.  Next, Buffer B2 was added and the mixture was incubated at 50°C for 30 
minutes, followed by phenol-chloroform-isoamyl alcohol extraction.  The total DNA was 
precipitated with isopropanol and pelleted by centrifugation.  The DNA pellet was washed with 
70% ethanol and resuspended in 10 mM Tris-HCl (pH 8.0).   
 
2.5.4 RNA isolation 
PA and AB cultures were grown in TSB and harvested at mid-log phase, when 
approximately 1 x 109 CFU/mL were present, at which point 0.25 mL aliquots were harvested by 
centrifugation and frozen at -80°C.  Total RNA was extracted using TRIzol reagent (Invitrogen) 
following a protocol adapted from the manufacturer’s instructions.  The frozen bacterial pellets 
were thawed and resuspended in 0.25 mL TRIzol reagent and sonicated using the Ultrasonic 
Processor (Heat System Ultrasonics, Inc.) for 10 seconds without pulse with the microtip at the 
half-maximal power (setting 5, 50% duty cycle).  Following sonication, an additional 0.75 mL 
TRIzol reagent was added and the cell suspension was incubated at room temperature for 5 
minutes.  Next, 0.2 mL chloroform was added and the tubes were shaken vigorously by hand for 
15 seconds.  The phases were separated by centrifugation at maximum speed for 15 minutes at 
4°C.  To further purify the RNA from the upper aqueous phase, an equal volume of acidified 
phenol-chloroform (5:1) (pH 4.7) (Sigma) was added and the solution was vortexed at maximum 
speed for 15 seconds and centrifuged at maximum speed for 10 minutes at 4°C.  This extraction 
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was repeated on the resultant upper aqueous phase, after which the RNA was precipitated by 
mixing with an equal volume of isopropanol and centrifuging at maximum speed for five minutes 
at room temperature.  The pellet was washed with 1 mL ice cold 70% ethanol, centrifuged 5 
minutes at 4°C, allowed to dry at room temperature for 5 minutes and resuspended in 100 µL 
RNase-free dH2O.  
To remove genomic DNA contamination, 20 µL of total RNA was treated with 50 units 
of Turbo DNase (Ambion) 37°C for at least 24 hours, followed by treatment with RNase-free 
DNase (Qiagen) according to the protocol for RNA clean-up with the on-column DNase 
digestion.  The RNA was eluted with 50 µL RNase-free dH2O.  The yield of DNA-free RNA 
from PA was typically low, ranging from 5-35 ng/µL. 
 
2.5.5 PCR analysis 
For all PA and AB strains, PCR amplification was performed from purified total DNA.  
Gene-specific internal primers were used to amplify the relBEPa, parDEPa, and higBAPa relBE-
1Ab, relBE-2 Ab, relBE-3 Ab, relBE-4 Ab, and ζAb.  TA genes and separate intergenic primers were 
used to amplify the upstream and dowstream flanking regions.  The oligonucelotide sequences of 
the primers are listed in Table 2.1, and Figure 2.2 depicts the homologous region of the primers 
for the PCR-based screen and the flanking region primers.  PCR amplification was carried out in 
a DNA thermal cycler (PTC-200, MJ Research, Inc.) under reaction conditions as described 
previously [15] with a lowering of the annealing temperature to 49°C for most primers.  PCR 
amplified products were analyzed by agarose gel electrophoresis in 1% agarose and stained with 
ethidium bromide. 
 
2.5.6 RT-PCR analysis 
RT-PCR was performed by using the SuperScript One-Step RT-PCR with Platinum Taq 
kit (Invitrogen).  The primers used to amplify the parDEPa, relBE-1Ab, ζAb, and recA sequence for 
RT-PCR are the same as those designed for PCR analysis, whereas RT-PCR for higBAPa and 
relBEPa was performed with separate intragenic primers designed from the P. aeruginosa PAO1 
sequence.  The sequences of all primers used in RT-PCR are listed in Table 2.1 and the 
homologous regions are depicted in Figure 2.2.  The extracted total RNA (up to 40 ng) was used 
in RT-PCR, as well as PCRs with Platinum Taq DNA polymerase (Invitrogen) to detect DNA 
contamination.  Reverse transcription and PCR amplification were carried out in a DNA thermal 
cycler (PTC-200, MJ Research, Inc.) under reaction conditions as described previously [15], with 
modifications made to the PCR annealing temperature as follows:  58°C for relBEPa, 50.8°C for 
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both higBAPa and parDEPa, and 49°C for relBE-1Ab, ζAb, and recA.  RT-PCR amplification 
products were analyzed by agarose gel electrophoresis in 1% agarose and stained with ethidium 
bromide. 
 
2.6 TABLES AND FIGURES 
 
Table 2.1 Primers used in this study, (+), sense primer; (-), antisense primer 
TA system Primer sequence (5' to 3') Product size Application 
    (nt)  
relBEPa (+)CAGGGGGTAATTTCGACTCTG 505 PCR 
 (-)ATGAGCACCGTAGTCTCGTTC   
parDEPa (+)GCGGCTGACCTGGATTTATC 556 PCR, RT-PCR 
 (-)CCAAGCAGTAGCGGATCAATTG   
higBAPa (+)CTCATGTTCGATCTGCTTGC 469 PCR 
 (-)CAATGCTTCATGCGGCTAC   
relBEPa (+)CGCAGTACCTGGAAAGGCAGC 349 RT-PCR 
 (-)GCCTTTAACCCGAAACGGG   
higBAPa (+)GGCCAACATAGCATCAGGATC 305 RT-PCR 
  (-)GGACGTATCAAAGTAACGCCC     
relBE-1Ab (+)ATCTCGCCTATCTACATCAAGAAC 533 PCR, RT-PCR 
 (-)GTGGTTCATGACGTTTCTCAT   
relBE-2Ab (+)GGATACAGTGTTAGCAGGTAAAG 455 PCR, RT-PCR 
 (-)GATGAAGCCAACTCTCGAC   
ζAb (+)GCTTTAGCTGTTAGTCAAGAAAC 496 PCR, RT-PCR 
 (-)GTATGGAACCAAAAAAAGCTGG   
relBE-3Ab (+)TGTATTTACATATACGGACGCACG 475 PCR, RT-PCR 
 (-)GTGACAGATGAACGAATCTCTATA   
relBE-4Ab (+)CTGTTAACTTCAGGGTTGATG 510 PCR, RT-PCR 
 (-)GCAAAAAAACGCATTAAAGACTAA   
relBE-5Ab (+)TCATCCAAAAATTTCGGAATGGC 555 PCR, RT-PCR 
 (-)CATATTGAAATTGACTGCGGACAT   
recA (+)CACAATGACATTGCAAGCAATTG 425 RT-PCR 
 (-)CCAATTTTCATACGAATCTGG   
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Table 2.2  TA systems detected by PCR in total genomic DNA of P. aeruginosa 
  Toxin-Antitoxin System 
Isolate parDEPa relBEPa higBAPa 
Carle 
CI01 (+) (+) (+) 
CI02 (-) (+) (+) 
CI03 (+) (+) (+) 
CI04 (+) (+) (+) 
CI05  (-) (+) (+) 
CI06  (+) (+) (+) 
CI07  (+) (+) (+) 
CI08  (-) (+) (+) 
CI09  (-) (+) (+) 
CI10  (-) (+) (+) 
CI11 (+) (+) (+) 
CI12  (+) (+) (+) 
CI13  (-) (+) (+) 
CI14  (-) (+) (+) 
CI15  (+) (+) (+) 
CI16  (+) (+) (+) 
CI17  (-) (+) (+) 
CI18  (-) (+) (+) 
CI19  (-) (+) (+) 
CI20  (-) (+) (+) 
Cubist  
996 (+) (+) (+) 
997 (-) (+) (+) 
998 (-) (+) (+) 
999 (+) (+) (+) 
1000 (-) (+) (+) 
1001 (-) (+) (+) 
1174 (+) (+) (+) 
1175 (+) (+) (+) 
1176 (-) (+) (+) 
1280 (-) (+) (+) 
1282 (-) (+) (+) 
1283 (-) (+) (+) 
1284 (-) (+) (+) 
1586 (-) (+) (+) 
1590 (-) (+) (+) 
1591 (-) (+) (+) 
1592 (-) (+) (+) 
1905 (-) (+) (+) 
1906 (-) (+) (+) 
2242 (-) (+) (+) 
2243 (-) (+) (+) 
2244 (-) (+) (+) 
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Table 2.3  TA systems detected by PCR in total genomic DNA of A. baumannii 
  Toxin-Antitoxin System 
Strain relBE-1Ab relBE-2Ab relBE-3Ab relBE-4Ab relBE-5Ab ζAb 
BD123 (+) (-) (-) (-) (-) (-) 
BD142 (+) (-) (-) (-) (-) (-) 
BD301 (-) (-) (-) (-) (-) (-) 
BD322 (+) (-) (-) (-) (-) (+) 
BD335 (+) (-) (-) (-) (-) (-) 
BD503 (+) (-) (-) (-) (-) (+) 
BK135 (+) (-) (-) (-) (-) (-) 
BV308 (-) (-) (-) (-) (-) (+) 
DM511 (-) (-) (-) (-) (-) (-) 
IF101 (+) (-) (-) (-) (-) (-) 
IF501 (-) (-) (-) (-) (-) (-) 
IF507 (-) (-) (-) (-) (-) (+) 
KB113 (+) (-) (-) (-) (-) (-) 
KB160 (+) (-) (-) (-) (-) (-) 
KB167 (+) (-) (-) (-) (-) (-) 
KB304 (+) (-) (-) (-) (-) (-) 
KB305 (-) (-) (-) (-) (-) (-) 
KB307 (-) (-) (-) (-) (-) (+) 
KB308 (+) (-) (-) (-) (-) (+) 
KB316 (-) (-) (-) (-) (-) (-) 
KB320 (-) (-) (-) (-) (-) (-) 
KB322 (-) (-) (-) (-) (-) (-) 
KB343 (+) (-) (-) (-) (-) (+) 
KB349 (+) (-) (-) (-) (-) (-) 
KB357 (+) (-) (-) (-) (-) (+) 
KC324 (-) (-) (-) (-) (-) (+) 
KC328 (-) (-) (-) (-) (-) (+) 
KC340 (-) (-) (-) (-) (-) (+) 
KC348 (-) (-) (-) (-) (-) (+) 
KH504 (+) (-) (-) (-) (-) (-) 
LI311 (+) (-) (-) (-) (-) (+) 
LU324 (+) (-) (-) (-) (-) (-) 
LU526 (-) (-) (-) (-) (-) (+) 
MA309 (-) (-) (-) (-) (-) (-) 
MA310 (-) (-) (-) (-) (-) (+) 
MA37 (+) (-) (-) (-) (-) (-) 
MA541 (+) (-) (-) (-) (-) (+) 
VM306 (-) (-) (-) (-) (-) (+) 
WO22 (+) (-) (-) (-) (-) (+) 
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Figure 2.7  Alignment of parDEPa sequences.  Three of the 13 clinical P. aeruginosa strains identified by PCR to 
contain the parDEPa genes were submitted for DNA sequencing.  Using a ClustalW Multiple Alignment (BLOSUM62 
Matrix) the sequences were aligned with the reference parDEPa sequence from the P. aeruginosa PA01 genome.  Bases 
underlined on the reference sequence indicate the location of the primers used to PCR for the parDEPa genes and bases 
highlighted in bold indicate non-conserved bases.  
 
 
 
Figure 2.8  Alignment of relBEPa sequences.  Four of the 42 clinical P. aeruginosa strains identified by PCR to contain 
the relBEPa genes were submitted for DNA sequencing.  Using a ClustalW Multiple Alignment (BLOSUM62 Matrix) 
the sequences were aligned with the reference relBEPa sequence from the P. aeruginosa PA01 genome.  Bases 
underlined on the reference sequence indicate the location of the primers used to PCR for the relBEPa genes and bases 
highlighted in bold indicate non-conserved bases.  
 
 
 
10        20        30        40        50        60        70        80        90       100 110                   
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
P. aeruginosa PA01 parDEPa GTGTTCCCACAGCAATGGAGGTACCGGCTCATGCGAGTCGAGACAATTAGTTATTTGAAACGTCATGCGGCTGACCTGGATTTATCCGAGCCAATGGTCGTCACGCAGAA 
CI03                      ------------------------------------------------------------------GCGGCTGACCTGGATTTATCCGAGCCAATGGTCGTCACGCAGAA 
CI11                      ------------------------------------------------------------------GCGGCTGACCTGGATTTATCCGAGCCAATGGTCGTCACGCAGAA 
1591                      ------------------------------------------------------------------GCGGCTGACCTGGATTTATCCGAGCCAATGGTCGTCACGCAGAA 
120       130       140       150       160       170       180       190       200       210       220          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
P. aeruginosa PA01 parDEPa CGGTGTTCCTGCCTATGTGGTTGAGTCATATGCTGAGCGGAAGCAGCGCGATGAAGCAATTGCGCTGGTGAAGTTGCTTGCGATTGGCTCCCGCCAGTACGCAGAAGGCA 
CI03                      CGGTGTTCCTGCCTATGTGGTTGAGTCATATGCTGAGCGGAAGCAGCGCGATGAAGCAATTGCGCTGGTGAAGTTGCTTGCGATTGGCTCCCGCCAGTACGCAGAAGGCA 
CI11                      CGGTGTTCCTGCCTATGTGGTTGAGTCATATGCTGAGCGGAAGCAGCGCGATGAAGCAATTGCGCTGGTGAAGTTGCTTGCGATTGGCTCCCGCCAGTACGCAGAAGGCA 
1591                      CGGTGTTCCTGCCTATGTGGTTGAGTCATATGCTGAGCGGAAGCAGCGCGATGAAGCAATTGCGCTGGTGAAGTTGCTTGCGATTGGCTCCCGCCAGTACGCAGAAGGCA 
230       240       250       260       270       280       290       300       310       320       330          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
P. aeruginosa PA01 parDEPa AGCATCGCTCTGTTGATGATTTGAAAGCTCGCCTTTCCAGGAGGTTCGCTCAGCCAGAATAAGGAGGTTTAATGTCCCCGGTCGTCATTCGTTTTACTGATACCGCAGAG 
CI03                      AGCATCGCTCTGTTGATGATTTGAAAGCTCGCCTTTCCAGGAGGTTCGCTCAGCCAGAATAAGGAGGTTTAATGTCCCCGGTCGTCATTCGTTTTACTGATACCGCAGAG 
CI11                      AGCATCGCTCTGTTGATGATTTGAAAGCTCGCCTTTCCAGGAGGTTCGCTCAGCCAGAATAAGGAGGTTTAATGTCCCCGGTCGTCATTCGTTTTACTGATACCGCAGAG 
1591                      AGCATCGCTCTGTTGATGATTTGAAAGCTCGCCTTTCCAGGAGGTTCGCTCAGCCAGAATAAGGAGGTTTAATGTCCCCGGTCGTCATTCGTTTTACTGATACCGCAGAG 
340       350       360       370       380       390       400       410       420       430       440          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
P. aeruginosa PA01 parDEPa CAAAGCATCGAAGACCAAGTCCACCACTTGGCTCCATTCCAAGGTGAACAGGCTGCACTCCAGTCAGTACTGAGCCTTTTGGATGAGATTGAAGAGAAGATTTCACTTGC 
CI03                      CAAAGCATCGAAGACCAAGTCCACCACTTGGCTCCATTCCAAGGTGAACAGGCTGCATTCCAGTCAGTACTGAGCCTTTTGGATGAGATTGAAGAGAAGATTTCACTTGC 
CI11                      CAAAGCATCGAAGACCAAGTCCACCACTTGGTTCCATTCCAAGGTGAACAGGCTGCATTCCAGTCAGTACTGAGCCTTTTGGATGAGATTGAAGAGAAGATTTCACTTGC 
1591                      CAAAGCATCGAAGACCAAGTCCACCACTTGGCTCCATTCCAAGGTGAACAGGCTGCACTCCAGTCAGTACTGAGCCTTTTGGATGAGATTGAAGAGAAGATTTCACTTGC 
450       460       470       480       490       500       510       520       530       540       550          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
P. aeruginosa PA01 parDEPa ACCTAAAGGTTACCCAGTCAGCCAGCAGGCGAGTCTTCTGGGGGTGCTGAGCTATCGCGAGCTTAATACCGGCCCCTATCGTGTTTTTTACGAATTCCACGAAGAGCAAG 
CI03                      ACCTAAAGGTTACCCAGTCAGCCAGCAGGCGAGTCTTCTGGGGGTGCTGAGCTATCGCGAGCTTAATACCGGCCCCTATCGTGTTTTTTACGAATTCCACGAAGAGCAAG 
CI11                      ACCTAAAGGTTACCCAGTCAGCCAGCAGGCGAGTCTTCTGGGGGTGCTGAGCTATCGCGAGCTTAATACCGGCCCCTATCGTGTTTTTTACGAATTCCACGAAGAGCAAG 
1591                      ACCTAAAGGTTACCCAGTCAGCCAGCAGGCGAGTCTTCTGGGGGTGCTGAGCTATCGCGAGCTTAATACCGGCCCCTATCGTGTTTTTTACGAATTCCACGAAGAGCAAG 
560       570       580       590       600       610       620       630             
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|.... Sequence Identity
P. aeruginosa PA01 parDEPa GCGAGGTGGCAGTGATCTTGGTTTTGCGACAGAAGCAGAGCGTTGAGCAGCAATTGATCCGCTACTGCTTGGTGGGGCCAATCGAGTGA 
CI03                      GCGAGGCGGCAGTGATCTTGGTTCTGCGACAGAAGCAGAGCGTTGAGCAGCAATTGATCCGCTACTGCTTG------------------ 99.4%
CI11                      GCGAGGTGGCAGTGATCTTGGTTTTGCGACAGAAGCAGAGCGTTGAGCAGCAATTGATCCGCTACTGCTTG------------------ 99.6%
1591                      GCGAGGTGGCAGTGATCTTGGTTTTGCGACAGAAGCAGAGCGTTGAGCAGCAATTGATCCGCTACTGCTTG------------------ 100%
10        20        30        40        50        60        70        80        90       100       110                   
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
P. aeruginosa PA01 relBEPa ATGAGCACCGTAGTCTCGTTCCGCGCCGATGACGCCCTGGTCGCGGCCCTCGACGAACTGGCCCGCGCCACCCACCGCGACCGACCCTACCACCTGCGGCAGGCGCTCGC 
CI14                      ATGAGCACCGTAGTCTCGTTCCGCGCCGATGACGCCCTGGTCGCGGCCCTCGACGAACTGGCCCGCGCCACCCACCGCGACCGCCCCTACCACCTGCGGCAGGCGCTCGC 
CI15                      ATGAGCACCGTAGTCTCGTTCCGCGCCGATGACGCCCTGGTCGCGGCCCTCGACGAACTGGCCCGCGCCACCCACCGCGACCGCCCGTATCACCTGCGGCAGGCGCTCGC 
997                       ATGAGCACCGTAGTCTCGTTCCGCGCCGATGACGCCCTGGTCGCGGCCCTCGACGAACTGGCCCGCGCCACCCACCGCGACCGCCCGTATCACCTGCGGCAGGCGCTCGC 
2243                      ATGAGCACCGTAGTCTCGTTCCGCGCCGATGACGCCCTGGTCGCGGCCCTCGACGAACTGGCCCGCGCCACCCACCGCGACCGCCCGTATCACCTGCGGCAGGCGCTCGC 
120       130       140       150       160       170       180       190       200       210       220          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
P. aeruginosa PA01 relBEPa GCAGTACCTGGAAAGGCAGCAGTGGCAGGTCGCTGCCATCGATGAAGGCTTGGCCGATGCCAATGCCGGTCGCCTGCTGGAACACATCGAGATCGAGAAGCGCTGGGGGC 
CI14                      GCAGTACCTGGAAAGGCAGCAGTGGCAGGTCGCTGCCATCGATGAAGGCTTGGCCGATGCCAATGCCGGTCGCCTGCTGGAACACACCGAGATCGAGAAGCGCTGGGGGC 
CI15                      GCAGTACCTGGAAAGGCAGCAGTGGCAGGTCGCTGCCATCGATGAAGGCTTGGCCGATGCCAATGCCGGTCGCCTGCTGGAACACACCGAGATCGAGAAGCGCTGGGGGC 
997                       GCAGTACCTGGAAAGGCAGCAGTGGCAGGTCGCTGCCATCGATGAAGGCTTGGCCGATGCCAATGCCGGTCGCCTGCTGGAGCACGCGGAGATCGAGAAGCGCTGGGGGC 
2243                      GCAGTACCTGGAAAGGCAGCAGTGGCAGGTCGCTGCCATCGATGAAGGCTTGGCCGATGCCAATGCCGGTCGCCTGCTGGAGCACGCGGAGATCGAGAAGCGCTGGGGGC 
230       240       250       260       270       280       290       300       310       320       330          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
P. aeruginosa PA01 relBEPa TGCAATGAGCCTGAAGTGGACCCGCAAGGCGGCCGCCGACCTGGACGCCATCTACGACCATTACGTCGTGCTGATCGGCCCGGAAAAAGCTCTGAAAGCCGTTCAGGACA 
CI14                      TGCAATGAGCCTGAAGTGGACCCGCAAGGCGGCCGCCGACCTGGACGCCATCTACGACCATTACGTCGTGCTGATCGGCCCGGAAAAAGCTCTGAAAGCCGTTCAGGACA 
CI15                      TGCAATGAGCCTGAAGTGGACCCGTAAGGCGGCCGCCGACCTGGACGCCATCTACGACCATTACGTCGTGCTGATCGGCCCGGAAAAAGCCCTGAAAGCCGTCCAGGACA 
997                       TGCAATGAGCCTGAAGTGGACCCGTAAGGCGGCCGCCGACCTGGACGCCATCTACGACCATTACGTCGTGCTGATCGGCCCGGAAAAAGCTCTGAAAGCCGTTCAGGACA 
2243                      TGCAATGAGCCTGAAGTGGACCCGTAAGGCGGCCGCCGACCTGGACGCCATCTACGACCATTACGTCGTGCTGATCGGCCCGGAAAAATCTCTGAAAGCCGTTCAGGACA 
340       350       360       370       380       390       400       410       420       430       440          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
P. aeruginosa PA01 relBEPa TCGTCGAGCAGGTGAAACCGCTGCAGCAGGTAGCCAACCAGGGGGCAGGGCGGCCCAGCGAGGTGCCAGGCGTACGCACCCTGACCCTGGAGCGCTGGCCGTTCAGCGCC 
CI14                      TCGTCGAGCAGGTGAAACCGCTGCAGCAGGTAGCCAACCAGGGGGCAGGGCGGCCCAGCGAGGTGCCAGGCGTACGCACCCTGACCCTGGAGCGCTGGCCGTTCAGCGCC 
CI15                      TCGTCGAGCAGGTGAAACCGCTGCAGCAGGTAGCCAACCAGGGGGCAGGGCGGCCCAGCGAGGTGCCAGGCGTACGCACCCTGACCCTGGAGCGCTGGCCGTTCAGCGCC 
997                       TCGTCGAGCAGGTGAAACCGCTGCAGCAGGTAGCCAACCAGGGGGCAGGGCGGCCCAGCGAGGTGCCAGGCGTACGCACCCTGACCCTGAAGCGCTGGCCGTTCAGCGCC 
2243                      TCGTCGAGCAGGTGAAACCGCTGCAGCAGGTAGCCAACCAGGGGGCAGGGCGGCCCAGCGAGGTGCCAGGCGTACGCACCCTGACCCTGAAGCGCTGGCCGTTCAGCGCC 
450       460       470       480       490       500           
....|....|....|....|....|....|....|....|....|....|....|....|....|. Sequence identity
P. aeruginosa PA01 relBEPa CCGTTTCGGGTTAAAGGCAAGGAAATCCAGATTTTGCGCATCGACAGAGTCGAAATTACCCCCTGA 
CI14                      CCGTTTCGGGTTAAAGGCAAGGAAATCCAGATTTTGCGCATCGACAGAGTCGAAATTACCCCCTG- 99.6%
CI15                      CCTTTTCGGGTAAAAGGCAAGGAAATCCAGATTTTGCGCATCGACAGAGTCGAAATTACCCCCTG- 98.2%
997                       CCGTTTCGGGTTAAAGGCAAGGAAATCCAGATTTTGCGCATCGACAGAGTCGAAATTACCCCCTG- 98.2%
2243                      CCGTTTCGGGTTAAAGGCAAGGAAATCCAGATTTTGCGCATCAACAGAGTCGAAATTACCCCCTG- 97.8%
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Figure 2.9  Alignment of higBAPa sequences.  Four of the 42 clinical P. aeruginosa strains identified by PCR to 
contain the higBAPa genes were submitted for DNA sequencing.  Using a ClustalW Multiple Alignment (BLOSUM62 
Matrix) the sequences were aligned with the reference higBAPa sequence from the P. aeruginosa PA01 genome.  Bases 
underlined on the reference sequence indicate the location of the primers used to PCR for the higBAPa genes and bases 
highlighted in bold indicate non-conserved bases.  
Figure 2.10  Alignment of parDEPa upstream (A) and downstream (B) flanking sequences.  The upstream and 
downstream flanking regions of parDEPa were analyzed by PCR amplification and subsequent DNA sequencing.  
Using a ClustalW Multiple Alignment (BLOSUM62 Matrix) the sequences were aligned with the reference upstream 
and downstream sequences from the P. aeruginosa PAO1 genome.  Bases underlined on the reference sequence 
indicate the location of the primers used to PCR for the region between the integrase and parDEPa genes (upstream 
region) and parDEPa and transferase genes (downstream region) and bases highlighted in bold indicate non-conserved 
bases.  
 
A 10         20         30         40         50         60         70         80         90        100        110                             
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 CGGTGATCTT TGCCAACACT AAGTCCAAGC GTGTGCGCTC GGTGCCGATC TCGGAAGAAT TGGGCGCCGA CCTTCGCCGG CATTGGCAGA CCCACGGGCC GTTCACGAAC  
996               CGGTGATCTT TGCCAACACT AAGTCCAAGC GTGTGCGCTC GGTGCCGATC TCGGAAGAAT TGGGCGCCGA CCTTCGCCGG CATTGGCAGA CCCACGGGCC GTTCACGAAC  
999               CGGTGATCTT TGCCAACACT AAGTCCAAGC GTGTGCGCTC GGTGCCGATC TCGGAAGAAT TGGGCGCCGA CCTTCGCCGG CATTGGCAGA CCCACGGGCC GTTCACGAAC  
CI15              CGGTGATCTT TGCCAACACT AAGTCCAAGC GTGTGCGCTC GGTGCCGATC TCGGAAGAAT TGGGCGCCGA CCTTCGCCGG CATTGGCAGA CCCACGGGCC GTTCACGAAC  
120        130        140        150        160        170        180        190        200        210        220                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 TGCCTTGGCG TGTTCCGCCT GGTGCTGCTG TCGACCTCGA TCAAGCTGCC GAAGGGGCAG GCCAGCCACG TACTGCGCCA CACGTTCGCC AGTCACTTCA TCATGAACGG  
996               TGCCTTGGCG TGTTCCGCCT GGTGCTGCTG TCGACCTCGA TCAAGCTGCC GAAGGGGCAG GCCAGCCACG TACTGCGCCA CACGTTCGCC AGTCACTTCA TCATGAACGG  
999               TGCCTTGGCG TGTTCCGCCT GGTGCTGCTG TCGACCTCGA TCAAGCTGCC GAAGGGGCAG GCCAGCCACG TACTGCGCCA CACGTTCGCC AGTCACTTCA TCATGAACGG  
CI15              TGTCTTGGCG TGTTCCGCCT GGTGCTGCTG TCGACCTCGA TCAAGCTGCC GAAGGGGCAG GCCAGCCACG TACTGCGCCA CACGTTCGCC AGTCACTTCA TCATGAACGG  
230        240        250        260        270        280        290        300        310        320        330                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 CGGGCACATC GTGACCCTAC AGCACATCCT GGGGCACGCC TCGTTGTCGA TGACGATGCG ATATGCGCAC CTCTCCCAAG ACCACCTATC TGAGGCTGTT CGATTCAACC  
996               CGGGCACATC GTGACCCTAC AGCACATCCT GGGGCACGCC TCGTTGTCGA TGACGATGCG ATATGCGCAC CTCTCCCAAG ACCACCTATC TGAGGCTGTT CGATTCAACC  
999               CGGGCACATC GTGACCCTAC AGCACATCCT GGGGCACGCC TCGTTGTCGA TGACGATGCG ATATGCGCAC CTCTCCCAAG ACCACCTATC TGAGGCTGTT CGATTCAACC  
CI15              CGGGCACATC GTGACCCTAC AGCACATCCT GGGGCACGCC TCGTTGTCGA TGACGATGCG ATATGCGCAC CTCTCCCAAG ACCACCTATC TGAGGCTGTT CGATTCAACC  
340        350        360        370        380        390        400        410        420        430        440                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 CGCTCATAGG TTGAAGGCTG CGGGGGTCGA CAGAGGGAAA GAAAAATAGA CTTGAGGTGG TTCAAATTCG GTCTGAATTC GGATTATGAT GTTGGAGCCG ACGGTAGACA  
996               CGCTCATAGG TTGAAGGCTG CGGGGGGCGA CAGAGGGAAA GAAAAATAGA CTTGAGGTGG TTCAAATTCG GTCTGAATTC GGATTATGAT GTTGGAGCCG ACGGTAGACA  
999               CGCTCATAGG TTGAAGGCTG CGGGGGTCGA CAGAGGGAAA GAAAAATAGA CTTGAGGTGG TTCAAATTCG GTCTGAATTC GGATTATGAT GTTGGAGCCG ACGGTAGACA  
CI15              CGCTCATAGG TTGAAGGCTG CGGGGGTCGA CAGAGGGAAA GAAAAATAGA CTTGAGGTGG TTCAAATTCG GTCTGAATTC GGATTATGAT GTTGGAGCCG ACGGTAGACA  
450        460        470        480        490        500        510        520        530        540        550                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 GACTGCCGAC GCGCGAATCC CACTCGTCGC CTGGATATGG AGCGTGGTGG AGTTCGAACA CCGTAGAACC TGAGTTCCAG GCCTTAAGTG TTCCCACAGC AATGGAGGTA  
996               GACTGCCGAC GCGCGAATCC CACTCGTCGC CTGGATATGG AGCGTGGTGG AGTTCGAACA CCGTAGAACC TGAGTTCCAG GCCTTAAGTG TTCCCACAGC AATGGAGGTA  
999               GACTGCCGAC GCGCGAATCC CACTCGTCGC CTGGATATGG AGCGTGGTGG AGTTCGAACA CCGTAGAACC TGAGTTCCAG GCCTTAAGTG TTCCCACAGC AATGGAGGTA  
CI15              GACTGCCGAC GCGCGTATCC CACTCGTCGC CTGGATATGG AGCGTGGTGG AGTTCGAACA CCGTAGAACC TGAGTTCCAG GCCTTAAGTG TTCCCACAGC AATGGAGGTA  
560        570        580        590        600        610        620        630        640        650        660                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 CCGGCTCATG CGAGTCGAGA CAATTAGTTA TTTGAAACGT CATGCGGCTG ACCTGGATTT ATCCGAGCCA ATGGTCGTCA CGCAGAACGG TGTTCCTGCC TATGTGGTTG  
996               CCGGCTCATG CGAGTCGAGA CAATTAGTTA TTTGAAACGT CATGCGGCTG ACCTGGACTT ATCCGAGCCA ATGGTCGTCA CGCAAAACGG T--------- ----------
999               CCGGCTCATG CGAGTCGAGA CAATTAGTTA TTTGAAACGT CATGCGGCTG ACCTGGATTT ATCCGAGCCA ATGGTCGTCA CGCAAAACGG TGTTCCTGCC TATGTGGTTG  
CI15              CCGGCTCATG CGAGTCGAGA CAATTAGTTA TTTGAAACGT CATGCGGCTG ACCTGGATTT ATCCGAGCCA ATGGTCGTCA CGCAGAACGG TGTTCCTGCC TATGTGGTTG  
670        680        690      
....|....| ....|....| ....|....| ... Sequence Identity
P. aeruginosa PAO1 AGTCATATGC TGAGCGGAAG CAGCGCGATG AAG 
996               ---------- ---------- ---------- --- 92.6%
999               AGTCATATGC TGAACGGAAG ---------- --- 98.1%
CI15              AGTCATATGC TGAACGGAAG ---------- --- 98.0%
10        20        30        40        50        60        70        80        90       100       110                   
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
P. aeruginosa PAO1 higBAPa ATGATTCTGACCTTTCGCTGCGACGAGACTCGTCAGCTTTTTGAGACGGGTCTTTCGAGGCGGTGGGGAGCGATCCTCACAGTCGCTACGCGTAAGCTCGCAATGCTTCA
CI02                      ----------------------------------------------------------------------------------------------------CAATGCTTCA 
CI19                      ----------------------------------------------------------------------------------------------------CAATGCTTCA 
1174                      ----------------------------------------------------------------------------------------------------CAATGCTTCA 
1591                      ----------------------------------------------------------------------------------------------------CAATGCTTCA 
120       130       140       150       160       170       180       190       200       210       220          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
P. aeruginosa PAO1 higBAPa TGCGGCTACGGAGCTTCGAGACCTGCGCTCTCCACCTGGAAACCGGTTGGAGCCGTTGCAGGGAAAGCGGGCGGGCCAACATAGCATCAGGATCAATGACCAGTGGCGTG 
CI02                      TGCGGCTACGGAGCTTCGAGACCTGCGCTCTCCACCTGGAAACCGGTTGGAGCCGTTGCAGGGAAAGCGGGCGGGCCAACATAGCATCAGGATCAATGACCAGTGGCGTG 
CI19                      TGCGGCTACGGAGCTTCGAGACTTGCGCTCTCCACCTGGAAACCGGTTGGAGCCGTTGCAGGGAAAGCGGGCGGGCCAACATAGCATCAGGATCAATGACCAGTGGCGTG 
1174                      TGCGGCTACGGAGCTTCGAGACTTGCGCTCTCCACCTGGAAACCGCTTGGAGCCGTTGCAGGGAAAGCGGGCGGGCCAACATAGCATCAGGATCAATGACCAGTGGCGTG 
1591                      TGCGGCTACGGAGCTTCGAGACTTGCGCTCTCCACCTGGAAACCGGTTGGAGCCGTTGCAGGGAAAGCGGGCGGGCCAACATAGCATCAGGATCAATGACCAGTGGCGTG 
230       240       250       260       270       280       290       300       310       320       330          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
P. aeruginosa PAO1 higBAPa TCTGTTTCGTCTGGACGGATGCGGGTCCCGAAGAAGTCGAAATAGTTGATTACCACTGAGGAGGTGGACCATGGCTACCAATGGTATGCGCCCCATCCATCCTGGGGAAA 
CI02                      TCTGTTTCGTCTGGACGGATGCGGGTCCCGAAGAAGTCGAAATAGTTGATTACCACTGAGGAGGTGGACCATGGCTACCAATGGTATGCGCCCCATCCATCCTGGGGAAA 
CI19                      TCTGTTTCGTCTGGACGGATGCGGGTCCCGAAGAAGTCGAAATAGTTGATTACCACTGAGGAGGTGGACCATGGCTACCAATGGTATGCGCCCCATCCATCCTGGGGAAA 
1174                      TCTGTTTCGTCTGGACGGATGCGGGTCCCGAAGAAGTCGAAATAGTTGATTACCACTGAGGAGGTGGACCATGGCTACCAATGGTATGCGCCCCATCCATCCTGGGGAAA 
1591                      TCTGTTTCGTCTGGACGGATGCGGGTCCCGAAGAAGTCGAAATAGTTGATTACCACTGAGGAGGTGGACCATGGCTACCAATGGTATGCGCCCCATCCATCCTGGGGAAA 
340       350       360       370       380       390       400       410       420       430       440          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
P. aeruginosa PAO1 higBAPa TATTGCGCGATGAGTTTCTGATGGAGTTTGATATCTCTCCAGCTGCTCTAGCACGCGCTTTGAAAGTCTCCGCTCCGACAGTGAACGATATCGTTCGTGAGCAGCGTGGT 
CI02                      TATTGCGCGATGAGTTTCTGATGGAGTTTGATATCTCTCCAGCTGCTCTAGCACGCGCTTTGAAAGTCTCCGCTCCGACAGTGAACGATATCGTTCGTGAGCAGCGTGGT 
CI19                      TATTGCGCGATGAGTTTCTGATGGAGTTGGATATCTCTCCAGCTGCTCTAGCACGCGCTTTGAAAGTCTCCGCTCCGACAGTGAACGATATCGTTCGTGAGCAGCGTGGT 
1174                      TATTGCGCGATGAGTTTCTGATGGAGTTGGATATCTCTCCAGCTGCTCTAGCACGCGCTTTGAAAGTCTCCGCTCCGACAGTGAACGATATCGTTCGTGAGCAGCGTGGT 
1591                      TATTGCGCGATGAGTTTCTGATGGAGTTGGATATCTCTCCAGCTGCTCTAGCACGCGCTTTGAAAGTCTCCGCTCCGACAGTGAATGATATCGTTCGTGAGCAGCGTGGT 
450       460       470       480       490       500       510       520       530       540       550          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
P. aeruginosa PAO1 higBAPa ATCTCCGCAGATATGGCGATTCGTCTGGGGCGTTACTTTGATACGTCCGCTCAGTTCTGGATGAATCTCCAGAGTGAGTATTCGTTAGCAACTGCTTATGCGGCGAATGG
CI02                      ATCTCCGCAGATATGGCGATTCGTCTGGGGCGTTACTTTGATACGTCCGCTCAGTTCTGGATGAATCTCCAGAGTGAGTATTCGTTAGCAACTGCTTATGCGGCGAATGG 
CI19                      ATCTCCGCAGATATGGCGATTCGTCTGGGGCGTTACTTTGATACGTCCGCTCAGTTCTGGATGAATCTCCAGAGTGAGTACTCGTTAGCAACTGCTTATGCGGCGAATGG 
1174                      ATCTCCGCAGATATGGCGATTCGTCTGGGGCGTTACTTTGATACGTCCGCTCAGTTCTGGATGAATCTCCAGAGTGAGTACTCGTTAGCAACTGCTTATGCGGCGAATGG 
1591                      ATCTCCGCAGATATGGCGATTCGTCTGGGGCGTTACTTTGATACGTCCGCTCAGTTCTGGATGAATCTCCAGAGTGAGTATTCGTTAGCAACTGCTTATGCGGCGAATGG 
560       570       580       590         
....|....|....|....|....|....|....|....|....|. Sequence identity
P. aeruginosa PAO1 higBAPa CAAGCAGATCGAACATGAGATTGAGCCGCTGCTTGCTCACGGATAG 
CI02                      CAAGCAGATCGAACATGAG--------------------------- 100%
CI19                      CAAGCAGATCGAACATGAG--------------------------- 99.3%
1174                      CAAGCAGATCGAACATGAG--------------------------- 99.1%
1591                      CAAGCAGATCGAACATGAG--------------------------- 99.3%
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Figure 2.11  Alignment of relBEPa upstream (A) and downstream (B) flanking sequences.  The upstream and 
downstream flanking regions of relBEPa were analyzed by PCR amplification and subsequent DNA sequencing.  Using 
a ClustalW Multiple Alignment (BLOSUM62 Matrix) the sequences were aligned with the reference upstream and 
downstream sequences from the P. aeruginosa PAO1 genome.  Bases underlined on the reference sequence indicate the 
location of the primers used to PCR for the region between the transcriptional regulator and relBEPa genes (upstream 
region) and relBEPa and hypothetical protein genes (downstream region) and bases highlighted in bold indicate non-
conserved bases.  
 
 
 
 
 
 
B 10         20         30         40         50         60         70         80         90        100        110                             
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 TGAGTCTTCT GGGGGTGCTG AGCTATCGCG AGCTTAATAC CGGCCCCTAT CGTGTTTTTT ACGAATTCCA CG-AAGAGCA AGG---CGAG GTG-GCAG-- ---TGATCTT  
CI07              TGAGTCTTCT GGGGGTGCTG AGCTATCGCG AGCTTAATAC CGGGCCCTAG CGTGTTTTTT ACGAATTCCA CGTAAGAGCA AGGTCGCGAG ATGAGCAGAT GTATCGTTGC
CI09              TTAGTCTTCT GGGGGTGCTG AGCTATCGCG AGCTTAATAA CGGCCCCTAT CGTGGTTTTT ACGAATTCCA CGTAATAGCA AGGTCGTAGG ATGAGCAGAT GTATGATCTT  
120        130        140        150        160        170        180        190        200        210        220                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 GGTTTTGCGA CAGAAGCAGA GCGTTGAGCA GCAATTGATC CG-CTACT-G CTTGGTGGGG CCAATCG-AG TGATGGCTTT CTACTCCTGA GCATGTAGCG CTGAATGCGC  
CI07              GCTTTTGCGA CAGAAGCAGA GCGTTGAGCA GCAATTGATC CGTCTACTTG CTTGGTGGGG CCAATCGTAG TGATGGATTT CTACTCCTGA GCATGTAGCG CTGAGTGCGC  
CI09              GGTTTTGCGA CAGAAGCAGA GCGTTGAGCA GCAATTGATC CGTCTACTTG CTTGGTGGGG CCAATCGTAG TGATGGATTT CTACTCCTGA GCATGTAGCG CTGAGTGCGC  
230        240        250        260        270        280        290        300        310        320        330                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 CTCGACACTT CTTCGACACC TTTCCTTCCC CCAAAAAGCA AAGCCCCCGA AACGCTAGGC ATTTCAGGGG CTTGGCAGGG TGATTTGGAG CGGGCGAAGG GAATCGAACC  
CI07              TTCGACACTT CTTCGACACC TTTCCTTCCC CCAAAAAGCA AAGCCCCCGA AACGCTAGGC ATTTCAGGGG CTTGGCAGGG TGATTTGGAG CGGGCGAAGG GAATCGAACC  
CI09              TTCGACACTT CTTCGACACC TTTCCTTCCC CCAAAAAGCA AAGCCCCCGA AACGCTAGGC ATTTCAGGGG CTTGGCAGGG TGATTTGGAG CGGGCGAAGG GAATCGAACC  
340        350        360        370        380        390        400        410        420        430        440                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 CTCGTCATGA GCTTGGGAAG CTCAGGTAAT GCCATTATAC GACGCCCGCT CGGACGGCTT TTGCGGCCAG GGCGCCTTTT TACCAGATGC GCGGCGGCAG GTGAAGCCCG  
CI07              CTCGTCATGA GCTTGGGAAG CTCAGGTAAT GCCATTATAC GACGCCCGCT CGGATGGCTT TTGCGGCCAG GGCGCCTTTT TACCAGATGC GCGGCGGCAG GTGAAGCCCG  
CI09              CTCGTCATGA GCTTGGGAAG CTCAGGTAAT GCCATTATAC GACGCCCGCT CGGATGGCTT TTGCGGCCAG GGCGCCTTTT TACCAGATGC GCGGCGGCAG GTGAAGCCCG  
450        460        470        480        490        500        510        520        530        540        550                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 GGGCGGGGTT TTTGTTGATT TCGCTGGGTT TTTCCGCCAG GGGAGCGGGG CTCCCCGTGG CGGTGGCGGT TAGCTGGCGA GGGCGGCGAG GGGGACGCTG GCGCCGTTGG  
CI07              GGGCGGGGTT TTTGTTGATT TCGCTGGGTT TTTCCGCCAG GGGAGCGGGG CTCCCCGTGG CGGTGGCGGT TAGCTGGCGA GGGCGGCGAG GGGGACGCTG GCGCCGTTGG  
CI09              GGGCGGGGTT TTTGTTGATT TCGCTGGGTT TTTCCGCCAG GGGAGCGGGG CTCCCCGTGG CGGTGGCGGT TAGCTGGCGA GGGCGGCGAG GGGGACGCTG GCGCCGTTGG  
560        570        580        590        600        610        620        630        640        650        660                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 GCTGGGG-GC GGTAGATCGG GTTGA-GCGG CTGCGTGCGC TGCGGGCGGA GGAAGGCCAG -CAGGGCGT- CCTGGGT-CT GCTGCCAGGC GGCCTTGTGC TCGACGTCGA  
CI07              GCTGGGGAGC GGTAGATCGG GTTGATGCGG CTGCGTGCGC TGCGGGCGGA GGAAGGCCAG ACAGGGCGTT CCTGGGTACT GTTGCCAGGC GGCCTTGTGC TCGACGTCAA  
CI09              GCTGGGGAGC GGTAGATCGG GTTGATGCGG CTGCGTGCGC TGCGGGCGGA GGAAGGCCAG ACAGGGCGTT CCTGGGTACT GTTGCCAGGC GGCCTTGTGC TCGACGTCAA  
670        680        690
....|....| ....|....| ....|....| ....|. Sequence Identity
P. aeruginosa PAO1 TGAAGTGGCC GGCATTGCGG ATGGTGTGGA ATTCC
CI07              TTAAGTGGCC CGCATTGCGG AAGGTGTGGA ATTCC 98.2%
CI09              TTAGATGGCC GGCATTGCGA ATGGTGTGGA ATTCC 97.5%
A                            10         20         30         40         50         60         70         80         90      100        110                             
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 CCGGAAAAAG CGCGAGAAAG CGTGCCCAGC GGGCGAGGTC GTCGGGTTTC GGAAAAATAC GGACGCATAT GGGAGCGAAG CATGAGTCAG CCAAAGAACT AATCAGGTCG  
CI01              CCGGAAAAAG CGCGAGAAAG CATGCCCAGC GGGCGAGGTC GTCGAGTTAC GGAAAAATAC GGACGCGTAT GGGAGCGAAG CATGAGTCAG CCAAAGAACT AATCAGGTCG  
CI13              CCGGAAAAAG CGCGAGAAAG CATGCCCAGC GGGCGAGGTC GTCGAGTTAC GGAAAAATAC GGACGCGTAT GGGAGCGAAG CATGAGTCAG CCAAAGAACT AATCAGGTCG  
997               CCGGAAAAAG CGCGAGAAAG CATGCCCAGC GGGCGAGGTC GTCGGGTTTC GGAAAAATAC GGATGCGTAT GGGAGCGAAG CATAAGTCAG TTAAAGAACT AATCAGGTTG  
1001              CCGGAAAAAG CGCGAGAAAG CATGCCCAGC GGGCGAGGTC GTCGGGTTAC GGAAAAATAC GGACGCGTAT GGGAGCGAAG CATGAGTCAG CCAAAGAACT AATCAGGTCG  
120        130        140        150        160        170        180        190        200        210        220                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 CAGTGGTCGC AAGTTGGTCG CTCTCATTGG TCTGGTCGAA AAATGTCCAT TTTTTGTGAT TTATGGATGT TTTGTCCGAA ATAAGCTACT CAGTACAAGT CAAGGGAAAT  
CI01              CAGTGGTCGC ATGATTGTCG CTCTCATTGG TCAGGTCGAA AAATGTCCAT TTTTTGTGAG TTATGGATGT TTCGTCCGAA ATAATTCACT ACGTACAAGT CAAGGGAAAT  
CI13              CAGTGGTCGC AAGTTGGTCG CCCTCATTGG CCCGGTCGAA AAATGTCCAT TTTTTGTGAG TTATGGATGT TTTGTCCGAA GTAAGCTACT CAGTACAAGT CAAGGGAAAT  
997               AAGTGGTCGC AAGTTGGTCG CTCTCATTTG TCTGGTCGAA AAATGTCCAT TTCTTGTGAG TTATGGATGT TTTGTCCGAA ATAGGTCACT ACGTACAAGT CAAGGTAAAT  
1001              CAGGTGTCGC AAGATTGTCG CCCTCATTGG CCCGGTCGAA AAATGTCCAT TTTTTGTGAG TTATGGATGT TTTGTCCGAA ATAAGCTACT CAGTACAAGT CAAGGGAAAT  
230        240        250        260        270        280        290        300        310        320        330                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 ATTCATTTTG AAACATCTTG TAACCGTGTG ACCACTTTCA GGGGGTAATT TCGACTCTGT CGATGCGCAA AATCTGGATT TCCTTGCCTT TAACCCGAAA CGGGGCGCTG  
CI01              ATTCATTTTG AAACATCTTG TAACCGTGTG ACCACTTTCA GGGGGTAATT TCGACCCTGT CGATGCGCAA AATCTGGATT TCCTTGCCTT TAACCCGAAA CGGGGCGCTG  
CI13              ATTCATTTTG AAACATCTTG TAACCGTGTG ACCACTTTCA GGGGGTAATT TCGACCCTGT CGATGCGCAA AATCTGGATT TCCTTGCCTT TAACCCGAAA CGGGGCGCTG  
997               ATTCGTTTTG AAATATCTTG TAACCGTGTG ACCACTTTCA GGGGGTAATT TCGACTCTGT CGATGCGCAA AATCTGGATT TCCTTGCCTT TAACCCGAAA CGGGGCGCTG  
1001              ATTCATTTTG AAACATCTTG TAACCGTGTG ACCACTTTCA GGGGGTAATT TCGACCCTGT CGATGCGCAA AATCTGGATT TCCTTGCCTT TAACCCGAAA CGGGGCGCTG  
340        350        360        370        380        390        400        410        420        430        440                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 AACGGCCAGC GCTCCAGGGT CAGGGTGCGT ACGCCTGGCA CCTCGCTGGG CCGCCCTGCC CCCTGGTTGG CTACCTGCTG CAGCGGTTTC ACCTGCTCGA CGATGTCCTG  
CI01              AACGGCCAGC GCTCCAGGGT CAGGGTGCGT ACGCCTGGCA CCTCGCTGGG CCGCCCTGCC CCCTGGTTGG CTACCTGCTG CAGCGGTTTC ACCTGCTCGA CGATGTCCTG  
CI13              AACGGCCAGC GCTCCAGGGT CAGGGTGCGT ACGCCTGGCA CCTCGCTGGG CCGCCCTGCC CCCTGGTTGG CTACCTGCTG CAGCGGTTTC ACCTGCTCGA CGATGTCCTG  
997               AACGGCCAGC GCTTCAGGGT CAGGGTGCGT ACGCCTGGCA CCTCGCTGGG CCGCCCTGCC CCCTGGTTGG CTACCTGCTG CAGCGGTTTC ACCTGCTCGA CGATGTCCTG  
1001              AACGGCCAGC GCTCCAGGGT CAGGGTGCGT ACGCCTGGCA CCTCGCTGGG CCGCCCTGCC CCCTGGTTGG CTACCTGCTG CAGCGGTTTC ACCTGCTCGA CGATGTCCTG  
450        460        470        480        490        500        510        520        530        540                          
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....  Identity
P. aeruginosa PAO1 AACGGCTTTC AGAGCTTTTT CCGGGCCGAT CAGCACGACG TAATGGTCGT AGATGGCGTC CAGGTCGGCG GCCGCCTTGC GGGTCCACTT CAGGCTCATT GCAGCCCCC
CI01              AACGGCTTTC AGAGCTTTTT CCGGGCCGAT CAGCACGACG TAATGGTCGT AGATGGCGTC CAGGTCGGCG GCCGCCTTGC GGGTCCACTT CAGGCTCATT GCAGCCCCC    97.1%
CI13              AACGGCTTTC AGAGCTTTTT CCGGGCCGAT CAGCACGACG TAATGGTCGT AGATGGTGTC CAGGTCGGCG GCCGCCTTGC GGGTCCACTT CAGGCTCATT GCAGCCCCC    98.0%
997               AACGGCTTTC AGAGCTTTTT CCGGGCCGAT CAGCACGACG TAATGGTCGT AGATGGCGTC CAGGTCGGCG GCCGCCTTAC GGGTCCACTT CAGGCTCATT GCAGCCCCC    96.2%
1001              GACGGCTTTC AGAGCTTTTT CCGGGCCGAT CAGCACGACG TAATGGTCGT AGATGGCGTC CAGGTCGGCG GCCGCCTTGC GGGTCCACTT CAGGCTCATT GCAGCCCCC    97.6%
58 
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B 10         20         30         40         50         60         70         80         90        100 110                             
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 GTGCTCATTT TCTGATCAAC TTCGTTTTCG ATGTATACGG TGTTTACAGT GAAAACGAAT GTATACGAAA GCTTTCGGGC GAGCAATCGC CCGGCTGTTT CGTCCGTCGA  
1001         GTGCTCATTT TCTGATCAAC TTCGTTTTCG ATGTATACGG TGTTTACAGT GAAAACGAAT GTATACGAAA GCTTTCGGGC GAGCAATCGC CCGGCTGTTT CGTCCGTCGA 
999          GTGCTCATTT TCTGATCAAC TTCGTTTTCG TTGTATACGG TGTTTACAGT GAAAACGAAT GTATACGAAA GCCCTCGGGC GAGCAATCGC CAGGCTGTTT CGTCCGACGA  
CI06         GTGCTCATTT TCTGATCAAC TTCGTTTTCG TTGTATACGG TGTTTACAGT GAAAACAAAT GTATACGAAA GCCCTCGGGC GAGCAATCGC CAGGCTGTTT CGTCCGACGA  
CI16         GTGCTCATTT TCTGATCAAC TTCGTTTTCG TTGTATACGG TGTTTACAGT GAAAACAAAT GTATACGAAA GCCCTCGGGC GAGCAATCGC CAGGCTGTTT CGTCCGACGA  
120        130        140        150        160        170        180        190        200        210 220                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 GAAAACCTTT ATCGATCAGT GGGTTGAATG AGGAGCCCGC CCCGAGCGGG GCGGGCGGAA GGACGGCGTT GGATTACCAG GCCTGGTTGA AGTGGAAGCC CTGCCTGGGC
1001         AAAAACCTTT ATCGATCAGT GGGTTGAATG AGGAGCCCGC CCCGAGCGGG GCGGGCGGAA GGACGGCGTG GGATTACCAG GCCTGGTTGA AGTGGAAGCC CTGCCTGGGC  
999          AAAAACCTTT ATCGATCAGT GGGTTGAATG AGGAGCCCGC CCCGAGCGGG GCGGGCGGAA GGGTGGCGCG GGATTACCAG GCCTGGTTGA AGTGGAAGCC CTGCCTGGGC  
CI06         AAAAACCTTT ATCGATCAGT GGGTTGAATG AGGAGCCCGC CCCGAGCGGG GCGGGCGGAA GGGGGGCGCG GGATTACCAG GCCTGGTTGA AGTGGAAGCC CTGCCTGGGC  
CI16         AAAAACCTTT ATCGATCAGT GGGTTGAATG AGGAGCCCGC CCCGAGCGGG GCGGGCGGAA GGGGGGCGCG GGATTACCAG GCCTGGTTGA AGTGGAAGCC CTGCCTGGGC  
230        240        250        260        270        280        290        300        310        320 330                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 GAGAAGCGGG TGTTGACGAG CTTGTAGCCT TCCTCGCCGC GTGGCTTGAC CAGCGAGACC TGGCCGACCT GCGGTTGGGT GATCTGTTGC AGGGTGGTCA GGCTGGCCTG
1001         GAGAAGCGGG TGTTGACGAG CTTGTAGCCT TCCTCGCCGC GTGGCTTGAC CAGCGAGACC TGGCCGACCT GCGGTTGGGT GATCTGTTGC AGGGTGGTCA GGCTGGCCTG  
999          GAGAAGCGGG TGTTGACGAG CTTGTAGCCT TCCTCGCCGC GTGGCTTGAC CAGCGAGACC TGGCCGACCT GCGGTTGGGT GATCTGTTGC AGGGTGGTCA GGCTGGCCTG  
CI06         GAGAAGCGGG TGTTGACGAG CTTGTAGCCT TCCTCGCCGC GTGGCTTGAC CAGCGAGACC TGGCCGACCT GCGGTTGGGT GATCTGTTGC AGGGTGGTCA GGCTGGCCTG  
CI16         GAGAAGCGGG TGTTGACGAG CTTGTAGCCT TCCTCGCCGC GTGGCTTGAC CAGCGAGACC TGGCCGACCT GCGGTTGGGT GATCTGTTGC AGGGTGGTCA GGCTGGCCTG  
340        350        360        370        380        390        400        410        420        430 440                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 CTTGAGCACC TCGGGGTTCT TCGCCCAGTC CTTCACTTCG CGTGGCTTGA CCTCGACGGT GACCAACCAG CCCTTTTCCA CGGCCGGGCC GTAGTCGTCG GGCTTGGCGG
1001         CTTGAGCACC TCGGGGTTCT TCGCCCAGTC CTTCACTTCG CGTGGCTTGA CCTCGACGGT GACCAACCAG CCCTTTTCCA CGGCCGGGCC GTAGTCGTCG GGCTTGGCGG  
999          CTTGAGCACC TCGGGGTTCT TCGCCCAGTC CTTCACTTCG CGTGGCTTGA CCTCGACGGT GACCAACCAG CCCTTTTCCA CGGCCGGGCC GTAGTCGTCG GGCTTGGCGG  
CI06         CTTGAGCACC TCGGGGTTCT TCGCCCAGTC CTTCACTTCG CGTGGCTTGA CCTCGACGGT GACCAACCAG CCCTTTTCCA CGGCCGGGCC GTAGTCGTCG GGCTTGGCGG  
CI16         CTTGAGCACC TCGGGGTTCT TCGCCCAGTC CTTCACTTCG CGTGGCTTGA CCTCGACGGT GACCAACCAG CCCTTTTCCA CGGCCGGGCC GTAGTCGTCG GGCTTGGCGG  
450        460        470        480        490        500        510        520        530        540 550                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 GGTCCACCGA ACGGACGCTG ACGTCGAAGC CGCTGCTGTA GCAGAAGGCC TTCGACTCGG GCTTGTAGTC CTCGCGGCCG GCGGGCGTGA GGTCGTAGGA ATCGCCGTCG
1001         GGTCCACCGA ACGGACGCTG ACGTCGAAGC CGCTGCTGTA GCAGAAGGCC TTCGACTCGG GCTTGTAGTC CTCGCGGCCG GCGGGCGTGA GGTCGTAGGA ATCGCCGTCG  
999          GGTCCACCGA ACGGACGCTG ACGTCGTAAC CGCTGCTGTA GCAGAAGGCC TTCGACTCGG GCTTGTAGTC CTCGCGGCCG GCGGGCGTGA GGTCGTAGGA ATCGCCGTCG  
CI06         GGTCCACCGA ACGGACGCTG ACGTCGAAGC CGCTGCTGTA GCAGAAGGCC TTCGACTCGG GCTTGTAGTC CTCGCGGCCG GCGGGCGTGA GGTCGTAGGA ATCGCCGTCG  
CI16         GGTCCACCGA ACGGACGCTG ACGTCGAAGC CGCTGCTGTA GCAGAAGGCC TTCGACTCGG GCTTGTAGTC CTCGCGGCCG GCGGGCGTGA GGTCGTAGGA ATCGCCGTCG  
560        570        580        590        600        610        620        630        640           
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| .. Sequence Identity
P. aeruginosa PAO1 CGGCGCAGCA GGCCGACGCC GACCAGCGCG TCGTAGACCG CGGCGTTGCC TTTCGCCGGG CCGGGGCCGG AGAAGCTGTC GGAGAGCGTC AC 
1001         CGGCGCAGCA GGCCGACGCC GACCAGCGCG TCGTAGACCG CGGCGTTGCC TTTCGCCGGG CCGGGGCCGG AGAAGCTGTC GGAGAGCGTC -- 99.4%
999          CGGCGCAGCA GGCCGACGCC GACCAGCGCG TCGTAGACCG CGGCGTTGCC TTTCGCCGGG CCGGGGCCGG AGAAGCTGTC GGACAGCATC AC 97.8%
CI06         CGGCGCAGCA GGCCGACGCC GACCAGCGCG TCGTAGACCG CGGCGTTGCC TTTCGCCGGG CCGGGGCCGG AGAAGCTGTC GGAGAGCGTC AC 98.3%
CI16         CGGCGCAGCA GGCCGACGCC GACCAGCGCG TCGTAGACCG CAGCGTTGCC TTTCGCCGGG CCGGGGCCGG AGAAGCTGTC GGAGAGCGTC AC 98.1%
59 
Figure 2.12  Alignment of higBAPa upstream (A) and downstream (B) flanking sequences.  The upstream and 
downstream flanking regions of higBAPa were analyzed by PCR amplification and subsequent DNA sequencing.  Using 
a ClustalW Multiple Alignment (BLOSUM62 Matrix) the sequences were aligned with the reference upstream and 
downstream sequences from the P. aeruginosa PAO1 genome.  Bases underlined on the reference sequence indicate the 
location of the primers used to PCR for the region between the hypothetical protein and higBAPa genes (upstream 
region) and higBAP and Ton-B dependent receptor genes (downstream region) and bases highlighted in bold indicate 
non-conserved bases.  
 
  
 
 
 
 
 
 
 
 
 
A 10         20         30         40         50         60         70         80         90        100        110                             
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1  GATCCGACCC CTTCCGTCTA AACGATTGAA AGATCAGAAA ATTATCTAGC CCCAGGGGTT GACAGCCCCG CCCGAGATAC GGAAAATGCG CGCCACTCGG CTACATAGCT  
1000              ---------- ---------- ---------- --ATCAGAAA ATTATATAGG CCCAGGGGTT GACAGCCCCG CCCGAGATAC GGAAAATGCG CGCCACTCGG CTACATAGCT  
CI14              ---------- ---------- ---------- --ATCAGAAA ATTATCTAGC CCCAGGGGTT GACAGCCCCG CCCGAGATAC GGAAAATGCG CGCCACTCGG CTACATAGCT  
1283              ---------- ---------- ---------- ---------- --------GG CCCGGGGGTT GACAGCCCCG CCCGAGATAC GGAAAATGCG CGCCACTCGG CTACATAGCT  
2242              ---------- ---------- ---------- --ATCAGAAA ATTATCTAGC CCCAGGGGTT GACAGCCCCG CCCGAGATAC GGAAAATGCG CGCCACTCGG CTACATAGCT  
120        130        140        150        160        170        180        190        200        210        220                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 CAGTCGGTTA GAGCGCAGCA TTCATAATGC TGATGTCCCA GGTTCAAGTC CCGGTGTAGC CACCATATTT TTCAAGGGGT TAGCGCAAGC TAACCCCTTT TTGTTTTGGT  
1000              CAGTCGGTTA GAGCGCAGCA TTCATAATGC TGATGTCCCA GGTTCAAGTC CCGGTGTAGC CACCATATTT TTCAAGGGGT TAGCGCAAGC TAACCCCTTT TTGTTTTGGT  
CI14              CAGTCGGTTA GAGCGCAGCA TTCATAATGC TGATGTCCCA GGTTCAAGTC CCGGTGTAGC CACCATATTT TTCAAGGGGT TAGCGCAAGC TAACCCCTTT TTGTTTTGGT  
1283              CAGTCGGTTA GAGCGCAGCA TTCATAATGC TGATGTCCCA GGTTCAAGTC CCGGTGTAGC CACCATATTT TTCAAGGGGT TAGCGCAAGC TAACCCCTTT TTGTTTTGGT  
2242              CAGTCGGTTA GAGCGCAGCA TTCATAATGC TGATGTCCCA GGTTCAAGTC CCGGTGTAGC CACCATATTT TTCAAGGGGT TAGCGCAAGC TAACCCCTTT TTGTTTTGGT  
230        240        250        260        270        280        290        300        310        320        330                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 CGGCAGACTA CAAACCGACT ACAAACCGTC TACGCCCCCC TTTACCGATT TACGGTTCGC ATAAAAAAGC CCCGCATCTG CGGGGCTCTA CGATCAACGT CACTGCTATC  
1000              CGGCAGACTA CAAACCGTCT AC-------- ---GCCCCCC TTTACCGATT TACGGTTCGC ATAAAAAAGC CCCGCATCTG CGGGGCTCTA CGATCAACGT CACCGCTATC  
CI14              CGGCAGACTA CAAACCGACT ACAAACCGTC TACGCCCCCC TTTACCGATT TACGGTTCGC ATAAAAAAGC CCCGCATCTG CGGGGCTCTA CGATCAACGT CACTGCTATC  
1283              CGGCAGACTA CAAACCGACT ACAAACCGTC TACGCCCCCC TTTACCGATT TACGGTTCGC ATAAAAAAGC CCCGCATCTG CGGGGCTCTA CGATCAACGT CACTGCTATC  
2242              CGGCAGACTA CAAACCGACT ACAAACCGTC TACGCCCCCC TTTACCGATT TACGGTTCGC ATAAAAAAGC CCCGCATCTG CGGGGCTCTA CGATCAACGT CACTGCTATC  
340        350        360        370        380        390        400        410        420        430        440                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 CGTGAGCAAG CAGCGGCTCA ATCTCATGTT CGATCTGCTT GCCATTCGCC GCATAAGCAG TTGCTAACGA ATACTCACTC TGGAGATTCA TCCAGAACTG AGCGGACGTA  
1000              CGTGAGCAAG CAGCGGCTCA ATCTCATGTT CGATCTGCTC GCCATTCGCC GCATAAGCAG TTGCTAACGA ATACTCACTC TGGAGATTCA TCCAGAACTG AGCGGACGTA  
CI14              CCTGAGCAAG CAGCGGCTCA ATCTCATGTT CGATCTGCTT GCCATTCGCC GCATAAGCAG TTGCTAACGA ATACTCACTC TGGAGATTCA TCCAGAACTG AGCGGACGTA  
1283              CGTGAGCAAG CAGCGGCTCA ATCTCATGTT CGATCTGCTT GCCATTCGCC GCATAAGCAG TTGCTAACGA ATACTCACTC TGGAGATTCA TCCAGAACTG AGCGGACGTA  
2242              CGTGAGCAAG CAGCGGCTCA ATCTCATGTT CGATCTGCTT GCCATTCGCC GCATAAGCAG TTGCTAACGA ATACTCACTC TGGAGATTCA TCCAGAACTG AGCGGACGTA  
450        460        470        480        490        500        510        520        530        540        550                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 TCAAAGTAAC GCCCCAGACG AATCGCCATA TCTGCGGAGA TACCACGCTG CTCACGAACG ATATCGTTCA CTGTCGGAGC GGAGACTTTC AAAGCGCGTG CTAGAGCAGC  
1000              TCAAAGTAAC GCCCCAGACG AATCGCCATA TCTGCGGAGA TACCACGCTG CTCACGAACG ATATCATTCA CTGTCGGAGC GGAGACTTTC AAAGCGCGTG CTAGAGCAGC  
CI14              TCAAAGTAAC GCCCCAGACG AATCGCCATA TCTGCGGAGA TACCACGCTG CTCACGAACG ATATCGTTCA CTGTCGGAGC GGAGACTTTC AAAGCGCGTG CTAGAGCAGC  
1283              TCAAAGTAAC GCCCCAGACG AATCGCCATA TCTGCGGAGA TACCACGCTG CTCACGAACG ATATCGTTCA CTGTCGGAGC GGAGACTTTC AAAGCGCGTG CTAGAGCAGC  
2242              TCAAAGTAAC GCCCCAGACG AATCGCCATA TCTGCGGAGA TACCACGCTG CTCACGAACG ATATCGTTCA CTGTCGGAGC GGAGACTTTC AAAGCGCGTG CTAGAGCAGC  
560        570        580        590        600        610        620        630        640        650        660                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 TGGAGAGATA TCAAACTCCA TCAGAAACTC ATCGCGCAAT ATTTCCCCAG GATGGATGGG GCGCATACCA TTGGTAGCCA TGGTCCACCT CCTCAGTGGT AATCAACTAT  
1000              TGGAGAGATA TCCAACTCCA TCAGAAACTC ATCGCGCAAT ATTTCCCCAG GATGGATGGG GCGCATACCA TTGGTAGCCA TGGTCCACCT CCTCAGTGGT AATCAACTAT  
CI14              TGGAGAGATA TCCAACTCCA TCAGAAACTC ATCGCGCAAT ATTTCCCCAG GATGGATGGG GCGCATACCA TTGGTAGCCA TGGTCCACCT CCTCAGTGGT AATCAACTAT  
1283              TGGAGAGATA TCCAACTCCA TCAGAAACTC ATCGCGCAAT ATTTCCCCAG GATGGATGGG GCGCATACCA TTGGTAGCCA TGGTCCACCT CCTCAGTGGT AATCAACTAT  
2242              TGGAGAGATA TCCAACTCCA TCAGAAACTC ATCGCGCAAT ATTTCCCCGG GATGGATGGG GCGCATACCA TTGGTAGCCA TGGTCCACCT CCTCAGTGGT AATCAACTAT  
670        680        690        700        710        720        730        740        750        760        770                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 TTCGACTTCT TCGGGGACCC GCATCCGTCC AGACGAAACA GACACGCCAC TGGTCATTGA TCCTGATGCT ATGTTGGCCC GCCCGCTTTC CCTGCAACGG CTCCAACCGG  
1000              TTCGACTTCT TCGGG-ACCC GCATCCGTCC AGACGAAACA GACACGCCAC TGGTCATTGA TCCTGATGCT ATGTTGGCCC GCCCGCTTTC CCTGCAACGG CTCCAACCGG  
CI14              TTCGACTTCT TCGGG-ACCC GCATCCGTCC AGACGAAACA GACACGCCAC TGGTCATTGA TCCTGATGCC ATGTTGGCCC GCCCGCTTTC CCTGCAACGG CTCCAACCGG  
1283              TTCGACTTCT TCGGG-ACCC GCATCCGTCC AGACGAAACA GACACGCCAC TGGTCATTGA TCCTGATGCT ATGTTGGCCC GCCCGCTTTC CCTGCAACGG CTCCAACCCG  
2242              TTCGACTTCT TCGGG-ACCC GCATCCGTCC AGACGAAACA GACACGCCAC TGGTCATTGA TCCTGATGCT ATGTTGGCCC GCCCGCTTTC CCTGCAACGG CTCCAACCGG  
780        790        800        810        820          
....|....| ....|....| ....|....| ....|....| ....|....| …               Sequence Identity
P. aeruginosa PAO1 TTTCCAGGTG GAGAGCGCAG GTCTCGAAGC TCCGTAGCCG CATGAAGCAT TGC 
1000              TTTCCAGGTG GAGAGCGCAA GTCTCGAAGC TCCGTAG--- ---------- --- 91.8%
CI14              TTTCCAGGTG GAGAGCGCAG GTCTCGAAGC TCCGTAG--- ---------- --- 93.7%
1283              TTTCGGGGTG GAGAGCGCAG GTCTCGAAGC TCC------- ---------- --- 91.0%
2242TTTCCAGGTG GAGAGCGCAG GTCTCGAAGC TCCGTAG--- ---------- --- 93.8%
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Figure 2.12 (cont.) 
 
 
Figure 2.13  Alignment of relBE-1Ab sequences.  Three of the 21 clinical A. baumannii strains identified by PCR to 
contain the relBE-1Ab genes were submitted for DNA sequencing.  Using a ClustalW Multiple Alignment (BLOSUM62 
Matrix) the sequences were aligned with the reference relBE-1Ab sequence from the A. baumannii ACICU genome.  
Bases highlighted in bold on the reference sequence indicate the location of the primers used to PCR for the relBE-1Ab 
genes.   
 
B 10         20         30         40         50         60         70         80         90        100        110                             
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 CAGGTGGAGA GCGCAGGTCT CGAAGCTCCG TAGCCGCATG AAGCATTGCG AGCTTACGCG TAGCGACTGT GAGGATCGCT CCCCACCGCC TCGAAAGACC CGTCTCAAAA  
CI05              CAGGTGGAGA GCGCAGGTCT CGAAGCTCCG TACCCGCATG AAGCATTGCG AGCTTACGCG TAGCGACTGT GAGGATCGCT CCCCACCGCC TCGAAAGACC CGTCTCAAAA  
CI11              --------GA GCGCAGGTCT CGAAGCTCCG TAGCCGCATG AAGCATTGCG AGCTTACGCG TAGCGACTGT GAGGATCGCT CCCCACCGCC TCGAAAGACC CGTCTCAAAA  
1000              ---------- ---------- ---------G TAGCCGCATG AAGCATTGCG AGCTTACGCG TAGCGACTGT GAGGATCGCT CCCCACCGCC TCGAAAGACC CGTCTCAAAA  
1284              --------GA GCGCAGGTCT CGAAGCTCCG TAGCCGCATG AAGCATTGCG AGCTTACGCG TAGCGACTGT GAGGATCGCT CCCCACTGCC TCGAAAGACC CGTCTCAAAA  
120        130        140        150        160        170        180        190        200        210        220                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 AGCTGACGAG TCTCGTCGCA GCGAAAGGTC AGAATCATTC ATTAACCCTT AACGTTAAGC GTTAACTTCA CTACAGATTA CCACAGATCC TCATGTGGTC AATTTGTAGC  
CI05              AGCTGACGAG TCTCGTCGCA GCGAAAGGTC AGAATCATTC ATTAACCCTT AACGTTAAGC GTTAACTTCA CTATAGATTA CCACAGATCC TCATGTGGTC AATTTGTAGC  
CI11              AGCTGACGAG TCTCGTCGCA GCGAAAGGTC AGAATCATTC ATTAACCCTT AACGTTAAGC GTTAATTTCA CTACAGACTA CCACAGATCC TCATGTGGTC AATTTGTAGC  
1000              AGCTGACGAG TCTCGTCGCA GCGAAAGGTC AGAATCATTC ATTAACCCTT AACGTTAAGC GTTAACTTCA CTACAGATTA CCACAGATCC TCATGTGGTC AATTTGTAGC  
1284              AGCTGACGAG CCTCGTCGCA GCGAAAGGTC AGAATCATTC ATTAACTCTT AACGTTAAGC GTTAACTTCA CTACAGATTA CCACAGATCC TCATGTGGTC AATTTGTAGC  
230        240        250        260        270        280        290        300        310        320        330                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 CAGACTGAGT AATCGGAGAA AAGCGCATCG CCGATTCCAA GTGCTCCGGC GACAGATGTG CATACCGCAT CATCATCGAG GAATGCCCGA GGATCCGCTG TAGGGCCACG  
CI05              CAGACTGAGT AATCGGAGAA AAGCGCATCG CCGATTCCAA GTGCTCCGGC GACAGATGTG CATACCGCAT CATCATCGAG GAATGCCCGA GGATCCGCTG TAGGGCCACG  
CI11              CAGACTGAGT AATCGGAGAA AAGCGCATCG CCGATTCCAA GTGCTCCGGC GACAGATGTG CATACCGCAT CATCATCGAG GAATGCCCGA GAATCCGCTG TAGGGCCACG  
1000              CAGACTGAGT AATCGGAGAA AAGCGCATCG CCGATTCCAA GTGCTCCGGC GTTAGGTGCG CATACCGCAT CGTCATCGAG GAATGCCCGA GGATCCGCTG TAGGGCCACG  
1284              CAGACTGAGT AATCGGAGAA AAGCGCATCG CCGATTCCAA GTGCTCCGGC GTTAGGTGCG CATACCGCAT CGTCATCGAG GAATGCCCGA GGATCCGCTG TAGGGCCACG  
340        350        360        370        380        390        400        410        420        430        440                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 CCATGCGCAG CGCCCCGTGT CAGGCATTTC ATCTTGCTTT GGATGCCAGG CATGCCTCAT TGAAACAGTT CGAATCATTT GATAATCATT ATCGATTTGT TTAGCTTTGC  
CI05              CCATGCGCAG CGCCCCGTGT CAGGCATTTC ATCTTGCTTT GGATGCCAGG CATGCCTCAT TGAAACAGTT CGAATCATTT GATAATCATT ATCGATTTGT TTAGCTTTGC  
CI11              CCATGCGCAG CGCCCCGTGT CAGGCATTTC ATCTTGCTTT GGATGCCAGG CATGCCTCAT TGAAACAGTT CGAATCATTT GATAATCATT ATCGATTTGT TTAGCTTTGC  
1000              CCATGCGCAG CGCCCCGTGT CAGGCATTTC ATCTTGCTTT GGAAGCCAGG CATGCCTCAT TGAAACAGTT CGAATCATTT GATAATCATT ATCGATTTGT TTAGCTTTGC  
1284              CCATGCGCAG CGCCCCGTGT CAGGCATTTC ATCTTGCTTT GGAAGCCAGG CATGCCGCAT TGAAACAGTT CGAATCATTT GATAATCATT ATCGATTTGT TTAGCTTTGC  
450        460        470        480        490        500        510        520        530        540        550                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 CGCCCATCAA AACAACAGCA ACTCGGAAAT CTCCTCATGC CCCGCTCCAT CCCTTTGCGC CCGGCTCCCC TGGCGCTTTC CCTGTCCCTC TTCGCTTCGT TTTCCGCTCC  
CI05              CGCCCATCAA AACAACAGCA ACTCGGAAAT CTCCTCATGC CCCGCTCCAT CCCTTTGCGC CCGGCTCCCC TGGCGCTTTC CCTGTCCCTC TTCGCTTCGT TTTCCGCTCC  
CI11              CGCCCATCAA AACAACAGCA ACTCGGAAAT CTCCTCATGC CCCGCTCCAT CCCTTTGCGC CCGGCTCCCC TGGCGCTTTC CCTGTCCCTC TTCGCTTCGT TTTCCGCTCC  
1000              CGCCCATCAA AACAACAGCA ACTCGGACAT CTCCTCATGC CCCGCTCCAT CCCTTCGCGC CCGGCTCCCC TGGCGCTTTC CCTGTCCCTT TTCGCTTCGT TTTCCGCTCC  
1284              CGCCCATCAA AACAACAGCA ACTCGGACAT TTCCTCATGC CCCGCTCCAT CCCTTCGCGC CCGGCTCCCC TGGCGCTTTC CCTGTCCCTC TTCGCTTCGT TTTCCGCTCC  
560        570        580        590        600        610        620        630        640        650        660                    
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
P. aeruginosa PAO1 TGCGCTGGCT GCCGATCCGG TGGAGCAGCA GATGGTGGTG ATCGGCTCGC GCGCGCCGAC CAGCATCAGC GAGTTGCCCG GCACGGTCTG GGTGATCGAG CGCGAGCAAC  
CI05              TGCGCTGGCT GCCGATCCGG TGGAGCAGCA GATGGTGGTG ATCGGCTCGC GCGCGCCGAC CAGGATCAGC GAGTTGCCCG GCACGGTCTG GGTGATCGAG CGCGAGCAAC  
CI11              TGCGCTGGCT GCCGATCCGG TGGAGCAGCA GATGGTGGTG ATCGGCTCGC GCGCGCCGAC CAGCATCAGC GAGTTGCCCG GCACGGTCTG GGTGATCGAG CGCGAGCAAC  
1000              TGCGCTGGCT GCCGATCCGG TGGAGCAGCA GATGGTGGTG ATCGGCTCGC GCGCGCCGAC CAGCATCAGC GAGTTGCCCG GCACGGTCTG GGTGATCGAG CGCGAGCAAC  
1284              TGCGCTGGCT GCCGATCCGG TGGAGCAGCA GATGGTGGTG ATCGGCTCGC GCGCGCCGAC CAGCATCAGC GAGTTGCCCG GCACGGTCTG GGTGATCGAA CGCGAGCAAC  
670        680        690        700        710          
....|....| ....|....| ....|....| ....|....| ....|....| ... Sequence identity
P. aeruginosa PAO1 TGGACCAGCA GACCCAGGCC GGCGTGCCGC CGAAGGAGGC GTTGGGACAA TTG
CI05              TGGACCAGCA GACCCAGGCC GGCGTGCCGC CGAAGGAGGC GTTGGGACAA TTG 99.4
CI11              TGGACCAGCA GACCCAGGCC GGCGTGCCGC CGAAGGAGGC GTTGGGACAA TTG 98.2
1000              TGGACCAGCA GACCCAGGCC GGCGTGCCGC C--------- ---------- --- 91.6
1284              TGGACCAGCA GACCCAGGCC GGCGTGCCGC CGAAGGAGGC GTTGGG---- --- 95.7
10        20        30        40        50        60        70        80        90       100       110                   
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
A. baumannii ACICU relBE-1Ab ATGAGAAACGTCATGAACCACATAATCCATAGTCGATTTGTGGCTAGTGTTTCTGAATTAAAAAAGAATCCTACAGCAGTTGTACAAAATGCTTTTGGCGAAGCAGTAGC 
KB342                       ATGAGAAACGTCATGAACCACATAATCCATAGTCGATTTGTGGCTAGTGTTTCTGAATTAAAAAAGAATCCTACAGCAGTTGTACAAAATGCTTTTGGCGAAGCAGTAGC 
LU324                       ATGAGAAACGTCATGAACCACATAATCCATAGTCGATTTGTGGCTAGTGTTTCTGAATTAAAAAAGAATCCTACAGCAGTTGTACAAAATGCTTTTGGCGAAGCAGTAGC 
MA541                       ATGAGAAACGTCATGAACCACATAATCCATAGTCGATTTGTGGCTAGTGTTTCTGAATTAAAAAAGAATCCTACAGCAGTTGTACAAAATGCTTTTGGCGAAGCAGTAGC 
120       130       140       150       160       170       180       190       200       210       220          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
A. baumannii ACICU relBE-1Ab TATTCTGAATAGAAATAATCCAGAATTCTACTGTGTTCCGGCAGCAATGTATGAACGCATGATGGATCTAATTGAAGATCAGGAACTAATTAAACTAGCCGAGCAAGTTG 
KB342                       TATTCTGAATAGAAATAATCCAGAATTCTACTGTGTTCCGGCAGCAATGTATGAACGCATGATGGATCTAATTGAAGATCAGGAACTAATTAAACTAGCCGAGCAAGTTG 
LU324                       TATTCTGAATAGAAATAATCCAGAATTCTACTGTGTTCCGGCAGCAATGTATGAACGCATGATGGATCTAATTGAAGATCAGGAACTAATTAAACTAGCCGAGCAAGTTG 
MA541                       TATTCTGAATAGAAATAATCCAGAATTCTACTGTGTTCCGGCAGCAATGTATGAACGCATGATGGATCTAATTGAAGATCAGGAACTAATTAAACTAGCCGAGCAAGTTG 
230       240       250       260       270       280       290       300       310       320       330          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
A. baumannii ACICU relBE-1Ab ATACTGACGAAACTGTGAAGGTATCTATTAATGAGTTACGAGCTAGAGTTCTCAAAAACAGCTCTTAAAAAGTTTGACAAACTTAACCCACAAATCGCTGAGCAGTTTAT 
KB342                       ATACTGACGAAACTGTGAAGGTATCTATTAATGAGTTACGAGCTAGAGTTCTCAAAAACAGCTCTTAAAAAGTTTGACAAACTTAACCCACAAATCGCTGAGCAGTTTAT 
LU324                       ATACTGACGAAACTGTGAAGGTATCTATTAATGAGTTACGAGCTAGAGTTCTCAAAAACAGCTCTTAAAAAGTTTGACAAACTTAACCCACAAATCGCTGAGCAGTTTAT 
MA541                       ATACTGACGAAACTGTGAAGGTATCTATTAATGAGTTACGAGCTAGAGTTCTCAAAAACAGCTCTTAAAAAGTTTGACAAACTTAACCCACAAATCGCTGAGCAGTTTAT 
340       350       360       370       380       390       400       410       420       430       440          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
A. baumannii ACICU relBE-1Ab TCGTAAGCTGGAAGCAATCCTAGATAACCCTAAGATACCGAAGAATAAGCTGAGAGGATCAGTTGATCTATATAAGATTAAACTGAAATCAGCAGGATACCGCCTTTTAT 
KB342                       TCGTAAGCTGGAAGCAATCCTAGATAACCCTAAGATACCGAAGAATAAGCTGAGAGGATCAGTTGATCTATATAAGATTAAACTGAAATCAGCAGGATACCGCCTTTTAT 
LU324                       TCGTAAGCTGGAAGCAATCCTAGATAACCCTAAGATACCGAAGAATAAGCTGAGAGGATCAGTTGATCTATATAAGATTAAACTGAAATCAGCAGGATACCGCCTTTTAT 
MA541                       TCGTAAGCTGGAAGCAATCCTAGATAACCCTAAGATACCGAAGAATAAGCTGAGAGGATCAGTTGATCTATATAAGATTAAACTGAAATCAGCAGGATACCGCCTTTTAT 
450       460       470       480       490       500       510            
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|.. Sequence identity
A. baumannii ACICU relBE-1Ab ATCAAGTCAAGGATGATGTAGTCGTAGTTCTTGTTCTTGATGTAGATAGGCGAGATGTTATCTATAAACAGATGTGA 
KB342                       ATCAAGTCAAGGATGATGTAGTCGTAGTTCTTGTTCTTGATGTAGATAGGCGAGAT--------------------- 100%
LU324                       ATCAAGTCAAGGATGATGTAGTCGTAGTTCTTGTTCTTGATGTAGATAGGCGAGAT--------------------- 100%
MA541                       ATCAAGTCAAGGATGATGTAGTCGTAGTTCTTGTTCTTGATGTAGATAGGCGAGAT--------------------- 100%
61 
Figure 2.14  Alignment of ζAb sequences.  Two of the 18 clinical A. baumannii strains identified by PCR to contain the 
ζA gene were submitted for DNA sequencing.  Using a ClustalW Multiple Alignment (BLOSUM62 Matrix) the 
sequences were aligned with the reference ζA sequence from the A. baumannii pACICU plasmid.  Bases highlighted in 
bold on the reference sequence indicate the location of the primers used to PCR for the ζAb gene.   
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Ab
10        20        30        40        50        60        70        80        90       100       110                   
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
A. baumannii pACICU2 ζAb ATGGTAACAAATAATTTTGAAAATTCTCTAAATTCTAGTTTGAATTCGGAAGAAAACATTAATCAACAATTTACTCAATTTGTAGATAAGTATTTTAGTTTTTCTAAAGC
KB357                      ------------------------------------------------------------------------------------------------------------GC 
MA309                      ------------------------------------------------------------------------------------------------------------GC 
120       130       140       150       160       170       180       190       200       210       220          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
A. baumannii pACICU2 ζAb TTTAGCTGTTAGTCAAGAAACTCCAACAGCTATATTAACTGTGGGTACTCATGATTCAGGTAAAGACGTAATCGTTGCACAAGCACAAGATGAATTAAATAAAAAAGGTG 
KB357                      TTTAGCTGTTAGTCAAGAAACTCCAACAGCTATATTAACTGTGGGTACTCATGATTCAGGTAAAGACGTAATCGTTGCACAAGCACAAGATGAATTAAATAAAAAAGGTG 
MA309                      TTTAGCTGTTAGTCAAGAAACTCCAACAGCTATATTAACTGTGGGTACTCATGATTCAGGTAAAGACGTAATCGTTGCACAAGCACAAGATGAATTAAATAAAAAAGGTG 
230       240       250       260       270       280       290       300       310       320       330          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
A. baumannii pACICU2 ζAb GTTCAATTTTAATTGACCAATCAATTTTTAAAGTTGCGGATCCGCAACAAGATAAAGACCATTCAATTCATCAATTGATTTCTACTATTAGTAATGAAAAATATAATTTG 
KB357                      GTTCAATTTTAATTGACCAATCAATTTTTAAAGTTGCGGATCCGCAACAAGATAAAGACCATTCAATTCATCAATTGATTTCTACTATTAGTAATGAAAAATATAATTTG 
MA309                      GTTCAATTTTAATTGACCAATCAATTTTTAAAGTTGCGGATCCGCAACAAGATAAAGACCATTCAATTCATCAATTGATTTCTACTATTAGTAATGAAAAATATAATTTG 
340       350       360       370       380       390       400       410       420       430       440          
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
A. baumannii pACICU2 ζAb CTTTTAAATCATGAATTTAAAAATGAAAATGTTTTAAATGATATTACTGAATCGCTTAAGAGTAAAAATTATACGATTGAAATCAGAGCAGTTTCTTCATTCCCCCCTAA 
KB357                      CTTTTAAATCATGAATTTAAAAATGAAAATGTTTTAAATGATATTACTGAATCGCTTAAGAGTAAAAATTATACGATTGAAATCAGAGCAGTTTCTTCATTCCCCCCTAA 
MA309                      CTTTTAAATCATGAATTTAAAAATGAAAATGTTTTAAATGATATTACTGAATCGCTTAAGAGTAAAAATTATACGATTGAAATCAGAGCAGTTTCTTCATTCCCCCCTAA 
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....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
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....|....|....|....|....|....|....|....|....|....|....|.... Sequence identity
A. baumannii pACICU2 ζAb AAATTTACTCAAACATGCGTAATGATGAAGGGGTATGGAACCAAAAAAAGCTGGTTTAA 
KB357                      AAATTTACTCAAACATGCGTAATGATGAAGGGGTATGGAACCAAAAAAAGCTGG----- 100%
MA309                      AAATTTACTCAAACATGCGTAATGATGAAGGGGTATGGAACCAAAAAAAGCTGG----- 100%
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CHAPTER 3 
TARGETING RELBE AS AN ANTIBACTERIAL STRATEGY 
 
3.1 INTRODUCTION 
 The RelBE toxin-antitoxin system was first discovered in Escherichia coli and 
homologues of it have been identified on many other bacterial chromosomes and plasmids [5, 13, 
18, 20, 23, 26, 32, 33].  The relB gene encodes a 9.07 kDa labile antitoxin protein that inhibits the 
toxic activity of the relE-encoded metabolically-stable 11.2 kDa toxin by direct protein-protein 
interaction [1, 13, 27].  The RelB antitoxin is susceptible to proteolysis by the Lon protease, with 
a half-life of ~15 min [8].  The relBE operon structure follows the TA system paradigm, in which 
the relB stop codon and relE start codon overlap, as described in Section 1.3.4.  Additionally, 
transcriptional repression is autoregulated by the antitoxin RelB and the toxin RelE acts as a co-
repressor by increasing the DNA binding affinity of the antitoxin [13, 16, 25]. 
The highly sensitive transcriptional regulation phenomenon employed by the relBE 
system is called “conditional  cooperativity,”  which  describes  the  cooperative  binding  of  TA  
complexes to the operator DNA that can only occur under proper stoichiometric relationships 
between the toxin and antitoxin [3, 25].  Various levels of transcriptional autoregulation are 
achieved, dependent upon the ratio of proteins present.  If RelB forms a dimer, the RelB2 
complex will repress transcription; however if RelE is present in sufficient concentrations to bind 
the RelB dimer, the RelB2RelE complex will bind tightly and cooperatively to the operator to 
further repress transcription [25].  Moreover, if RelE levels greatly exceed RelB, binding of RelE 
to the RelB2RelE complex forms RelB2RelE2, which is destabilized from the promoter, allowing 
transcription to proceed [25].  Modeling of the crystal structure of the fully RelE-saturated 
RelB2RelE2 complex with the operator DNA showed that the distance between the two operator 
sites would not allow the RelB2RelE2 complex to bind, providing further evidence for the 
conditional cooperativity phenomenon [2].  The sensitivity of this transcriptional control system 
ensures low level of toxin under normal conditions and also allows for fast response to amino 
acid starvation [3].   
During steady state growth, the relBE promoter is severely repressed, but onset of amino 
acid starvation results in a rapid and significant increase in relBE transcription [3, 8, 13, 25].  As 
diagrammed in Figure 3.1, Lon protease-mediated degradation of RelB is required for both 
induction of relBE transcription and for activation of the ribonuclease activity of RelE by 
relieving the inhibition by RelB [7, 8, 24].  Interestingly, Lon protease is also activated by the 
stringent response [31], and it has been proposed that Lon is specifically activated to degrade  
65 
 
 
antitoxins involved in the stringent response [12].  Upon release from its inactive complex, RelE 
associates with the ribosome and mediates sequence-specific cleavage of mRNAs in the 
ribosomal A site (Figure 3.1); thus, RelE is a ribosome-dependent mRNA interferase, 
preferentially cleaving stop codons (UAG > UAA > UGA) and the sense codons UCG and CAG 
[6, 11, 28].  Translation arrest is reversed by RelB neutralization of RelE and rescue of stalled 
ribosomes by tmRNA, which tags polypeptides for degradation, increasing the supply of amino 
acids  
The X-ray crystal structure of E. coli RelBE (Figure 3.2C) is a heterotetramer, in which 
two RelB molecules dimerize via an N-terminal leucine-zipper like motif.  The C-terminus of 
RelB wraps around the surface of RelE, forming extensive intermolecular electrostatic and 
hydrophobic interactions [2, 17, 30].  Examination of the interactions of E. coli RelE and a C-
terminal region of RelB, RelBC (Lys47-Leu79) using an intrinsic tryptophan fluorescence assay to 
determine the KD of RelBC for wild-type RelE to be 154 nM [17].  Additionally, the NMR 
structure of a reduced-activity mutant RelER81A/R83A and its complex with RelBC were solved 
(Figures 3.2A and B).  In the free RelER81A/R83A structure, the C-terminal  α4-helix is in a closed 
position,  forming  contacts  with  the  β-strand core domain [17].  A highly conserved cluster of 
positively charged residues adjacent to this interface contains the putative mRNA binding site.  
Binding of RelBC to RelER81A/R83A displaces the RelER81A/R83A α4-helix, creating an open 
conformation, which is expected to be responsible for RelE inhibition[17].  In addition to 
occupying the active site, the binding of RelB to RelE may also preclude entry of RelE into the 
ribosomal A site [17]  
 
 
Figure 3.1  Genetic organization and 
components of the E. coli relBE operon.  
The relB promoter that is autoregulated by 
RelB and by the RelBE complex.  The 
hexameric protease (green) cleaves free and 
toxin-bound RelB.  The large and small 
ribosomal subunits are shown in purple and 
green, respectively.  In the ribosomal A 
site, RelE mediates cleavage between the 
2nd and 3rd bases of the UAA stop codon.  
tmRNA (orange) enters the A site and 
delivers an alanine to the growing peptide 
chain via trans-translation, thus rescuing 
the stalled ribosome.  Figure adapted from 
[8].   
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Figure 3.2  Structures of RelER81A/R83A, RelBC- RelER81A/R83A, RelB2RelB2 and RelE in a ribosome.  (A) Ribbon 
representation of the NMR structure of E. coli RelER81A/R83A showing   the  β-sheet  core   surrounded  by   four  α-helices. 
The  interface  between  the  β-sheet  core  and  α4-helix forms the mRNA binding and cleavage site [17].  (B) Binding of 
RelBC (red) displaces of RelER81A/R83A (blue)   α4   helix,   neutralizing   the  mRNA  binding   site [17].  (C) X-ray crystal 
structure of the E. coli RelB-RelE complex.  RelB (red) wraps around RelE (blue) forming extensive electrostatic and 
hydrophobic contacts.  The N-terminal   α-helices of RelB form a leucine zipper motif-like structure, comprising the 
DNA-binding domain (structure from [2]).  (D) Crystal structure of the precleavage complex of the 70S ribosome from 
T. thermophilus with the two subunits surrounding RelE in the A site (structure from [22]).  
 
Although RelE contains an RNA binding site, the canonical catalytic triad observed in the 
well characterized RNase SA is not conserved in RelE [16].  However, RelE displays the similar 
microbial RNase fold [16].  Interestingly, RelE is unable to cleave free mRNA, but RelE-
mediated cleavage occurs when both mRNA and RelE are associated with the ribosome [28].  
Indeed, crystal structures of E. coli RelE and Thermus thermophilus 70S ribosomes before and 
after mRNA cleavage showed that both RelE and the ribosome are required for mRNA cleavage 
(Figure 3.2D) [22].  The crystal structure revealed that RelE interacts closely with conserved 
regions of the 16S rRNA and that conserved basic side chains on RelE interact with the phosphate 
backbone of the mRNA, inducing a conformational change in the mRNA that is stabilized by 
stacking with bases in the 16S rRNA [22].  Thus, the 16S rRNA supplies the missing interactions 
necessary to properly orient the mRNA for cleavage by RelE [22].   
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The well-studied RelBE-mediated stringent response has been shown to induce a 
temporary RelE-dependent metabolically-dormant state until the supply of amino acids is 
replenished, at which point the cells recover due to inhibition of RelE by RelB.  This 
phenomenon has become the paradigm for the cell stasis model.  However, the inherent toxicity 
of RelBE has been shown by its ability to stabilize an unstable plasmid in bacterial culture [13].  
Furthermore, overexpression of RelE results in a drastic and significant inhibition of protein 
synthesis and cell viability (Figure 3.3) [8, 27].  Thus, the artificial activation of RelBE would 
likely result in cell death and thus is a viable antibacterial strategy.   
Figure 3.3  RelE inhibits protein synthesis and cell growth.  (A) Induction of RelE alone on a low-copy number 
plasmid under control of the lac promoter rapidly inhibits protein synthesis, but has minimal effect on DNA and RNA 
synthesis (figure from [8]).  (B) Expression of RelE alone, but not the inactive mutant RelER81A, from a low-copy 
number plasmid under control of the arabinose promoter causes a significant decrease in viable cell counts (figure from 
[27]).    
 
The prevalence of relBE in clinical isolates further supports this strategy.  The relBE 
locus was found in 35/75 VRE clinical isolates [20], a homologue relBEPa was identified in 42/42 
P. aeruginosa isolates [32], and another homologue, relBE-1Ab was detected in 21/39 A. 
baumannii clinical samples (Section 2.2.1) (Figure 3.4).  The epidemiological data combined 
with the extensive knowledge of RelBE role in the cell and structure lends great support for its 
exploitation as an antibacterial target.  This chapter describes efforts towards identifying a 
molecule capable of modulating the interaction between RelB and RelE, employing the strategies 
of high-throughput screening, peptide fragment analysis and phage-displayed peptide library 
screens. 
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3.2 HIGH THROUGHPUT SCREEN FOR RELBE DISRUPTORS USING PHOTONIC-
CRYSTAL BIOSENSOR 
Given that RelE is a ribosome-dependent ribonuclease, we reasoned that full disruption 
from RelB was required for activation of RelE.  Thus, a high-throughput screen of 170,000 small 
molecules was undertaken to identify compounds capable of disrupting the RelB-RelE complex.  
To perform the screen in vitro, a sensitive, high-throughput assay was employed using the 
photonic crystal (PC) biosensor.   
3.2.1 Development of PC biosensor for use in a high-throughput screen 
PC biosensors are a recently developed technology that enables the highly sensitive 
detection of biomolecules binding to its surface [4, 9, 10].  The PC biosensor is formed by the 
periodic grating of a subwavelength surface structure comprised of dielectric low and high 
refractive index material.  When illuminated with white light, the subwavelength structure allows 
for the coupling of discrete wavelengths of light, resulting in the formation a standing wave from 
which constructive interference results in reflected light at the resonant wavelength (Figure 3.5).  
The reflected light is reported as a peak wavelength value (PWV) shift.  Reflectance is modulated 
by the composition of the media above the biosensor, thus binding of biomolecules to the surface 
of the biosensor causes an increase in the PWV of the reflected light.  The biosensor is 
functionalized with streptavidin and a biotin-tris-nitrilotriacetic acid (BTN) linker that can be 
charged with Ni2+, facilitating the binding of His-tagged proteins.  Stripping of the Ni2+ with 
EDTA removes the His-tagged protein, allowing for the reuse of the PC biosensor.  This design, 
when used in 384-well microplate format, greatly facilitates the applicability of this technology to 
high-throughput screening [4, 14]. 
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Figure 3.4  Prevalence of relBE TA system 
in three collections of clinical isolates.  The 
relBE TA system was detected by PCR in 
100% of P. aerugniosa [32], 53% of A. 
baumannii and 47% of vancomycin-
resistant enterococci (VRE) [20].  
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Figure 3.5  Photonic crystal biosensor.  (A) Schematic of the PC biosensor. A broadband LED illuminates the crystal 
surface from the bottom; reflected light is gathered and transferred to a spectrometer which measures the peak 
wavelength value.  (B) Image of the PC biosensor films adhered to the bottom of black 384-well plates (figure from 
[4]). 
 
 All assays performed using the PC biosensor plate follow the same general protocol [4, 
14].  An initial baseline PWV shift is measured (Figure 3.6A).  Following each step described 
hereafter, the PWV shift is measured.  Assay buffer containing Ni2+ is added to charge the BTN 
(Figure 3.6B), and the plate is washed.  Protein is then added to the plate and incubated for 30 
minutes (Figure 3.6C) to achieve maximal binding and excess protein is removed in subsequent 
washing.  The BTN surface is regenerated by addition of buffer containing EDTA to remove the 
His6-tagged protein (Figure 3.6D) 
 
3.2.2 Dose-dependent binding of RelBE to the PC biosensor 
The RelBE complex is expressed and purified as a His6 fusion protein in E. coli, with the 
His-tag on the C-terminus of RelE.  To assess the PWV shift in response to RelBE binding of the 
sensor,  concentrations  ranging  from  100μg/mL  to  2mg/mL  were  tested.    The  absence of binding 
in control wells lacking Ni2+ confirms that RelBE binding is specific to Ni2+-NTA (Figure 3.6).  
Monitoring the PWV shift every 30 seconds revealed that binding plateaus approximately 25-30 
minutes after addition of RelBE, as indicated by a leveling off of the PWV shift.  Dose dependent 
binding of RelBE to the biosensor was observed, with a minimal PWV shift of 0 nm for 100 
μg/mL  RelBE  and  1.28nm  for  the  highest  concentration,  2mg/mL (Figure 3.6).  A PWV shift of 
~1 nm is desired to give a robust signal without saturating the biosensor surface; thus, subsequent 
experiments will be carried out using 0.05mg/mL RelBE, which resulted in a 1.10 nm shift.   
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Figure 3.7  Quantification of RelBE(His)6 
deposited on PC biosensor. 2 μM (500 μg/mL) 
RelBE(His)6 was added to the charged 
biosensor plate and eluted with EDTA 
stripping buffer. Eluted protein was analyzed 
as 1X, 5X ,10X solutions by SDS-PAGE 
alongside known amounts of RelBE(His)6 and 
visualized by Western blot (A) or Sypro Ruby 
Stain (B).  Densitometry analysis using Image 
J software revealed that approximately 150 ng 
RelBE(His)6 binds the PC biosensor (~170 nM 
in a standard 40 μL well volume).  
 
Figure 3.6  Schematic and graphical data representation of the PC biosensor assay.  A PC biosensor surface coated 
with biotin (purple spheres) is functionalized with a biotin-tris-NTA linker.  Measurement of this surface establishes 
the baseline, as shown on the graph.  Addition of Ni2+ causes a slight bulk increase in the PWF shift, which is restored 
to baseline after a wash (B).  Addition of 0.001 – 2 mg/mL RelBE(His)6 results in a dose-dependent increase in PWV 
shift as the protein immobilizes (C) and binding stabilizes within approximately 35 minutes.  A wash step removes 
excess protein and reveals that binding is saturated at approximately 0.1 mg/mL.  The optimal PWV shift for the 
protein surface is 1 nm, so 0.05 mg/mL RelBE(His)6 is optimal.  Addition of EDTA chelates the Ni2+ and strips the 
protein (E) restoring the PWV shift to baseline.  
 
3.2.3 Quantification of (His)6RelBE bound to the biosensor surface 
Although  approximately  2  μg  (40μL  of  0.5mg/mL)  of  RelBE(His)6 was added to the 
biosensor plate, only a small fraction bound the BTN-Ni2+ on the surface.  To quantify the 
amount of RelBE(His)6 bound to the chip, 0.05 mg/mL RelBE(His)6 was added and allowed to 
bind for at least 30 minutes.  After the wells were washed, EDTA stripping buffer was added and 
the plate was incubated overnight.  The protein eluted from the BTN was collected and 
concentrated.  Various concentrations of eluted RelBE(His)6 were subjected to tris-tricine 
polyacrylamide gel electrophoresis and visualized by both post-staining with Sypro Ruby protein  
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dye and a gradient of RelBE(His)6 ranging from 1 to 750 ng was included for reference.  ImageJ 
was used to perform densitometry analysis of known amounts of RelBE(His)6 and the protein 
eluted from the BTN revealed that approximately 150ng of the RelBE added binds to the sensor 
(Figure 3.7), which is 0.75% of the total amount loaded.   
 
3.2.4 High-throughput screen preparation 
The screen was performed using 384-well format PC biosensor plates.  The High-
Throughput Screening Facility on campus houses the Chembridge, HTSF and Marvel libraries, 
which contain 150,000, 4700, and 10,000 compounds, respectively.  Compounds were tested at 
100 μM  and  were multiplexed at 10 compounds per well.  RelBE(His)6 was added to the plate at a 
concentration of 2 μM  (approximately  0.05 mg/mL) of which 200 nM (approximately 150 ng) 
binds the plate, thus compounds will be in ~500-fold excess over RelBE.  The plates were 
incubated at room temperature for at least 12 hours and then washed to remove compound and 
protein.  Finally, the PWV shift was determined to assess disruption.  To determine a hit 
compound, two values were compared:  the PWV shift observed after the excess RelBE has been 
washed away, and the shift observed after the final wash step following the 14-hour incubation 
(after removal of compound and disrupted RelB).  A hit compound was expected to result in a 
decreased PWV shift measured after the final wash. 
 To assess the stability of RelBE(His)6 at room temperature and the variability across the 
plate, 2 μM  RelBE(His)6 was added to each of the 384 wells and incubated in assay buffer for 14 
hours at room temperature.  Figure 3.8A shows the average PWV shift observed across the plate 
at each step in the procedure, with the error bars reporting the standard deviation.  The average 
PWV shift observed after washing away excess RelBE(His)6 was 1.22 ± 0.046 nm, and for the 
wash step following the 14-hour incubation was 1.09 ± 0.046 nm.  Thus there was a small 
decrease in the amount of RelBE(His)6 bound to the sensor; however, no further decrease was 
observed in the subsequent wash step.   
 The compounds in the library are dissolved in DMSO.  Since 10 compounds were tested 
per well, the final concentration of DMSO in the assay buffer was 10%, thus the effect of 10% 
DMSO was also determined across an entire 384-plate.  Again, 2 μM  RelBE(His)6 was added to 
each well and after removal of excess protein, the plate was incubated for 14 hours at room 
temperature in assay buffer containing 10% DMSO.  Figure 3.8B shows the average PWV shift 
for each step of the procedure, with the standard deviation reported.  The average PWV shift after 
washing away excess RelBE(His)6 was 1.25 ± 0.033 nm and following the final wash was 1.33 ± 
0.059 nm.  A significant increase in PWV shift is observed in response to the DMSO, but the 
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Figure 3.8  PC biosensor assay test plates.  Assay 
plates were set up to determine the stability of RelBE 
in assay buffer (A), assay buffer with 10% DMSO (B) 
and assay buffer with compounds from the Marvel 
Library plates 1-9 (C).  Each chart shows the average 
PWV shift values across a 384-well sensor plate for the 
baseline read, the Ni2+ charge and subsequent wash, 
RelBE binding measured 30 minutes after addition of 
RelBE to the plate and the subsequent wash, and after a 
14-hour incubation at room temperature and 
subsequent wash.  An initial read was also taken after 
addition of DMSO and compound. 
lower pre-DMSO PWV shift was mostly restored after washing.  Incubation with DMSO does not 
affect the stability of RelBE(His)6; however, additional wash steps were performed during the 
screen to further restore the PWV shift to the RelBE(His)6 baseline value. 
 
 
 To test the stability of RelBE(His)6 on the PC biosensor in the presence of compound, 
one plate comprising compounds from Marvel Library plates 1-9 was tested.  In this case, 9 
compounds were included in each well, so the final DMSO concentration was 9%.  The PWV 
shift was measured for each step and the averages, along with standard deviations, are reported in 
Figure 3.8C.  The average PWV after washing away excess RelBE was 1.26 ± 0.044 nm and 
after the final wash was 1.50 ± 0.148 nm.  The PWV shift observed after the 14 hour incubation 
and wash step increased measurably.  This confirmed that extensive washing is necessary to 
properly measure any hit compounds.   
 
3.2.5 High-throughput screen results 
The screen was performed as described above.  Briefly, a streptavidin-coated PC 
biosensor plate was functionalized with BTN and charged with Ni2+.  After RelBE(His)6 was 
immobilized and the  PWV  shift  was  measured,  compounds  were  added  at  100  μM  and  incubated  
at room temperature for 14 hours.  The wells were washed extensively the final PWV shift was 
determined.  The change in PWV shift was plotted and  “hit”  compounds  were  those  that  caused a 
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PWV shift three standard deviations below the average of the DMSO control wells, as shown in 
Figure 3.9.   
Figure 3.9  Representative screening plate.  The data are reported as the change in peak wavelength value (PWV) after 
~12 hours incubation with the compound.  The red dashed line represents three standard deviations from the mean of 
the RelBE + DMSO  control  wells;;   any   point   below   that   line   represents   a   “hit”   compound.      The  points  with  highly  
positive PWV shifts likely represent wells with precipitated compound.  
 
From the 170,000 compounds tested in the 10 compound/well multiplex, 110 multiplexed 
compounds resulted in a decreased PWV and were scored as hits, 59 of which were confirmed in 
the re-test.  Deconvolution of the multiplexed wells revealed 66 active compounds (Figure 
3.10B), which all contained a common metal-binding motif; representative compounds are shown 
in Figure 3.10A.  We hypothesized that these compounds acted by chelating the Ni2+ required to 
immobilize the His-tagged proteins to the BTN.  Thus, the 66 compounds were tested against an 
unrelated His-tagged protein (FKBP) and also caused a decrease in the PWV shift (Figure 
3.10C), confirming them as chelators.  Thus, all compounds were eliminated in the counterscreen. 
 
Figure 3.10  Results of HTS for RelBE disruptors.  (A) Representative hits from the screen, all of which contain a 
common metal-chelating motif.  (B) Graph representing approximately half of the deconvoluted hits, which caused a 
PWV shift.  (C) Counterscreen of the hit compounds against an unrelated His-tagged protein also caused a decrease in 
the PWV shift, confirming them as non-specific metal-chelators that strip the His-tagged protein from the PC biosensor 
surface by chelating the Ni2+.   
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3.3 RELE PEPTIDE FRAGMENT ANALYSIS 
The RelBE interaction is characterized by extensive electrostatic interactions and many 
contact surface areas (Figure 3.2).  However, the importance of each region of interaction is not 
well understood, so we employed peptide fragment analysis to further define the interactions 
between RelB and RelE and identify a peptide able to modulate that interaction.  Peptide 
fragments of RelE were analyzed because they may have the capacity to bind the antitoxin RelB, 
preventing or inhibiting its interaction with the toxin RelE, allowing RelE to bind the ribosome 
and inhibit translation.   
 
3.3.1 Assessment of RelE peptide fragment binding to RelB(His)6 
To perform the peptide fragment analysis, 30-amino acid fragments overlapping by 10 
amino acids and spanning the entire primary sequence of RelE (Figure 3.11) were obtained from 
Genscript as crude preparations and purified by HPLC.  Some peptides were insoluble and thus 
unable to be purified and tested:  peptide 4, 7, and 9-14.  Peptides 1, 2, 3, 5, 6, and 8 were soluble 
and purified to ~90% purity as assessed by MALDI.  The purified peptides were tested for 
binding to RelB(His)6 using the PC biosensor.  In this assay, RelB(His)6 was immobilized to the 
PC biosensor surface and peptides that bound to RelB(His) 6 caused an increase in the PWV shift.   
 
Figure 3.11  RelE secondary structure and peptide fragments.  The secondary structure corresponding to each region is 
depicted as orange arrows for the β-sheets and green cylinders as the α-helices.  Fourteen of peptides 30-amino acid, 
overlapping by 5 amino acids and spanning the entire sequence of RelE were included in the peptide fragment analysis.   
 
Each pure peptide fragment was tested from 0-500  μM  and  the  results  are  summarized  in  
Figure 3.12.  As a positive control, pure RelE (0-18  μM)  was  bound  to  immobilized  RelB(His)6 
(Figure 3.12); however, the interaction between RelE and RelB(His)6 was much tighter, as noted 
by the much lower concentration of RelE required to give comparable increases in the PWV as 
the peptides.  Peptide fragment 8 corresponding to RelE sequence 36-65 was the strongest 
binding peptide, so derivatives of it were obtained analyzed.   
MAYFLDFDERALKEWRKLGSTVREQLKKKL
VEVLESPRIEANKLRGMPDCYKIKLRSSGY
SPRIEANKLRGMPDCYKIKLRSSGYRLVYQ
ANKLRGMPDCYKIKLRSSGYRLVYQVIDEK
LKKKLVEVLESPRIEANKLRGMPDCYKIKL
GMPDCYKIKLRSSGYRLVYQVIDEKVVVFV
DFDERALKEWRKLGSTVREQLKKKLVEVLE
ALKEWRKLGSTVREQLKKKLVEVLESPRIE
RKLGSTVREQLKKKLVEVLESPRIEANKLR
TVREQLKKKLVEVLESPRIEANKLRGMPDC
YKIKLRSSGYRLVYQVIDEKVVVFVISVGK
RSSGYRLVYQVIDEKVVVFVISVGKRERSE
RLVYQVIDEKVVVFVISVGKRERSEVYSEA
VIDEKVVVFVISVGKRERSEVYSEAVKRIL
α1β1 β2 β3 β4α2 α3 α4
1
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Figure 3.12  Results of the peptide fragment analysis.  (A) RelB(His)6 was immobilized to the PC biosensor surface the 
PWV shift in response to binding by RelE (0, 1.125, 2.25, 4.5, 9, or 18 μM) or 30-amino acid full-length peptide 
fragment (0, 32.25, 62.5, 125, 250 and 500 μM) was measured.  (B) Truncated derivatives of peptide fragment 36-65 
(0-500 μM) also bound RelB(His)6 .  Pink bars, weak binders; orange bars, moderate binders; green bars; strong 
binders.   
 
Two truncations, corresponding to the first and last 25 amino acids of RelE36-65 
(RelE36-60 and RelE41-65, respectively) were ordered, along with an extended peptide, RelE31-
70, including the 5 amino acids on either side of RelE36-65.  The longer peptide, RelE31-70, was 
insoluble and unable to be tested.  The truncated derivatives bound similarly to RelE36-65, with 
RelE41-65 showing slightly higher binding (Figure 3.12).  Thus, two additional truncations were 
obtained, RelE42-57 and RelE50-63 to identify a minimal peptide required for binding to 
RelB(His)6.  As shown in Figure 3.12B, the 14-mer RelE50-63 appeared to bind RelB(His)6 the 
best, whereas the 16-mer RelE42-57 did not bind as well.   
 
3.3.2 Quantification of binding of RelE36-65 derivatives by SPR 
The PC biosensor assay is useful as an initial assay to provide a binary assessment of 
binding; however, it does not provide quantitative data since it is a static assay.  Thus, surface-
plasmon resonance was used to quantify the binding of the peptides to RelB(His)6.  RelB(His)6 
was immobilized to 900-1000 RU (arbitrary response units) on a NTA chip.  Increasing 
concentrations of each peptide were tested for their binding to and dissociation from RelB(His)6.  
As shown in Figure 3.13, saturated binding was never achieved, even with very high 
concentrations of the peptides.  Furthermore, the rapid dissociation suggested a low affinity of the 
peptide for RelB(His)6.  These SPR profiles are suggestive of non-specific binding [21, 29].  
Additionally, 4 peptide derivatives, RelE45-61, RelE52-61, RelE50-59 and RelE54-63, showed 
no binding to RelB(His)6 by SPR.  Thus the RelE peptide fragments were no long pursued.  A full 
summary of the RelE peptide fragments and their binding to RelB(His)6 is included in Table 3.1.   
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RelE peptides attributes % hydrophobic 
residues
Binding to RelB(His)6
peptide # location sequence Mol Wt pI charge PC biosensor SPR
1 1-30 MAYFLDFDERALKEWRKLGSTVREQLKKKL 3700.33 10.36 3 37 weak nd
2 6-35 DFDERALKEWRKLGSTVREQLKKKLVEVLE 3644.2 9.31 1 33 weak nd
3 11-40 ALKEWRKLGSTVREQLKKKLVEVLESPRIE 3564.2 10.61 3 33 weak nd
4 16-45 RKLGSTVREQLKKKLVEVLESPRIEANKLR 3519.17 11.29 5 30 insoluble nd
5 21-50 TVREQLKKKLVEVLESPRIEANKLRGMPDC 3481.11 9.51 2 30 moderate nd
6 26-55 LKKKLVEVLESPRIEANKLRGMPDCYKIKL 3513.28 10.29 4 37 moderate nd
7 31-60 VEVLESPRIEANKLRGMPDCYKIKLRSSGY 3453.01 9.25 2 33 insoluble nd
8 36-65 SPRIEANKLRGMPDCYKIKLRSSGYRLVYQ 3543.15 10.45 5 33 strong nd
9 41-70 ANKLRGMPDCYKIKLRSSGYRLVYQVIDEK 3545.16 10.06 4 37 insoluble nd
10 46-75 GMPDCYKIKLRSSGYRLVYQVIDEKVVVFV 3506.16 9.17 2 50 insoluble nd
11 51-80 YKIKLRSSGYRLVYQVIDEKVVVFVISVGK 3487.16 10.36 4 53 insoluble nd
12 56-85 RSSGYRLVYQVIDEKVVVFVISVGKRERSE 3499 9.92 2 43 insoluble nd
13 61-90 RLVYQVIDEKVVVFVISVGKRERSEVYSEA 3498.01 6.73 0 47 insoluble nd
14 66-95 VIDEKVVVFVISVGKRERSEVYSEAVKRIL 3448.03 9.22 1 47 insoluble nd
8.1 31-70 VEVLESPRIEANKLRGMPDCYKIKLRSSGYRLVYQVIDEK 4697.46 9.61 2 38 insoluble nd
8.2 36-60 SPRIEANKLRGMPDCYKIKLRSSGY 2883.37 10.33 4 28 strong nonspecfic
8.3 41-65 ANKLRGMPDCYKIKLRSSGYRLVYQ 2960.49 10.45 5 36 stronger nonspecfic
8.4 42-57 NKLRGMPDCYKIKLRS 1922.33 10.64 4 31 moderate nonspecfic
8.5 50-63 CYKIKLRSSGYRLV 1686.04 10.46 4 43 stronger nonspecfic
8.6 45-61 RGMPDCYKIKLRSSGYR 2030.39 10.03 3 29 nd no binding
8.7 50-59 CYKIKLRSSG 1154.39 9.79 3 38 nd no binding
8.8 52-61 KIKLRSSGYR 1207.44 11.1 3 50 nd no binding
8.9 54-63 KLRSSGYRLV 1178.39 11 3 50 nd no binding
Figure 3.13  Surface-plasmon resonance analysis of RelE36-65 derivatives.  Each of the 4 peptides was tested for 
binding to immobilized RelB(His)6 by SPR.  The expected threshold RU (arbitrary response units) are indicated by the 
black dashed line.   
 
Table 3.1  Peptide characteristics and results in RelB(His)6-binding experiments.  nd, not determined.    
 
3.4 PHAGE-DISPLAYED PEPTIDE LIBRARY SCREEN 
Since the RelE peptide fragments suffered from minimal or nonspecific binding to 
RelB(His)6, we set out to identify peptides that could bind RelB with high affinity and specificity.  
The powerful tool of phage display offers a robust screening method to identify high-affinity 
peptides that bind specifically to the bait protein, which was RelB(His)6 in this case.  Peptides of 
RelE 42-57RelE 36-60 RelE 50-63RelE 41-65
100 μM 50 μM
25 μM12.5 μM
100 μM 50 μM
25 μM 12.5 μM
6.3 μM 3.1 μM
1.6 μM 0.8 μM
25 μM 12.5 μM
6.3 μM 3.1 μM
1.6 μM 0.81 μM
12.5 μM 6.3 μM
3.1 μM 1.6 μM
1.0 μM 0.05 μM
0.025 μM
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a specified length displayed on the T7 phage capsid are incubated with the bait protein, subjected 
to stringent washes, and then eluted from the bait protein.  Captured phages are propagated in E. 
coli and the resultant lysate (T7 is a lytic phage) is applied to the bait protein in the subsequent 
round, constituting the iterative process called biopanning (Figure 3.14).  After 4 biopan rounds, 
the eluted phage are propagated in E. coli on agar plates and plaques are analyzed by PCR and 
DNA sequencing to reveal the sequence of the displayed peptide.  Typically, the appearance of a 
consensus sequence indicates specific binding of the phage-displayed peptides to the bait protein 
and synthetic peptides based on this consensus sequence can be tested in a variety of “off-phage”  
assays.   
A variety of phage libraries were constructed by Amy Larson in the Hergenrother Lab.  
The first two libraries constructed were using phage that displayed 415 copies of the 9 amino acid 
recombinant peptide on their capsid.  Library X9.1 contained 2.4x106 primary recombinants and 
Library X9.2 contained 1.8x107 primary recombinants (Table 3.2), so offered 10-fold more 
diversity than the first library.  Although these libraries resulted in consensus peptides, the 
peptides did not appear to have high affinity  
Figure 3.14  Schematic of biopanning.  The bait protein, RelB(His)6 was immobilized to a solid support via its His6 tag 
and incubated with the phage library.  Phage bound to RelB(His)6 are eluted after a series of stringent washes, then 
propagated in E. coli and subjected to another round.  After 4 iterative rounds, individual plaques are analyzed to reveal 
the peptide sequence.   
 
for the bait protein (discussed in more detail in the following sections) and there was concern of a 
possible avididty effect due to the high density of peptides on the phage capsid.  Thus, to increase 
the chances of capturing high affinity peptides, we constructed four libraries displaying only 10 
peptides on the phage surface, one displaying 9 linear amino acids (Library X9.3) with 3.05x106 
primary recombinants, and three displaying amino acids that are cyclic under oxidizing 
conditions due to terminal cysteine residues:  CX7C with 2.85x106 primary recombinants, CX9C 
with 1.1x106 primary recombinants, CX10C with 1.0x106 primary recombinants (Table 3.2).   
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Library
Copies 
displayed
Motif 
displayed
Primary 
recombinants
# Biopans 
performed Consensus sequence
X9.1 415 9 aa, linear 2.4  x 106 9 X5PWX(V/L)
X9.2 415 9 aa, linear 1.8 x 107 5 X6VCF
X9.3 10 9 aa, linear 3.05 x 106 1 TPYWLFSIL
CX7C 10 7  aa, cyclic 2.85 x 106 3 no consensus
CX9C 10 9 aa, cyclic 1.1 x 106 3 no consensus
CX10C 10 10 aa, cyclic 1.0 x 106 3 CWWRSAGVWVAC
Pre-clear vol solid support for 
RelB(His)6 immobilization
Blocking 
agent
Phage 
incubation
Washes
solid support vol solid support vol phage Number % Tween-20
Round 1 Ni-NTA resin 0.5 mL 0.5 mL 10  μL 5% milk 25 min 5 0.2
Round 2 MagneHis beads 0.05 mL 0.2 mL 6  μL 5% BSA 22 min 6 0.5
Round 3 Ni-NTA resin 0.5 mL 0.5 mL 5  μL 5% milk 18 min 7 0.8
Round 4 MagneHis beads 0.05 mL 0.2 mL 3  μL 5% BSA 15 min 8 0.8
Table 3.2  Characteristics of phage libraries and consensus sequence recovered.   
 
Throughout the biopanning experiments performed with Library X9.1, a variety of 
conditions were tested with the main goal being high stringency to increase the likelihood of 
recovering phage that specifically interacted with RelB(His)6 with a high affinity.  A basic high 
stringency protocol is summarized in Table 3.3, with variations summarized listed in Table 3.4.  
For some of the biopan experiments, the phage solutions were first  subjected  to  a  “pre-clear”  
involving just phage and solid support to remove any phage that bound to the solid support.  Also, 
the solid support and the blocking solution were switched between each round to select against 
phage that bound the solid support or the blocking agent.  With each subsequent round, 
decreasing amounts of immobilized RelB(His)6 was used and the incubation time between phage 
and RelB(His)6 was decreased.  Lastly, the number of washes and sometimes the concentration of 
Tween-20 were increased with each round.  Following four rounds of biopanning, the eluted 
phage were propagated in E. coli on agar plates and 15 plaques from each biopan were analyzed.  
The recombinant region in the phage genome was amplified by PCR, which was then sequenced 
to reveal the specific peptide that was displayed on the phage capsid.  Importantly, analogous 
biopan experiments lacking RelB(His)6 were always performed alongside to provide a benchmark 
for the specificity of the recovered peptides.   
 
Table 3.3  Standard biopan protocol.    
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Library, biopan
number
Pre-clear Washes
elution solutionNumber % Tween-20
X9.1 #3 yes 5, 6, 7, 8 0.2 0.5 M imidazole
X9.1 #4 no 5, 6, 7, 8 0.2 1% SDS
X9.1 #5 yes 5, 6, 7, 8 0.2 1% SDS
X9.1 #7 no 5, 6, 7, 8 0.2 100  μL  of  1.6  
mg/mL MBP-
RelE(His)6 
X9.1 #8 no 15, 6, 20, 14 0.2
X9.1 #9-X9.2 all no 15, 6, 20, 14 0.2, 0.5, 0.8, 1.1
X9.3, CXC all no 10, 11, 12, 13 mL 0.2, 0.5, 0.8, 1.1 1% SDS
Table 3.4  Variations to the standard biopan protocol  
 
3.4.1  T7 415-1b Library X9.1  
As described above, this library displayed 415 copies of 9-amino acid recombinant 
peptides on its surface.  Nine biopan experiments were performed with this library; biopans 1, 2 
and 6 resulted in peptides that appeared to bind non-specifically as they were very similar to the 
peptides recovered from the (-)RelB(His)6 biopan.  The protocol for each biopan varied slightly 
and the details can be found in Experimental Procedures section.  For each biopan, the phage 
DNA from 15 plaques was analyzed and the results giving rise to the consensus sequence 
X5PWX(V/L) from biopans 3-5 and 7-9 are summarized in Figure 3.15.  Three peptides, 
AESESPWRV, NGKGHPWSL and DKPPSPWTV were recovered from multiple biopans.  Many 
other peptides containing the PWX(V/L) motif were only recovered from a single plaque from 
one biopan.  Some of the PWX(V/L)-containing phage were assessed, along with other recovered 
phage, in a competitive biopan 
 
 
Figure 3.15  Biopanning from Library X9.1 resulted in the consensus sequence X5PWX(V/L).  (A) Dominant peptides 
that arose from Biopans 3-9 are shown on the right, with the PW-V/L alignment highlighted in red.  In the left column, 
the large number refers to the biopan number and the superscript refers to the number of plaques (out of 15) from 
which the sequence was recovered.  (B) A WebLogo plot displaying the consensus sequence of the dominant peptides.  
The majority of the peptides recovered had the P in the 6th position, thus this became the consensus sequence.  
 
 
Biopan#plaques Sequence
35,51,74,91 AESESPWRV
41, KSPSPWA  
44,91 NGKGHPWSL
43,55,84,91 DKPPSPWTV
42 FPSKNPWQV
81 AAHSPWAVS 
91 VSNPWQLGA
91 SRGPWSLSG
91 QKESPWRVG
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3.4.1.1 Competitive biopan of hit phage 
The purpose of the competitive biopan was to “rediscover”  the  hit  phage.    The  hit  phage  
was mixed with WT phage in approximately the expected starting ratio from the initial 
experiment, based on the number of primary recombinant.  Since there were ~1x106 primary 
recombinants in Library X9.1, the hit phage was mixed with WT phage in a ratio of 1:1x106.  The 
biopan was carried out according to the protocol used for the initial discovery biopan and the 
plaques were screened after each round to determine when the hit phage was in high enough 
numbers to be detected by PCR.  The phage subjected to the competitive biopan displayed the 
following peptide sequences:  DSCSSVCVE, AESESPWRV, NGKGHPWSL, DKPPSPWTV 
and FPSKNPWQV.  The peptide DSCSSVCVE was recovered from one plaque in biopan 3, 
whereas AESESPWRV was recovered from 5 plaques in Biopan 3, plus from Biopans 5, 7 and 9.  
However, both recombinant phage were selected for by Round 4 in the (+)RelB(His)6 competitive 
biopan and were not selected by the (-)RelB(His)6, as shown in Figure 3.16.  Recovering the 
recombinant phage in 4 rounds (the number of rounds used in the original biopan) suggests that 
the phage are specifically binding RelB(His)6.  Unfortunately the PCR results for the competitive 
biopans with the remaining three phages were ambiguous as the PCR products were of 
unexpected sizes (data not shown).   
Figure 3.16  Competitive biopan to assess the specificity of phage for RelB(His)6.  Recombinant phage 3-1 (A) or 3-5 
(B) were mixed with WT phage in a 1:1x106 ratio and carried through the biopan protocol (+)RelB(His)6 (left) or  
(-)RelB(His)6 (right).  Plaques were analyzed by PCR and separated on a high-resolution agarose to distinguish the 
bands corresponding to wild-type (350 bp) and recombinant (386 bp) phage.  M, DNA marker.  WT, wild-type.  WT/3-
1 or 3-5, starting ratio 1:1x106.  3-1 and 3-5 correspond to the phage displaying the sequence DSCSSVCVE and 
AESESPWRV, respectively.  
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3.4.1.2 ELISA of phage displaying consensus peptides 
The affinity of the phage for RelB(His)6 was evaluated by ELISA.  Briefly, RelB(His)6 
was adsorbed to a Maxisorp immunoplate (Nunc) plate, blocked with 5% milk, incubated for 1 
hour with phage lysate.  An Anti-T7 HRP-conjugated antibody was added and developed with 
colorimetric substrate ABTS, the absorbance of which was measured at 405 nm.  The results of 
the ELISA with select phage recovered from Library X9.1 (listed in Figure 3.17A) are 
summarized in Figure 3.17B.  From this graph, 4-9 appears to bind the best, followed by 4-6 and 
8-9, then 4-5 and 3-5 and finally 3-1, 4-3, 9-6, 9-10 and 9-15.  Phage clone 3-12 was included as 
a negative control; although it was recovered from a (+)RelB(His)6 biopan, its sequence was 
similar to those recovered from (-)RelB(His)6 biopans.  Three phage clones were shown to have 
dose-response binding to RelB(His)6 as shown in Figure 3.17C, with 3-5 performing much better 
in this assay than the previous ELISA.   
 
Figure 3.17  ELISA of Biopan 1 phage lysates.  (A) Name and sequence of the 11 recombinant phage evaluated in the 
ELISA assay.  (B) Each phage was tested at 1x109 phage/well for binding to adsorbed RelB(His)6.  (C) Dose response 
of three recombinant phage determined by ELISA.   
 
Based on the number of times they were recovered from the biopan experiments and the 
dose-response binding to RelB(His)6, the following peptides (with corresponding phage clone 
name) were ordered from Genscript:  AESESPWRV (3-5), DKPPSPWTV (4-6) and 
FPSKNPWQV (4-9).  Additionally, an alanine-substituted derivative of 4-9, FPSKNAAQV, was 
purchased to assess the importance of the PW motif characteristic of the consensus sequence.  
These peptides were evaluated for binding to RelB(His)6 by the PC biosensor and SPR. 
 
3.4.1.3 PC biosensor and SPR analysis of synthetic peptides 
To evaluate the binding of the synthetic peptides, the PC biosensor assay was used, with 
the RelE50-63 derivative peptide (described in Section 3.3.1) as a positive control.  A range of 
concentrations of the peptides were tested against immobilized RelB(His)6 and as shown in 
Figure 3.18, although RelE50-63 bound as expected,  the  “off-phage”  synthetic  peptides  showed 
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minimal, if any, binding to RelB(His)6.  To confirm this result, the peptides were also tested for 
binding to RelB(His)6 by SPR and not surprisingly, the peptides showed no binding (data not 
shown).  Thus, these peptides were no longer pursued.  
Figure 3.18  Assessment  of  synthetic  “off-phage”  peptides.    (A)  Sequence  and  attributes  of  the  synthetic  peptides.    (B)  
Peptide binding to RelB(His)6 evaluated by the PC biosensor.   
 
3.4.2 T7 415-1 Library X9.2 
To increase the chances of identifying a peptide that could specifically bind to 
RelB(His)6, biopanning with the second generation linear 9-amino acid library, X9.2, was 
performed.  Five biopan experiments were performed following the standard biopan protocol, 
omitting the pre-clear of the lysate and eluting the phage using MBP-RelE(His)6, (MBP, maltose-
binding protein) which may have specifically competed for binding with RelB(His)6 or 
nonspecifically competed for binding to the NTA solid surface.  The peptides recovered along 
with the frequency of their recovery throughout the five biopans are shown in Figure 3.19A.  The 
peptides displaying the X6VCF consensus did not constitute the majority of the peptides 
recovered from each biopan; however, they did form the only pattern observed amongst the 
phage-displayed peptides.  Interestingly, the peptides shared some homology with the RelE43-51 
amino acids (Figure 3.19B).  Nonetheless, the binding of these phage to RelB(His)6 assessed by 
ELISA was minimal.  Recall that the hit phage from X9.1 gave absorbance readings of 2-4 
(Figure 3.17B) in the ELISA, whereas clone 5-2 is best with an absorbance of 0.45 (Figure 
3.19C).  Since these phage appeared to bind RelB(His)6 with lower affinity than those recovered 
from Library X9.1, the phage from X9.2 were no longer pursued.   
 
3.4.3 T7 10-3 libraries against RelB(His)6 
Although the phage recovered from the 415-copy library series resulted in consensus 
sequences, they did not perform well enough once the corresponding synthetic peptides were 
tested.  We hypothesized this was due to an avidity effect and thus focused our efforts on libraries 
in which only 10 copies of the peptide were displayed on the phage capsid.  Four libraries were 
tested:  X9.3, CX7C, CX9C, CX10C, as well as mixture containing the three cyclic libraries. 
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Figure 3.19  Biopanning from Library X9.2 resulted in the consensus sequence X6VCF.  (A) Dominant peptides that 
arose from Biopans 1-5 are shown on the right, with the VCF alignment highlighted in red.  In the left column, the 
large number refers to the biopan number and the superscript refers to the number of plaques (out of 15) from which 
the sequence was recovered.  (B) Alignment of the RelE43-51 sequence with the 5 VCF peptides.  Residues highlighted 
in purple, green and blue indicate low, moderate and high homology, respectively.  (C) ELISA of 1x109 phage/well 
against adsorbed RelB(His)6.   
 
3.4.3.1 Biopan with 9-amino acid linear peptide library X9.3 
One biopan was performed with the X9.3 library.  Ten plaques were analyzed, seven of 
which had the sequence CLNAQVGRR and three of which were TPYWLFSIL (Figure 3.20A).  
The presence of the proline and aromatic amino acids in the latter peptide made it more 
structurally interesting, whereas the former peptide contained mostly uncharged or hydrophobic 
residues.  Three biopans each were performed with the CX7C and CX9C libraries; however, no 
real consensus sequence emerged from these.  Although phage displaying certain peptides 
appeared in multiple plaques, it was unclear if these were specifically binding RelB(His)6 since 
no pattern was observed.   
Three biopans were also performed with the CX10C libraries and one clone with the 
sequence CWWRSAGVWVAC was present in 13 out of 15 plaques analyzed.  Interestingly, this 
same clone was also recovered from 6 out of 15 plaques from the mixed cyclic peptide biopan.   
The phage displaying TPYWLFSIL and CWWRSAGVWVAC were tested in an ELISA 
using the X9.1 clone 4-9 as a benchmark (Figure 3.20).  Although the X9-10 and CX10C-1 phage 
did not bind with the same affinity as 4-9, their corresponding synthetic peptides were ordered 
from Genscript and tested for binding to RelB(His)6 by SPR.  Unfortunately the TPYWLFSIL 
showed no binding and the CWWRSAGVWVAC was insoluble in water, acetonitrile and DMF 
and thus could not be tested.   
Biopan#plaques
11
22,33,44,56
32
31
52
-0.1
0
0.1
0.2
0.3
0.4
0.5
WT 1-4 2-7 3-2 3-9 5-2
Ab
so
rb
an
ce
 4
05
 n
m
RelE43-51 KLRGMPDCY
1-4       KLVNRGVCF
2-7       KLVNRKVCF
3-2       NKLSTEVCF
3-9       TNKSGRVCF
5-2       SLDSRKVCF
. . *:
A B C
Sequence
KLVNRGVCF
KLVNRKVCF
NKLSTEVCF
TNKSGRVCF
SLDSRKVCF
84 
Figure 3.20  Results of the biopans with X9.3 and CX10C.  (A) Dominant peptides that arose from biopans with the 
third generation linear 9-amino acid library X9.3 and the cyclic 10-amino acid CX10C are shown in the right column.  In 
the left column, the large number refers to the biopan number and the superscript refers to the number of plaques (out 
of 10 or15) from which the sequence was recovered.  (B) ELISA of 1x109 phage/well against adsorbed RelB(His)6.   
 
Considering the vast success using phage display in the literature, we were surprised by 
our results of no peptides that bound RelB with high affinity.  We hypothesized that the nature of 
the bait protein must be negatively influencing the outcome of the biopan experiments but 
confirmed that the protein remained stable during the biopan rounds and was not degraded by 
proteases released into the phage lysate.  Thus, it seemed likely that the antitoxin, due to its 
unfolded nature, served as a poor target for in vitro binding studies.  Overcoming this inherent 
pitfall, however, required conquering the challenge of purifying sufficient quantities of stable 
toxin protein. 
 
3.5 EFFORTS TOWARDS PURIFICATION OF RELE 
 
3.5.1 Purification of untagged RelE using the pTWIN2 vector 
The pTWIN2 vector series enables expression of a recombinant protein fused to an intein, 
which will catalyze its own cleavage under the proper conditions.  Our hypothesis was that 
expression of a large fusion protein containing RelE would abrogate its toxicity and allow 
sufficient quantities to accumulate in the cell.  The intein is fused to a chitin binding domain 
(CBD), allowing for affinity purification using chitin beads.  Thus the construct CBD-intein-RelE 
or (Figure 3.21A) was expressed in E. coli and purified under native conditions.  Cleavage 
between the intein and RelE was induced by decreasing the pH from 8.5 to 6.0 and liberated RelE 
was collected off the column (Figure 3.21B).  Although sometimes the CBD-intein co-purified, a 
second size-exclusion chromatography (Figure 3.21B) separated the two proteins.  This method 
worked brilliantly a handful of times and facilitated performance of the experiments using 
untagged RelE as described in Section 3.2; however, for unknown reasons after a certain time, 
cleavage never proceeded to sufficient levels again.   
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Figure 3.21  Purification of untagged RelE from CBD-intein fusion.  (A) Schematic of the T7-promoter controlled 
CBD-intein-RelE construct showing the intein autocleavage site.  (B) Purification of RelE from the intein resulted in an 
elution fraction containing a mixture of the fusion, the free intein and RelE.  Subsequent purification size exclusion 
chromatography separated RelE from the intein.   
 
3.5.2 RelE triple mutant:  R81A, R83A, Y87A 
The pET-28a-relBE construct had been mutated to carry the RelER81A mutant, which was 
shown to be less toxic than the WT protein [27].  The relER81A mutant was sub-cloned by itself, 
but could not be overexpressed.  Thus, a second mutation, R83A, was introduced using the 
quickchange (QC) primers listed in Table 3.5.  However, the RelER81A/R83A double mutant could 
also not be expressed on its own.  As a last effort, a third mutation, Y87A, was introduced as it 
was found that RelER81A/Y87A double mutant had no activity [22].  Unfortunately, the triple mutant 
was also unable to be expressed.  
 
3.5.3 pMBP fusion with TEV cleavage 
The pMBP vector carries maltose binding protein (MBP) and a multiple cloning site 
juxtaposed by a TEV protease cleavage site, allowing for expression of RelE as a non-toxic MBP 
fusion and subsequent release of RelE from the MBP, as diagrammed in Figure 3.22A.  
Construction and expression of the pMBP-RelE(His)6 proceeded as expected and the fusion was 
purified to homogeneity on amylose resin (Figure 3.22B).  The addition of the MBP-fused TEV 
protease liberated RelE(His)6 from the fusion, although only ~50% cleavage was ever achieved.  
A final affinity purification step over an amylose resin was expected to retain the liberated MBP 
and MBP-TEV constructs, allowing pure RelE(His)6 to flow through.  Unexpectedly, RelE(His)6 
was never collected in the flow through.  The mixture was subjected to purification by size 
exclusion chromatography, ion exchange chromatography, further amylase affinity 
chromatography, and Ni-NTA affinity chromatography, but despite these extensive efforts, the 
liberated RelE(His)6 was never captured and thus this method abandoned. 
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Figure 3.22  Purification of untagged RelE(His)6 from MBP.  (A) Schematic of the T7-promoter controlled MBP-
RelE(His)6 construct showing the intein autocleavage site.  (B) The elution fractions containing only MBP-RelE (His)6  
(expected size:  57.8 kDa) were pooled and used in subsequent experiments.  FT, flow through.  
 
3.5.4 RelB trypsinolysis 
One clever strategy was to take advantage of the increased proteolytic susceptibility of 
RelB over RelE and use trypsin to selectively degrade RelB, leaving free RelE.  A similar method 
had been reported in the literature, wherein the VapBC TA system was used to degrade VapB, 
leaving active VapC [19].  To establish more controlled conditions, sequencing-grade trypsin was 
added to affinity-purified RelBE(His)6 in a range of concentrations and allowed to incubate for at 
4, 25 and 37°C for various time points; however, although it appeared that some degradation of 
RelB occurred, complete degradation was never achieved.  Perhaps success would have been 
realized if Lon, a specific RelBE-specific protease was used, however, this was never pursued. 
 
3.6 CONCLUSIONS 
The work with RelBE, although it did not lead to a disruptor was highly informative, 
revealing that the antitoxin is not the best target for two reasons:  experimentally, due to its 
unstructured nature and theoretically, because merely binding the antitoxin is at least one step 
away from the major goal of the project which is to artificially activate the toxin.  The high-
throughput screen for RelBE disruptors gave perhaps the best chances to achieve our goal; 
however, although it was satisfying that the technology worked (PWV shift decreased when 
protein was removed from the surface) the screen only revealed chelators.  There were many 
factors contributing to the low chance for success with the HTS, primarily including the 
subnanomolar Kd between RelB and RelE in the absence of a protease and working in a static 
system which puts the small molecules in constant competition with the high affinity binding 
partners.  Recapitulating the in vivo effect of a specific protease in vitro is potentially possible 
and could be pursued in the future.  Additionally, current technology limits the throughput of 
compounds tested in flow cells so this particular challenge could not be readily overcome. 
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A peptide capable of binding RelB could have worked by directly preventing or 
inhibiting the interaction between RelB and RelE or have an indirect effect by competing with 
RelE for binding to RelB, weakening the interaction between RelB and RelE, and effectively 
making RelB more available for proteolysis in the cell.  Either strategy would require a peptide 
with extraordinary affinity for RelB to overcome the subnanomolar affinity between RelB and 
RelE.  The peptide fragment analysis may not have taken into account the complex, multi-faceted 
interactions that exist between the globular RelE and RelB.  It is possible that a peptide based on 
RelB would bind RelE, as the crystal structure shows that RelB resembles an extended 
polypeptide throughout its contact with RelE.  An argument against this strategy is that a peptide 
of RelB may actually inhibit RelE, either by occupying its active site, by obstructing RelE 
entrance into the ribosomal A site due to increased size, or by masking some of the RelE residues 
required for stable interaction with the ribosome to carry out mRNA cleavage.   
The possibilities for the lack of success with the phage display seem endless.  As there is 
plentiful literature precedent for success and since analogous biopanning experiments against the 
antitoxin YefM-Sa1 [15] were also unsuccessful, the inherent unfolded nature of the antitoxin 
proteins may explain some of the challenges.  A high-affinity peptide may have been discovered 
using a larger library, biopanning under different conditions, or using the M15 phage system 
which may remove some selection placed on the phage in culture due to its slower infection time 
than T7 phage.  Nonetheless, despite approximately 25 biopan experiments, the peptides 
identified to bind RelB in the context of the phage failed to do so when tested on their own.   
Recovering peptides with certain sequences from multiple biopans, specifically the 
X5PWXV/L and X6VCF motifs, suggests that these peptides did confer binding to immobilized 
RelB(His)6.  The fact that these peptides were not recovered in the control biopan experiments 
lacking RelB(His)6 further supports the notion that the peptides specifically interacted with 
RelB(His)6 and not the other materials used in the biopan.  The high titer of phage required for 
interaction as detected by ELISA suggests that the peptides bound RelB(His)6 with low affinity or 
due to an avidity effect.  The multiple conformations adopted by an unfolded protein may also 
explain the apparent low affinity interaction between the phage-displayed peptide and RelB.  The 
inability of the synthetic peptides to bind RelB(His)6 may indicate that in the context of the phage 
capsid protein, the peptides adopted a certain secondary structure that was required for binding to 
RelB(His)6.  Recovering fewer peptides with consensus sequences in the phage libraries 
displaying only 10 copies of the peptide on the capsid protein further suggests that the unfolded 
nature of RelB precluded high affinity interactions with the peptides.  It was predicted that phage-
displayed peptides recovered from the libraries displaying 10 copies would have higher affinity 
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for RelB(His)6 than the phage displaying 450 peptides, but were in fact shown to have lower 
affinity by ELISA.  This further implicates avidity effects for the initial results observed with the 
seemingly promising X5PWXV/L and X6VCF motifs. 
The inability to reliably purify RelE presented another set of challenges for this project.  
Despite attempting literature-reported expression and purification methods and previously 
successful methods in the lab, an established protocol to consistently obtain pure RelE remained 
elusive.  Additional issues with RelE center around its ribosome-dependent ribonuclease activity 
which complicates the ability to perform in vitro activity assays on any large scale.  The 
advantage of a ribosome-independent ribonuclease is the facile nature of testing its in vitro 
enzymatic activity, which could allow for direct toxin activation experiments.  The culmination of 
the above-mentioned factors provided the motivation to turn to another TA system, MazEFSa 
which is discussed in Chapter 4.   
 
3.7 EXPERIMENTAL PROCEDURES 
 
3.7.1 Construction of plasmids 
All primers used to construct expression vectors are listed in Table 3.5.  Standard cloning 
procedures were followed.  The pET28a-relBE(His)6, pET-28a-relB(His)6 and pET-21a-
relE(His)6 plasmids were obtained from Elizabeth Moritz.   
To construct pTWIN2-RelE, relE was amplified from pET28a-relBE(His)6 using the 
primers RelE-NcoI-For and RelE-PstI-Rev.  pTWIN2-relE produces a CBD-SspB-RelE fusion 
upon induction with IPTG in E. coli BL21(DE3).   
To construct pMBP-RelE, the RelE-BamHI F and RelE-XhoI R primers were used to 
amplify relE from pET-21a-relE(His)6.  pMBP-relE produces a MPB-RelE fusion protein upon 
induction with IPTG in E. coli BL21(DE3).   
To construct pMBP-RelE(His)6, RelE-BamHI F and His6-stop-XhoI R primers were used 
to amplify relE(his)6 from pET-21a-relE(His)6.  pMBP-relE(His)6 produces a MPB-RelE fusion 
protein upon induction with IPTG in E. coli BL21(DE3). 
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construct primer name sequence (5'-3')
pTWIN2-RelER81A RelE-NcoI GGACTCCCATGGCGTATTTTCTG
RelE-PstI-Rev GGTATACTGCAGTCAGAGAATGCGTTTGAC
pTWIN2-RelER81A(His)6
RelE-NotI GGACTCGCGGCCGCATGGCTTATTTTCTGGATTTT 
His6-stop-
BamHI-Rev GGTATAGGATCCTCAGTGGTGGTGGTGGTGGTG
pMBP-RelE RelE-BamHI F ATGAGGATCCATGGCGTATTTTCTGGATTTTG
RelE-XhoI R TATACTCGAGTCAGAGAATGCGTTTGAC
pMBP-RelE(His)6
RelE-BamHI F ATGAGGATCCATGGCGTATTTTCTGGATTTTG
His6-stop-XhoI RTATACTCGAGTCAGTGGTGGTGGTGGTGGTG
pET-28a-relBER81A/R83A R83A QC-F CTGTTGGGAAAGCAGAAGCCTCGGAAGTATATAGCGAG
R83A QC-R CTCGCTATATACTTCCGAGGCTTCTGCTTTCCCAACAG
pET-28a-relBER81A/R83A/Y87A
Y87A QC-F GCAGAAGCCTCGGAAGTATTTAGCGAGGCGGTCAAAGCG
Y87A QC-R CGCTTTGACCGCCTCGCTAAATACTTCCGAGGCTTCTGC
Table 3.5  Primers used in the construction of expression vectors 
 
3.7.2 Purification of RelBE(His)6 and RelB(His)6 under native conditions 
Clones were obtained from Elizabeth Moritz (see thesis for details).  The plasmids pET-
28a/RelBE(His)6 or pET-28a/RelB(His)6 were transformed by electroporation into E. coli 
BL21(DE3) and transformants were selected on LB agar containing 50 µg/mL kanamycin.  
LB/Kan50 broth was inoculated with a single colony for an overnight culture which was used to 
seed 2 L in a 100-fold dilution.  The culture was grown at 37°C until the OD600 reached 0.4-0.6, at 
which point expression was induced with 1 mM IPTG (final concentration) for 4 hours at 37°C.  
Pellets were stored at -20°C.   
 RelBE(His)6 and RelB(His)6 was purified under native conditions and all steps were 
performed on ice or at 4°C.  A pellet corresponding to 2L culture was thawed for 5-10 min and 
resuspended in cold binding buffer (20 mM Tris, pH 7.9, 0.5 M NaCl).  The cells were lysed by 5 
min sonication with 1 s pulse at 50% amplitude.  The lysate was cleared by 30 min centrifugation 
at 35000g at 4°C and the supernatant was batch loaded with 1.0 mL 1:1 Ni-NTA resin slurry 
(Qiagen) for 30 min at 4°C with inversion.  The resin was washed with 10 mL binding buffer, 
followed with 10 mL wash buffer (binding buffer containing 60 mM imidazole).  RelBE(His)6 
and RelB(His)6 were eluted with 5 mL binding buffer containing 0.5 M imidazole, concentrated 
to ~0.5 mL and dialyzed against assay buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 20 M 
EDTA, 0.005% Tween-20).  Purity and concentration were assessed using SDS-PAGE (Figure 
3.23) and the  BCA  Assay  following  manufacturer’s  instructions (Pierce).   
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Figure 3.23  Expression and purification of RelBE(His)6 pET28a/RelBE-His6.  (A) Bands corresponding to RelE(His)6 
and RelB are not present in the uninduced culture but are visible 4 hours after expression.  The protein complex was co-
purified via Ni2+-NTA affinity chromatography and the elution fraction shows highly pure RelE(His)6 and RelB, at 9.07 
and 12.76 kDa, respectively.  (B) RelB(His)6 is purified in high quantities using Ni2+-NTA affinity chromatography.   
 
3.7.3 Expression and purification of RelE from pTWIN2 
Overnight cultures started from single colonies of E. coli BL21(DE3) pTWIN2-RelE 
were  used  to  seed  1.5  L  cultures  in  LB  +  100  μg/mL  ampicilin.    The  cultures  were  induced  with  1  
mM IPTG (final concentration) at OD600 = 04.-0.6 and harvested after 3 hours growth at 37°C 
with shaking.   
The pellet was resuspended in cold 10 mL Buffer B1 (20 mM Tris, pH 8.5, 0.5 M NaCl, 
1 mM EDTA, 0.1% Tween-20) and sonicated on ice for two cycles of 3 min with 1 sec pulse, 
with 3 min rest in between.  A 5 mL bed volume of chitin resin was equilibrated with 10 column 
volumes  of  Buffer  B1  and  23  gauge  1”  needed  was  affixed  to  the  column  to  control  the  flow  rate.  
The lysate was centrifuged at 35000 g for 30 min at 4°C, brought up to 50 mL with Buffer B1 and 
applied to the column.  For  the  wash  step,  a  22  gauge  1”  needle  was used to slightly increase the 
flow rate.  The column was washed with 10 column volumes of cold Buffer B1 and then the 
needed was removed to allow a quick flush of 3 column volumes of cold Buffer B2 (20 mM Tris, 
pH 6.0, 0.5 M NaCl, 1 mM EDTA, 0.1% Tween-20) to induce intein autocleavage.  The column 
was capped to retain sufficient buffer to cover the resin and then incubated at room temperature 
overnight.  To elute liberated RelE, the column was washed with 5 column volumes of room 
temperature Buffer B2 which was collected multiple fractions.   
Because the intein typically co-eluted with RelE, a gel filtration step was used to separate 
RelE from the intein.  Bio-Gel P-100 was packed to a 9 cm bed height and equilibrated with 
binding buffer (20 mM Tris, pH 7.9, 0.5 M NaCl).  The elution fraction from the chitin column 
was concentrated to 0.5 mL, slowly applied to the column and binding buffer was added in 0.5-1 
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mL aliquots until the A220 returned to baseline.  The flow rate was ~ 1 mL/hr and 0.5 mL fractions 
were collected.  Protein purity was assessed by SDS-PAGE gel and stained with Sypro Ruby.   
 
3.7.4 Expression and purification of MBP-RelE(His)6 
The plasmids pMBP-RelE(His)6 was transformed by electroporation into E. coli 
BL21(DE3) and transformants were selected on LB agar containing 50 µg/mL kanamycin.  
LB/Kan50 broth was inoculated with a single colony for an overnight culture which was used to 
seed 2 L in a 100-fold dilution.  The culture was grown at 37°C until the OD600 reached 0.4-0.6, at 
which point expression was induced with 1 mM IPTG (final concentration) for 3 hours at 37°C.  
Pellets were stored at -20°C.   
For purification, a 1L pellet was resuspended in 10 mL cold column buffer (20 mM Tris, 
200 mM NaCl, 1 mM EDTA, pH 7.4) and sonicated for 5 min with a 1 sec pulse at 35-40% 
amplitude.  The cell debris was centrifuged at 35000 g for 30 min at 4°C.  Cold column buffer 
was added to bring the volume of the lysate to 150 mL, which was then passed over equilibrated 
amylose  resin  (Invitrogen)  in  a  column  affixed  with  a  22  gauge  1”  needle  to  control  flow  rate.    
The resin was washed with 50 mL cold column buffer and the protein was eluted with 30 mL 10 
mM maltose, collected in 10 equal fractions.  Purity was assessed by SDS-PAGE gel, stained 
with Coommassie Brilliant Blue.   
 
3.7.5 Set-up for PC biosensor assay 
To prepare the 384-well PC biosensor plate for His6–tagged protein binding, wells were 
washed using an automatic plate washer 3-4 times with 100 L assay buffer (10 mM HEPES, pH 
7.4, 150 mM NaCl, 20 M EDTA, 0.005% Tween-20).  Wells were then incubated with 5 M D-
biotin-tris-NTA hybrid compound (BTN) in assay buffer overnight at 4°C.  The next day, the 
wells were washed as before and charged with Ni2+ by incubating with 40 L charging buffer 
(assay buffer containing 0.5 mM NiCl2 ) for at least 5 minutes at room temperature to allow for 
His6-tagged protein binding.  Wells were washed with assay buffer three times before adding 
either 40 L 0.05 mg/mL RelBE(His)6 or RelB(His)6 in assay buffer or assay buffer alone and 
incubating at room temperature ~30 minutes or until PWV shift reached 1.0-1.1 nm.  Wells were 
again washed with assay buffer three times and the PWV shift measured with a BIND plate-based 
reader (SRU Biosystems).   
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3.7.6 Quantification of RelBE(His)6 eluted from PC biosensor surface 
The protocol for the PC bisoensor assay was followed to bind RelBE(His)6 to the surface.  
The protein was eluted from multiple wells using stripping buffer (10 mM HEPES, pH 8.3, 150 
mM NaCl, 350 mM EDTA, 0.005% Tween-20) and concentrated by speed vacuum to 5X and 
10X.  The 1X, 5X and 10X eluted samples were analyzed on a 4-20% 15 μL  tris-tricine gel 
(BioRad) alongside known amounts of RelBE(His)6. At 100 V for 1 hr 45 min, with cathode 
buffer (100 mM Tris, 100 mM Tricine, 0.1% SDS, pH 8.3) in the inner chamber and anode buffer 
(200 mM Tris, pH 8.9) in the outer chamber.  Protein in identical gels was visualized either by 
staining with Sypro Ruby (Invitrogen) for  16  hours  and  or  by  α-His tag Western blot.   
For the Western blot, protein was transferred to PVDF membrane in Towbin transfer 
buffer (25 mM Tris, 192 mM glycine, 20% v/v methanol, pH 8.3) at 60V for 2 hrs at 4°C.  The 
membrane was blocked in PBS + 1% BSA for 1 hour at room temperature then washed 3 times in 
PBS + 0.01% Tween-20.  The membrane was probed with 1:20,000 dilution of anti-His6 antibody 
in PBS + 0.01% Tween-20 for 1 hour at room temperature, followed with three washes.  The blot 
was incubated for 5 min with 3 mL each luminol and hydrogen peroxide solutions (BioRad) and 
developed by exposing to film for various times.  The bands in the gel and Western blot were 
quantified by using the Image J program.   
 
3.7.7 High-throughput screening protocol 
PC biosensor plates were prepared with RelBE(His)6 as described above.  Compound 
plates were prepared by multiplexing 10 compounds per well in assay buffer + DMSO  and  40  μL  
compound  was  added  to  give  100  μM of each compound and 10% DMSO at the final 
concentration.  Plates were sealed with foil seals and covered with a plate filled with water to 
prevent condensation.  The plates were incubated at room temperature for ~12 hours, then washed 
3  times  with  100  μL  assay  buffer  in  the  automatic  plate  washer.    To  take  the  final  read,  40  μL  
assay buffer was added.  Finally, the plate was stripped by adding stripping buffer (10 mM 
HEPES, pH 8.3, 150 mM NaCl, 350 mM EDTA, 0.005% Tween-20) for 10 min and washing 5 
times  with  100  μL  assay  buffer  using  the  automatic  plate  washer.     
The data were plotted as the change in PWV value (PWV shift of RelBE baseline – PWV 
shift of the final wash) to reveal any compounds that caused a decrease in the PWV shift, 
indicating that protein had been removed from the PC biosensor surface.  A hit was determined as 
any well that had a PWV shift three standard deviations below the average of the four 
RelBE(His)6 + DMSO control wells. 
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3.7.8 Detection of RelE or peptide binding to RelB(His)6 on PC biosensor 
RelB(His)6 was bound to the PC biosensor as described above in the basic set-up 
protocol, except that 50 mM sodium phosphate, pH 7.0 buffer was used.  RelE (0-18  μM)  or  
peptide (0-500  μM)  were  added  and incubated for 12 hours at 4°C.  The wells were washed 3 
times with sodium phosphate buffer and the final PWV shift was measured. 
 
3.7.9 Peptide purification 
Reverse-phase HPLC was performed on a Beckman analytical n-butyl (C4) column 
housed  in  the  van  der  Donk  laboratory  to  purify  the  RelE  peptides.    The  “A”  line  of  the  HPLC  
contained dH2O  and  0.1%  trifluoroacetic  acid  (TFA)  and  the  “B”  line  contained  80%  acetonitrile 
and 0.086% TFA.  Before subjecting a peptide to HPLC-purification, the A and B pumps were 
first primed with their respective solutions.  Next, 100% of the B solution was flowed through the 
C4 column at a flow-rate of 1 mL/min for 5 minutes, followed by 2% B/98% A for at least 5 
minutes  at  1  mL/min  to  equilibrate  the  column.    A  “blank”  was  then  run  to  examine  the  baseline  
absorbance at 220 nm.  The blank program used an acetonitrile gradient with the following steps:  
Minutes 1-21 increase from 2% B/98% A to 100% B, minutes 21-26 hold at 100% B, minutes 26-
31 decrease from 100% B to 2% B/98% A.  After the blank was run, the column was again 
equilibrated with 2% B/98% A for 8-10 minutes at 1 mL/minute. 
Approximately 1 mg of crude peptide was resuspended in 1 mL dH2O and 500 – 700 L 
was injected onto the HPLC.  The program for an acetonitrile gradient on the C4 column 
consisted of the following steps:  Minutes 1-46 increase from 2% B/98% A to 100% B, minutes 
46-51 hold at 100% B, minutes 51-56 decrease from 100% B to 2% B/98% A, minutes 56-66 
hold at 2% B/98% A.  After running peptide over the column, the blank program was repeated, 
followed by flowing a 50% acetonitrile solution through the column for 15 minutes at 1 
mL/minute and priming pumps A and B again.   
MALDI-TOF mass spectrometry analysis was performed by the UIUC SCS mass spec 
facility to confirm the identity and purity of each purified peptide.   
 
3.7.10 Surface plasmon resonance assay 
The  NTA  chip  (Biacore)  was  prepared  by  washing  with  10  μL  eluent buffer (10 mM 
HEPES, pH 7.4, 150 mM NaCl, 50 EDTA, 0.005% surfactant p-20)  at  a  flow  rate  of  20  μl/min,  
then  30  μL  regeneration/stripping  buffer  (10  mM  HEPES,  pH  8.3,  150  mM  NaCl,  350  mM  
EDTA, 0.005% surfactant P-20)  10  μL/min.    The  surface  was  charged  with  20  μL  of  charging  
buffer Eluent buffer containing 0.5 M NiCl2) at  20  μL/min,  then  washed  with  eluent  buffer  again.    
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To  immobilize  protein,  1  μg/mL  RelB(His)6, was injected to only one flow cell until the RU 
reached ~800-1000.  Various concentrations of the  peptides  were  injected  at  10  μL/min  to  both  
the reference cell (no immobilized protein) and the RelB(His)6-containing flow cell, with 120 sec 
contact time and 120 sec dissociation time.  All buffers used in SPR were filter-sterilized and 
degassed. 
 
3.7.11 Biopanning 
The basic protocol is outlined in Table 3.3 and the variations between each individual 
biopan are highlighted in Table 3.4.  For Biopans X9.1-3 and X9.1-5, the phage solutions were 
first  subjected  to  a  “pre-clear”  involving  just  phage  and  solid  support  to  remove  any  phage  that  
bound to the solid support.  To pre-clear the phage with Ni-NTA resin, 0.5 mL of phage and 0.5 
mL of Ni-NTA resin were incubated for 30 min at room temperature.  The pre-clear the phage 
with the MagneHis magnetic Ni-NTA  beads,  50  μL  beads  was  incubated  with  200  μL  phage  
lysate  for  30  min.    The  “cleared”  phage  lysate  was  then  applied  to  the  immobilized  protein.    To  
immobilize RelB(His)6,  100  or  200  μL  of  1.0  mg/mL  was  incubated  with  decreasing  volumes  of  
the solid support throughout each biopan round:    20  or  10  μL  Ni-NTA resin for Rounds 1 and 3 
and  6  μL  MagneHis  beads  for  Rounds  2  and  4.    The  incubation  proceeded  for  30  min  at  room  
temperature.  The blocking solution was 5% BSA for Rounds 1 and 3 and 5% milk for Rounds 2 
and 4.  The incubation time for the phage and the immobilized protein was 25, 22, 18 and 15 min 
for Rounds 1, 2, 3, and 4, respectively.  The washes were as follows:  for Biopans X9.1-3, 4, 5, 
and 7, TBS+0.2% Tween was used in 5, 6, 7, and 8 washes for Rounds 1, 2, 3, and 4 respectively.  
For Biopan X9.1-8, TBS+0.2% Tween was used for 15, 6, 20 and 14 washes for Rounds 1, 2, 3 
and 4, respectively.  For Biopan X9.1-9, X9.2-1, 2, 3, 4 and 5, the washes were:  Round 1, 
TBS+0.2% Tween, 15 mL of wash buffer; Round 2, TBS+0.5% Tween, 6 washes; Round 3, 
TBS+0.8% Tween, 20 mL of wash buffer; Round 4, TBS+1.1% Tween, 14 washes.  For the X9.3 
and CXC libraries the washes were:  Round 1, 1- mL of TBS+0.2% Tween; Round 2, 11 mL of 
TBS+0.5% Tween; Round 3, 20 mL of TBS+0.8% Tween; Round 4, 14 mL of TBS+1.1% 
Tween.  The solution used for elution of the phage varied between 500 mM imidazole, 1% SDS 
or 1.6 mg/mL MBP-RelE(His)6 according to Table 3.4.  Eluted phage were propagated in an E. 
coli culture at OD600 = 0.8.  Following four rounds of biopanning, the eluted phage were 
propagated in E. coli on agar plates and 15 plaques from each biopan were analyzed.   
Plaque analysis was performed by  scraping  along  the  plaque  with  a  sterile  200  μL  filter  
tip  and  resuspending  in  100  μL  filter-sterilized 10 mM Tris, pH 7.9.  The solution was vortexed 
for  5  sec,  heated  to  65°C  for  10  min  and  centrifuged  3  min  at  full  speed.    For  the  PCR,  2  μL  of  
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this solution was used along with T7-21346-Up  primer  (5’-GTTAAGCTGCGTGACTTGGC-3’)  
and T7-21696-Dn  primer  (5’-GTTAGCGTCACCTTCCAGCG-3’).    Purified PCR products were 
sequenced using T7-21346-Up primer. 
 
3.7.12 Competitive biopan 
The recombinant phage and WT phage were in a 1:1x106 ratio and the exact protocol 
used in the initial biopan was repeated.  Plaques were analyzed as described above.  To separate 
the amplicons generated from the WT and recombinant phage, a 2% gels was prepared with the 
high resolution MetaPhor agarose (Lonza),  according  to  manufacturer’s  instructions. 
 
3.7.13 ELISA 
To prepare the plates, 100  μL  of 0.1 mg/mL RelB(His)6 was adsorbed to wells of a 
MaxiSorp plate (Nunc) for 3-4 hours at room temperature or overnight at 4°C.  The wells were 
washed 5 times with 300  μL  binding  buffer,  blocked  with  200  μL  5%  milk  in  Tris-buffered saline 
(TBS, 50 mM Tris, 150 mM NaCl, pH 7.5), then washed 5 times with TBS.  Phage lysate was 
added to the wells in  100  μL  volumes and incubated for 1 hour at room temperature.  The wells 
were washed 10 times  with  300  μL  TBS  +  0.2%  Tween-20  (TBST)  and  100  μL  of  a  1:2000 
dilution of the anti-T7-HRP conjugated antibody (Novagen) in TBST was incubated for 1 hour.  
Following  5  washes  with  300  μL  TBST, 100  μL  of  1 mg/mL of freshly-prepared ABTS (Sigma) 
in 100 mM phosphate-citrate buffer, pH 4.0 mixed with 0.03% H2O2 (final concentration) was 
added and incubated for 30 min in the dark.  The absorbance was read at 405 nm.   
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CHAPTER 4 
INVESTIGATION INTO THE ACTIVATION OF MAZFSA BY SYNTHETIC PEPTIDES 
AND IN RESPONSE TO ENVIRONMENTAL STRESS 
 
Sections from Chapter 4 have been published in “Detection of endogenous MazF enzymatic 
activity in Staphylococcus aureus,”  Williams  JJ and Hergenrother PJ. (2013) Anal Biochem, in 
press. 
 
4.1 INTRODUCTION 
As discussed in Chapter 1, the mazEFSa toxin-antitoxin (TA) system was detected in 
100% (78 of 78) clinical isolates of MRSA, and the mazEFSa transcript was also detected in all of 
the 8 isolates analyzed [39].  Additionally, a BLAST search revealed the mazEFSa genes in 44 S. 
aureus chromosomes (Table 1.1).  The mazEFSa genes are organized similarly to other TA 
systems, wherein the toxin start codon overlaps the antitoxin start codon; however, unlike many 
other TA systems, MazEFSa does not autoregulate its transcription.   
The mazEFSa genes are located in the sigB operon (Figure 4.1) which encodes for the 
stress-activated  alternative  sigma  factor,  σB, which allows for rapid response to environmental 
insults.  Full sigB activity is dependent on PmazE, which is upstream of sigB [10, 14].  The PmazE 
promoter is induced in response to sub-MIC levels of certain antibiotics and other environmental 
stressors such as heat shock [10, 34] and it was found that the SarA protein binds to the DNA 
upstream mazEFSa [10].  A negative feedback loop appears to require sigB; however it is 
unknown how transcription is downregulated [10].   
Figure 4.1  Genetic organization of mazEFSa in the sigB operon.  Transcription from the PmazE promoter is upregulated 
in response to heat shock and subinhibitory levels of antibiotics.  The transcriptional activator SarA is thought to bind 
the -35 element in PmazE.  Transcription from PmazE significantly contributes to the expression levels of sigB, which 
encodes for the stress-induced sigma factor σB, and full σB activity is dependent on PmazE.  Repression of transcription at 
PmazE is dependent on sigB, likely through an intermediary factor.  Figure from [10]  
 
Canonical antitoxin proteins contain an N-terminal leucine-zipper domain to facilitate 
homodimerization and binding to operator DNA.  However, as mentioned above, mazEFSa is 
unique in that it does not autoregulate its transcription; indeed alignment with the B. anthracis 
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MoxX antitoxin reveals the absence of the N-terminal dimerization domain in MazESa (Figure 
4.2A).  Secondary structure prediction revealed a conserved RHH domain at the N-terminus of 
MoxX that was required for repression of the moxXT promoter [6].  Modeling of MoxX with the 
crystal structure of the MoxT dimer revealed an extended polypeptide structure of MoxX that 
binds the MoxT dimer interface (Figure 4.2B) [6].  This structure closely resembles that of the E. 
coli MazEF crystal structure (Figure 4.2C) [23].   
 
Figure 4.2  Alignment of MazESa sequence and MazEFEc structures.  (A) ClustalW alignment of the B. anthracis 
MoxX and MazESa sequences.  Within the MazESa sequence, 29% and 41% amino acids are identical and similar, 
respectively, to MoxX.  Blue  “*”,  identity;;  green  “:”,  strong  similarity  and  purple  “.”,  weak  similarity.    (B)  Structure of 
the B. anthracis MoxX dimer (purple and pink) showing the extended C-terminus of one monomer binding the MoxT 
(green and cyan) dimer interface, with the E. coli MazEEc C-terminus is modeled in (yellow ribbon).  Structure from 
[6].  (C) Crystal structure of the MazEFEc heterohexamer.  The extended C-terminus of each MazEEc molecule (blue 
and cyan) binds a homodimer of MazFEc (pink and red, green and yellow).  Structure from [23] 
 
In S. aureus, the ClpPC protease was demonstrated to specifically cleave MazESa.  Upon 
treatment with rifampicin to halt transcription, the ectopically overexpressed MazESa was rapidly 
degraded, with a half-life of approximately 18-20 min, whereas levels of endogenous MazFSa 
remained stable [11]  Indeed, the S. aureus clpPC transcript is also upregulated in response to 
various stressors, including heat shock [13].  Thus, exposure of S. aureus to certain stressors may 
result in the activation of MazFSa. 
The toxin MazFSa is a sequence-specific endoribonuclease that inhibits the growth of S. 
aureus and Escherichia coli upon ectopic overexpression [14, 15] (Figure 4.3A).  
Overexpression in S. aureus decreased cell viability by 2-log CFU/mL after 60 min of induction; 
however, there was only ~27% difference in cell death at the 60 minute time point, suggesting 
that MazFSa induces stasis and not cell death (Figure 4.3B) [15].  MazFSa preferentially cleaves 
RNA at U↓ACAU sites which are abundant in certain transcripts, including those that code for 
B. anthracis MoxX MSESSVTTEIVVRLPKQMVTELDGIGKQENKNRHELICQATQLLLRQHKTKKRYQHESMR
S. aureus MazESa -------------------------------------------MLSFSQNRSHSLEQSLK
:* :.:.: .:*::
B. anthracis MoxX RGYIEMGKINLGIASEAFLAEYEAAHTVERLVSGG----
S. aureus MazESa EGYSQMADLNLSLANEAFPIECEACDCNETYLSSNSTNE
.** :*..:**.:*.*** * **.. * :*..
A
B C
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virulence factors such as the serine-rich pathogen adhesion factor SraP [43].  Overexpression of 
MazFSa in S. aureus results in time-dependent cleavage of other virulence transcripts, including 
hla and spa, whereas essential housekeeping transcripts recA and gyrB were not cleaved [15].  
The sraP transcript has a total of 43 UACAU cleavage sites which makes it a likely target for 
MazFSa degradation in the cell [43].  Indeed it was shown that MazFSa degrades a portion of the 
sraP transcript containing nine cleavage sites faster than a region of sraP containing five 
cleavage sites [43].   
 
Figure 4.3  Reduction in cell viability by ectopic overexpression of MazFSa in S. aureus.  (A) Induction of MazFSa 
resulted in a 2-log decrease in CFU counts over 60 min, whereas uninduced cultures continued to grow.  (B) Live/dead 
staining revealed a 27% decrease in cell viability over 60 min.  Figure from [15].   
 
 The ten transcripts most susceptible to MazFSa cleavage, based on number of UACAU 
sites, are shown in Table 4.1.  It is unknown if cleavage at these sites is responsible for the 
observed cell growth inhibition upon overexpression of MazFSa.  It has been shown that MazFSa 
preferentially cleaves only single-stranded mRNA and secondary structure can prevent access to 
cleavage sites [43].  Thus, for example, although the 16S rRNA contains a UACAU site, its 
extensive secondary structure likely protects it from MazFSa cleavage and indeed 16S rRNA 
isolated from cells overexpressing MazFSa is intact [10, 15].   
 
Table 4.1  Top 10 MazFSa-susceptible transcripts.  Table adapted from [43].  
aFold increase of actual UACAU count over expected UACAU count for specific transcript 
A B
gene 
length
UACAU count fold 
increasea
locus gene product
expected actual
6816 11.42 43 3.77 SA2447 Serine-rich adhesin protein SraP
1215 2.51 9 3.59 SA0794 D-alanine transport protein DltB
1557 2.33 8 3.43 SA1626 Type I restriction modification protein on pathogenicity island
1026 1.71 7 4.09 SA1466 S-adenosylmethionine tRNA ribosyltransferase isomerase QueA
816 1.28 6 4.69 SA2252 oligopeptide transporter protein Opp-1D
378 0.79 5 6.33 SA0062 transposase
297 0.61 4 6.56 SA1222 truncated transposase
390 0.65 4 6.15 SA0830 Hypothetical protein (integral membrane protein)
210 0.14 3 21.43 SA0930 Hypothetical protein
327 0.46 3 6.52 SA0456 Regulatory protein SpoVG
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The activation of MazFSa may serve as an anti-virulence strategy by enhancing its ability 
to cleave virulence-factor encoding transcripts.  We set out to identify peptides capable of 
enhancing the endoribonucleolytic activity of MazFSa.  Given the difficulty experienced with 
targeting the high-affinity TA complex or the instrinsically disordered antitoxin (discussed in 
Chapter 3 and Appendix II), we elected to target the toxin.  Furthermore, the MazF toxin is 
conserved across Gram-positive positive bacteria, including the problematic pathogens Listeria 
monocytogenes and Bacillus anthracis (Figure 4.4) [29].  Thus, an activator of the MazFSa toxin 
may also activate the MazF homologues in these pathogens.  Additionally, the ribosome-
independent activity of MazF facilitates facile analysis of activators for their effect on such 
analogs. 
Figure 4.4  ClustalW alignment of MazF homologues from S. aureus, B. anthracis and L. monocytogenes,, which are 
120,   116   and   115   amino   acids,   respectively.      The   three   proteins   share   60%   identity   and   26%   similarity.   Blue   “*”,  
identity;;  green  “:”,  strong  similarity  and  purple  “.”,  weak  similarity.   
 
To identify peptides that increased the activity of MazFSa, peptide fragment analysis of 
the antitoxin MazESa was performed using a kinetic assay with a short fluorogenic chimeric 
olignoucleotide substrate and a gel-based assay that employed a more relevant transcript 
substrate.  Although peptide-mediated enhanced ribonuclease activity was not achieved, the 
assays developed to detect MazFSa activity led to the first detection of endogenous MazFSa 
activity in S. aureus lysate.  All studies characterizing the growth inhibitory effect of MazFSa and 
cleavage of specific transcripts have relied on overexpression systems [14, 15, 43], which likely 
do not faithfully recapitulate the effect of endogenous MazFSa on mRNA cleavage and growth 
inhibition.  Additionally, the role of MazFSa in S. aureus stress response has been limited to the 
identification of conditions that upregulate transcription of mazEFSa such as exposure to 
antibiotics [10, 14], without determining the effect of increased transcription such as increased 
MazFSa activity.  Thus it remains unknown if MazFSa is involved in stress response and conditions 
that result in its activation are undefined.  The robust, sensitive assays described in this chapter 
provide a toolkit for the identification, analysis, and validation of molecules or conditions that 
S. aureus -MIRRGDVYLADLSPVQGSEQGGVRPVVIIQNDTGNKYSPTVIVAAITGRINKAKIPTHV
B. anthracis MIVKRGDVYFADLSPVVGSEQGGVRPVLVIQNDIGNRFSPTVIVAAITAQIQKAKLPTHV
L. monocytogenes MMVKRGDVYYADLSPVVGSEQGGIRPVLIIQNDIGNRFSPTVIVAAITAKIQKAKLPTHV
:::***** ****** ******:***::**** **::**********.:*:***:****
S. aureus EIEKKKYKLDKDSVILLEQIRTLDKKRLKEKLTYLSDDKMKEVDNALMISLGLNAVAHQKN
B. anthracis EIDAKKYGFERDSVILLEQIRTIDKQRLTDKITHLDEVMMIRVDEALQISLGLIDF-----
L. Monocytogenes EATRKD-GFERDSVILLEQIRTIDKQRLTDKITHLDEDLMAKVNKALEVSLGVVEF-----
* *. :::***********:**:**.:*:*:*.: * .*::** :***: .
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induce MazFSa activity and should assist in the discovery of both artificial and natural activators 
of the MazEFSa TA system. 
 
4.2 CLONING, EXPRESSION AND PURIFICATION OF MAZEFSA 
The mazEFSa genes were cloned from the MRSA isolate C2, which was previously 
shown to carry mazEFSa [39], into the T7 promoter-controlled expression vector pET-28a; 
expression of this clone results in the C-terminal His6-tagged protein complex, MazFSa(His)6.  
Additionally, mazESa alone was cloned from MRSA C2 into pET-28a to facilitate expression of 
(His)6MazESa.   
Initial expression and purification efforts revealed that the MazEFSa proteins were not 
expressed to high levels in E. coli BL21(DE3), thus purification by Ni2+-NTA affinity 
chromatography resulted in the co-purification of common contaminants (data not shown).  Thus, 
the expression vectors were introduced into E. coli NiCo21, a derivative of strain BL21(DE3) 
engineered to reduce the co-purification of proteins that have high intrinsic affinity for Ni2+-NTA 
resin [32].  The common contaminants were fused to chitin binding domains in the engineered 
strain [32], thus chitin-bead affinity chromatography removes these proteins.   
The MazFSa toxin was obtained by expression of the MazEFSa(His)6 complex in E. coli 
NiCo21 and subsequent denaturing purification on Ni2+-NTA resin to disrupt the interaction 
between MazESa and MazFSa (His)6.  On-column refolding by stepwise reduction of the urea 
concentration from 8 M to 0 M and subsequent purification over chitin resin resulted in highly 
pure MazFSa(His)6 (Figure 4.5).  The size and identity of MazFSa were confirmed by SDS-PAGE, 
mass spectrometry and trypsin digest. 
 
 
The MazESa protein was obtained from cultures of E. coli NiCo21 expressing 
(His)6MazESa by Ni2+-NTA affinity chromatography under native conditions.  Mass spectrometry 
revealed the susceptibility of MazESa to degradation by cellular proteases during the purification.  
The addition of protease inhibitors to the buffers used in purification allowed for purification of 
25
20
15
10
37
M(kDa)
Figure 4.5  Purification of (His)6MazESa 
and MazFSa(His)6.  Purified proteins were 
separated by SDS-PAGE and visualized 
by staining with Sypro RED.  The bands 
correspond to the theoretical molecular 
weights are 8.415 kDa and 14.506 kDa 
for (His)6MazESa and MazFSa(His)6, 
respectively.   
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intact MazESa, which was confirmed by SDS-PAGE (Figure 4.5) and mass spectrometry.  The 
MazESa sequence contains only two arginines and one lysine and is thus not suitable for 
identification by tryptic digestion.   
 
4.3 CHARACTERIZATION OF MAZFSA AND MAZESA 
MazFSa optimally  cleaves  at  the  sequence  U↓ACAU  in  single-stranded RNA and was 
also  shown  to  cleave  the  synthetic  RNA  substrate  5’-AAGUCUACAUCAG-3’  [43].  Based on 
this substrate, a chimeric DNA-RNA substrate consisting of DNA bases at all positions except for 
the U and the A surrounding the cleavage site was designed.  The DNA bases offer greater 
stability than RNA bases as well as protection from general ribonucleases.  The synthetic 
chimeric  substrate  5’-AAGUCrUrACATCAG-3’  (Figure 4.6A) was subjected to cleavage by 
MazFSa and analyzed by HPLC [41].  The HPLC trace in Figure 4.6B shows the cleavage of the 
chimeric substrate by MazFSa [41].  The mass of each product separated by HPLC was 
determined by MALDI mass spectrometry and the expected products were observed (data not 
shown).  Furthermore, the addition of (His)6MazESa inhibited the ribonculease activity of 
MazFSa(His)6 (Figure 4.6C) [41].   
 
Figure 4.6  Substrate cleavage by MazFSa(His)6.  (A) Non-fluorogenic   substrate   design,   “r”   denotes   RNA.      (B)  
Products from 16 hour incubation of oligonucleotide (32 μM) in the absence (black) or presence (blue) of 16 μM 
MazFSa(His)6 were separated by HPLC and analyzed by MALDI mass spectrometry.  The peak at the longest retention 
time corresponds to intact oligonucleotide (expected molecular weight [MW] = 3960.6).  The peaks at shorter retention 
times  correspond  to  5’  and  3’  fragments generated from MazFSa(His)6 cleavage; expected MWs = 1854.68 and 2105.4, 
respectively.  (C) 34  μM MazESa and  5  μM  MazFSa were incubated separately (black and blue line, respectively) or 
together  (green  line)  with  12  μM  substrate  at  37°C  for  12  hours  and  the products were analyzed by HPLC. 
 
The interaction between MazESa and MazFSa was demonstrated by native gel 
electrophoresis (Figure 4.7).  (His)6MazESa and MazFSa(His)6 were mixed in 2:1, 2:2 or 1:2 and 
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analyzed on a native gel.  Complex formation was observed in all ratios, but no free antitoxin 
band was detected in the 1:2 MazE:MazF ratio.  Although the crystal structure for MazEFSa has 
not been solved and there is no definitive data describing the ratio between the two proteins in 
complex, the E. coli MazE:MazF complex forms in a 1:2 ratio [23], suggesting the MazEFSa 
complex may be similar.   
 
Figure 4.7  Interaction of MazESa and MazFSa detected by native gel electrophoresis.  Various ratios of 
(His)6MazESa:MazFSa(His)6 were analyzed by native gel and stained with Sypro Ruby dye.  (His)6MazESa, with a 
theoretical pI of 5.63, is able to enter the pH 8.0 gel whereas the theoretical pI of MazFSa(His)6 is 9.55, precluding its 
entrance into the gel.   
 
4.4 KINETIC ASSAY FOR DETERMINATION OF MAZFSA KINETIC PARAMETERS 
The continuous fluorometric assay developed for MazFEc [37] was modified for kinetic 
evaluation of MazFSa.  The chimeric substrate was created with a 6-FAM fluorescein on  the  5’  
end and a quencher (Black Hole Quencher, BHQ) on  the  3’  end (Figure 4.9A).  Analysis of 
MazFSa cleavage in sodium phosphate buffer from pH 6.0-8.0 revealed that the optimal pH was 
~6.5, with activity declining as the pH of the buffer increased (Figure 4.8A).  Additionally, the 
fluorescence of the intact substrate (Figure 4.8B) and cleavage products (Figure 4.8C) increased 
with higher pH.  Thus, it was determined that a pH of 6.5 was optimal for MazFSa activity as well 
as reduction of background fluorescence in the assay. 
Figure 4.8  pH dependence on fluorogenic assay.  (A) Initial velocity of  0.8 μM MazFSa cleavage reaction with 0.25 
μM fluorogenic substrate in phosphate citrate buffer, pH 6.4-7.0 and phosphate buffer, pH 7.1-8.0.  Fluorescence of 
intact substrate (B) and cleavage products (C) in phosphate buffer from pH 6.0-8.0  
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Cleavage of this fluorogenic substrate by MazFSa resulted in increased fluorescence over 
time, allowing progress curves to be generated at various substrate concentrations (Figure 4.9B) 
[41].  The continuous nature of the fluorometric assay enabled the characterization of 
MazFSa(His)6 enzyme kinetics (Vmax = 0.12 pmol/min, KM = 0.56 µM, kcat/KM = 0.0079 M-1s-1) 
(Figure 4.9C) [41].  As has been noted previously, the absolute rate of processing of the 
fluorogenic substrate by recombinantly expressed and purified toxins is low and thus requires 
higher concentrations of enzyme than normally used in standard assays [5, 37].  Thus, although 
the Michaelis-Menten equation was fit to the data, the enzymatic parameters observed for 
MazFSa(His)6 do not follow standard Michaelis-Menten kinetics.   
 
Figure 4.9  Substrate cleavage by MazFSa(His)6.      (A)   Fluorogenic   substrate   design,   “r”   denotes   RNA.      (B)  
Representative   set   of   progress   curves   showing   cleavage   of   the   fluorogenic   substrate   (5’-6-FAM-
AAGTCrUrACATCAG-BHQ-3’)   by   MazFSa(His)6. Enzyme (0.8 uM) was added to the indicated concentration of 
substrate and the fluorescence was monitored over time in 384 well plates.  (C) Slopes from progress curves were fit to 
the Michaelis–Menten equation (solid line).  Error bars represent standard deviation, n=3.  
 
4.5 GEL-BASED ASSAY FOR MAZFSA ENDORIBONUCLEASE ACTIVITY 
Although the fluorogenic substrate is useful for kinetic assessment, MazFSa naturally 
cleaves mRNA transcripts.  Thus, a method for the detection of MazFSa(His)6 endoribonuclease 
versus mRNA was developed.  An RNA substrate was generated by in vitro transcription as 
described in the Materials and Methods.  The resultant transcript from this template contained 
three MazFSa cleavage sites, including one preferentially cleaved site (site 1, UACAU), a sub-
optimal site at which cleavage was not detected (site 2, UACGU) and a secondarily-cleaved sub-
optimal site (site 3, UACAU) (Figure 4.10, left).  The primary cleavage site was 86 bases from 
the  5’  end  of  the  full  length  transcript,  complicating  analysis  of  the  cleavage  products  by  gel  
electrophoresis (Figure 4.10, Left) [41].  To improve the resolution of the cleavage products on 
gels, the original template was engineered by site-directed mutagenesis by removing sites 1 and 2 
and optimizing site 3, such that the new substrate contained only one cleavage site of the optimal 
sequence UACAU (Figure 4.10, Right) [41].  Cleavage of this substrate by MazFSa resulted in 
easily distinguishable products (Figure 4.10, Right).   
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Figure 4.10  Development of transcript substrates for MazFSa(His)6 generated by in vitro transcription.  Left:  Cleavage 
of the 3-site substrate (50 nM) produces 4 cleavage products within 240 s incubation with MazFSa(His)6 (50 nM).  
Right:  Cleavage of the 1-site substrate results in two well-separated products.  RNA was separated on a denaturing 
3.5% polyacrylamide gel and stained with ethidium bromide. 
 
The sensitivity of this substrate for MazFSa(His)6 activity was tested with lower and 
perhaps more physiologically relevant concentrations of MazFSa.  A time course experiment with 
1 nM MazFSa(His)6 and 25 nM RNA resulted rapid cleavage, with approximately 50% processing 
of the substrate in 5 minutes (Figure 4.11) [41].  To our knowledge, this is the most sensitive 
assay for in vitro assessment of the ribonuclease activity of purified MazFSa.  Furthermore, 
MazFSa(His)6 activity was inhibited by (His)6MazESa, demonstrating the specificity of the 
cleavage of this substrate (Figure 4.11) [41]. 
 
 
Figure 4.11  Timecourse of MazFSa endoribonuclease activity.  MazFSa(His)6 (1 nM) was incubated at room 
temperature with 25 nM single site substrate.  Activity is detected within 10 s and >50% processing is achieved by 5 
min.  To inhibit MazFSa(His)6, (His)6MazESa was added prior to reaction with RNA for 60 seconds (+E lane).  RNA 
was separated on a denaturing 5% polyacrylamide gel and stained with ethidium bromide. 
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4.6 MAZESA PEPTIDE FRAGMENT ANALYSIS 
Peptide fragment analysis of the antitoxin MazESa was performed to identify peptides that 
increased the activity of MazFSa.  Ten peptides of 10 or 11 amino acids covering the MazESa 
sequence and overlapping by 5 amino acids (Figure 4.12A) were obtained in ~90% purity from 
Genscript (Table 4.2).  The effect of these peptides on MazFSa activity was assessed in both the 
kinetic and gel-based assays.   
 
Figure 4.12  Peptide fragment analysis of MazESa.  (A) A collection of ten-amino acid peptide fragments overlapping 
by five amino acids spanning the entire 56-residue MazESa were investigated.   (B) Each peptide 1-10 was incubated at 
60 μM for 3 hours with 0.8 μM MazFSa prior to incubation with 0.25 μM fluorogenic substrate.  The activity of MazFSa 
with no peptide is represented by the dotted line at 100% and the activity of MazFSa in the presence of each peptide is 
plotted.   
 
4.6.1 Assessment of peptides in kinetic assay 
For an initial screen, each  peptide  was  tested  at  60  μM  for  its  effect  on  MazFSa activity 
and as shown in Figure 4.12B, peptide 6 appeared to enhance the activity of MazFSa by 30%, 
whereas the others had minimal to no effect on the activity. 
To further examine its effects on MazFSa enzymatic activity, peptide 6 was tested at three 
concentrations,  5  μM,  25  μM  and  100  μM,  with  three  substrate  concentrations  corresponding  to  
0.089KM, 0.45KM, and 3.6KM.  As shown in Figure 4.13A, peptide 6 enhances MazFSa enzymatic 
activity in a dose-dependent manner across the three substrate concentrations.  Kinetic data was 
obtained for MazFSa in  the  presence  or  absence  of  100  μM  peptide  6  and  it  was  shown  that  
peptide 6 enhances the catalytic efficiency of MazFSa 1.7-fold (Figure 4.13C).  To assess the 
specificity of peptide 6 enhancement, it was tested with MazFSa and RNaseA.  As shown in 
Figure 4.13B, peptide 6 does not enhance the activity of RNaseA, thus suggesting that peptide 6 
specifically enhances MazFSa enzymatic activity. 
 
4.6.2 Assessment of peptides 5 and 6 in gel based assay 
The peptide fragments of were assessed for their effect on MazFSa ribonuclease activity.  
Each  of  the  10  peptides  was  incubated  at100  μM  with  100  nM  MazFSa for 3 hours prior to 
incubation for 1 min at room temperature with the single-site RNA substrate.  As shown in 
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Figure 4.14A, peptides 5 and 6 enhance the ribonuclease activity of MazFSa; in the absence of 
peptide, MazFSa activity is not detectable at this timepoint in the assay.   
 
Figure 4.13  The effect of peptide 6 on MazFSa and RNaseA acitivty.  (A) MazFSa was treated with 0, 5, 25 or 100 μM 
peptide 6 prior to addition of 0.05, 0.25 or 2 μM fluorogenic substrate.  MazFSa activity in the absence of peptide was 
set at 1.0 and the relative increase in initial velocity is shown for each concentration of peptide 6.  Error bars indicate 
standard deviation; P, statistical significance between designated groups.  (B) Increasing concentrations of peptide 6 
was added to MazFSa or to RNaseA.  The initial velocity of each enzyme in the absence of peptide 6 was set to 1.0 and 
the velocity of the enzyme in the presence of 25 or 100 μM peptide 6 was plotted as a fold-change over enzyme alone.  
(C) The effect of 100 μM peptide 6 on the kinetic parameters of 0.8 μM MazFSa with increasing concentrations of 
fluorogenic substrate (0.025-4 μM) was determined as described in Figure 4.9C.  Relative Vmax, KM and kcat/KM values 
were determined from the Lineweaver-Burk plot of the kinetic (data not shown).  
 
Peptide 5 and 6 showed a dose-dependent response on enhancement of MazFSa activity.  
Peptide 5 was tested from 5-200  μM  and  showed  optimal  activity  as  low  as  20  μM  (Figure 
4.14B).  Peptide 6 was tested from 10-200  μM  and  showed  optimal  activity  at  100  μM.    Both  
peptides  were  tested  at  100  μM  in  the  absence  of  MazFSa and had no effect on the RNA substrate 
(Figure 4.14B).   
 
 
Figure 4.14  MazESa peptide fragment analysis assessed by gel-based assay.  (A) MazESa peptide fragments were tested 
at 100 μM for their effect on the endoribonculease activity of 100 nM MazFSa using the single-site substrate in the 
absence (-) or presence (1-10) of peptide was incubated with 100 nM RNA for 1 min at room temperature.  (B) Dose-
response of peptides 5 and 6.  Peptides 5 and 6 were tested from 0-200 μM.  Both peptides were tested with RNA in the 
absence of MazFSa (P5, P6) and did not affect the RNA.  (C) Time-course assay with peptides 5 and 6.  200 nM MazFSa 
was incubated in the absence of (-) or presence of 100 μM peptide 5 or 6 (5, 6), followed by incubation with 100 nM of 
the three-site RNA substrate for 0-8 min at 37°C.   
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Peptides 5 and 6 were tested in a time-course assay with MazFSa using the 3-site 
substrate.  As shown in Figure 4.14C, quantitative cleavage of Site 1 is achieved by 
approximately 30 seconds and 3 minutes in the presence of peptide 5 and 6, respectively, whereas 
MazFSa alone shows minimal activity at 7 min.   
 
Table 4.2  Sequence and characteristics of peptides tested for MazFSa activity enhancement 
 
 
 
 
peptide # pI MW charge
1 1-10 MLSFSQNRSH 94.3 9.52 1206.34 1 20
2 6-15 QNRSHSLEQS 92.8 6.75 1185.21 1 10
3 11-20 SLEQSLKEGY 98 4.53 1153.24 -1 20
4 16-25 LKEGYSQMAD 93.8 4.37 1141.26 -1 20
5 21-30 SQMADLNLSL 97.5 3.8 1091.24 -1 40
6 26-35 LNLSLANEAF 91.4 4.0 1091.22 -1 40
7 31-40 ANEAFPIECE 96.4 3.67 1122.21 -3 20
8 36-45 PIECEACDCN 87.9 3.57 1096.22 -3 10
9 41-50 ACDCNETYLS 80 3.67 1118.2 -2 10
10 46-56 ETYLSSNSTNE 96.8 3.8 1244.22 -2 10
5-6 21-35 SQMADLNLSLANEAF 86.4 3.67 1623.79 -2 33
12 21-30 SQMADLNLSL 96.5 3.8 1091.24 -1 40
5-I 22-30    QMADLNLSL 91 3.8 876.4 -1 44.44
5-II 23-30       MADLNLSL 90.2 3.8 876.03 -1 50
5-III 24-30           ADLNLSL 93.4 3.8 744.84 -1 42.86
5-IV 25-30              DLNLSL 96.5 3.8 673.76 -1 50
5-V 26-30                 LNLSL 97.1 5.52 558.67 0 60
6-I 26-31                 LNLSLA 97.1 5.52 629.75 0 50
6-II 26-32                 LNLSLAN 97.2 5.52 743.85 0 42.86
6-III 26-33                 LNLSLANE 99.8 4 872.97 -1 37.5
6-IV 26-34                 LNLSLANEA 92.6 4 944.04 -1 30
5-Va 26-29                  LNLS 96.7 5.52 445.51 0 50
5-Vb 26-28                  LNL 99.5 5.52 358.43 0 66.60
5-Vc 27-30                    NLSL 96.4 5.52 455.51 0 50
5-Vd 27-29                    NLS 99.4 5.52 332.35 0 33.33
26-32 A1 26-32                 ANLSLAN 95.9 5.57 701.77 0 42.86
26-32 A2 26-32                 LALSLAN 97.7 5.52 700.83 0 71.43
26-32 A3 26-32                 LNASLAN 97.2 5.52 701.77 0 57.14
26-32 A4 26-32                 LNLALAN 93.8 5.52 727.85 0 71.43
26-32 A5 26-32                 LNLSAAN 97.4 5.52 707.77 0 57.14
26-32 A7 26-32                 LNLSLAA 96.7 5.52 700.83 0 71.43
Ac26-32 26-34                 LNLSLAN 90.3 5.52* 785.87 -1 57.14
26-32Am 26-35                 LNLSLAN 91.8 5.52* 742.87 1 57.14
attributes
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4.6.3 Derivatives of peptides 5 and 6 
 Peptides 5 and 6 overlap by five amino acid residues, so the sequence they share in 
common became the building block for the second generation of peptides.  To identify the 
shortest active peptide, single amino acid truncations from either the N-terminus of peptide 5 or 
the C-terminus of peptide 6 were obtained (Figure 4.15A). Additionally, a new preparation of 
peptide 5 was obtained to rule out a non-specific effect of the original stock.  The old and new 
preparations of peptide 5 along with the second generation derivatives were assessed  at  20  μM  
with 100 nM MazFSa.  As shown in Figure 4.15B, both the original and a new preparation of 
peptide 5 are active.  Moreover, the truncated derivatives LNLSL and LNLSLAN enhanced 
MazFSa activity to a greater extent than peptide 5 (Figure 4.15B).   
Many of the experiments described were performed at one minute points with a 
concentration of MazFSa that does not cleave significant RNA in that timeframe to more clearly 
differentiate the most potently active peptides.  To show enhancement over an active MazFSa 
baseline,  the  peptides  were  assessed  at  10  μM  with  200  nM  MazFSa, which cleaves detectable 
RNA at the minute timepoint, as shown in Figure 4.15C.  Although all of the peptide 5 and 6 
derivatives enhance MazFSa, enhanced processing of the RNA by MazFSa is observed in the 
presence of LNLSL and LNLSLAN (Figure 4.15C).  The QMADLNLSL AND MADLNLSL 
derivatives also enhanced MazFSa activity, but given the results observed in the previous assay, 
the shorter derivatives LNLSL and LNLSLAN were further investigated. 
Figure 4.15  Peptide 5 and 6 derivatives.  (A) Nine peptide derivatives that correspond to N-terminal truncations of 
peptide 5 or C-terminal truncations of peptide 6 and a 15-amino acid peptide encompassing the sequence of both 
peptides 5 and 6 were tested.  (B) The peptides derivatives were incubated at 20 μM with 100 nM MazFSa prior to 
addition of 100 nM RNA and incubation at room temperature for 1 min.  (C)  To observe increased RNA processing, 
200 nM MazFSa was treated with 10 μM.peptide, followed with incubation with 100 nM RNA for 1 min at room 
temperature.  (D) Dose response of LNLSL and the E. coli Extracellular Death Factor NNWNN.  Each peptide was 
tested from 0-200 μM with 100 nM MazFSa and 100 nM RNA incubated at room temperature for 1 min.  RNA was 
separated on a denaturing polyacrylamide gel and stained with ethidium bromide. 
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 The E. coli Extracellular Death Factor (EDF) is a pentapetide with the sequence 
NNWNN and has been shown to enhance the enzymatic activity of MazFEc.  It was proposed that 
EDF binds at the interface of MazFEc dimers and increases its catalytic efficiency by decreasing 
the affinity of MazFEc for the RNA substrate.  EDF was tested from 6.25-200  μM  and  shown  to  
have no effect on MazFSa activity, whereas the active 5-amino acid derivative LNLSL was active 
at  12.5  μM  and  showed  optimal  activity  at  25  μM  (Figure 4.15D).   
 
4.6.4 Derivatives of LNLSL and LNLSLAN 
Based on the enhancement observed with the peptide LNLSL, three- and four-amino acid 
derivatives (Figure 4.16A) were assessed  at  10  and  20  μM  with  100  nM  MazFSa.  As shown in 
Figure 4.16B, none of the three- and four-amino acid peptide derivatives enhanced MazFSa 
activity.  Thus, LNLSL was the shortest active peptide.   
Figure 4.16 Derivatives of LNLSL and LNLSLAN. (A) Truncated derivatives of LNLSL, alanine-substituted 
derivatives of LNLSLAN and N-acetylated and C-amidated derivatives of LNLSLAN were obtained.  (B) Each peptide 
derivative was incubated at 10 μM (top) or 20 μM (bottom) with 100 nM MazFSa fpr 3 hours prior to incubation with 
100 nM RNA at room temperature for 1 min.  (C)  The   activity   of   each  peptide  was   ranked,  with   “—”  denoting  no  
activity,  and  increasing  activity  indicated  by  a  greater  number  of  “*”.    (D)  The  activity of each peptide was used to rank 
the   contribution   of   each   feature   of   the   parent   LNLSLAN   to   its   enhancement   activity,   with   “—”   indicating   no  
contribution,  “x”  indicating  a  negative  effect,  and  each  “*”  denoting  increasing  importance  of  the  specific  amino acid 
residue.  RNA was separated on a denaturing polyacrylamide gel and stained with ethidium bromide. 
 
To determine the important amino acid residues that contribute to the enhancement effect 
of peptide LNLSLAN, alanine-substituted derivatives were obtained (Figure 4.16A).  
Additionally, derivatives modified with an N-terminal acetylation or C-terminal amidation were 
obtained.  These  peptides  were  assessed  at  10  and  20  μM  with  100  nM  MazFSa.  As shown in 
Figure 4.16B, the A1, A3, A5 and C-terminal amidated peptides showed no enhancement of 
MazFSa; activity of these peptides was completely abolished.  However, the A2 derivative showed 
increased activity over the parent, the N-acetylated derivative had comparable activity to the 
parent peptide, the A4 derivative showed slightly reduced activity compared to the parent and the 
A7 derivative showed a further reduction in activity (Figure 4.16B).  The results are summarized 
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in Figure 4.16C, with the number of stars indicating the ranked level of activity of each peptide.  
These rankings were used to determine the contribution of each feature of the parent LNLSLAN 
peptide, depicted in Figure 4.16D.  In summary, each Leu residue and the carboxylic 
functionality are required for activity.  The C-terminal Asn residue also contributed to activity, as 
its removal reduced the enhancement effect on MazFSa.  The N-terminal functionality appears to 
be inconsequential to the activity.  Improved activity was observed when the Asn2 was replaced 
with Ala and activity appeared slightly  diminished  at  10  μM  when  the  Ser4  residue  was  replaced  
with Ala.   
 
4.6.5 Peptide 5 non-specifically prevents protein adsorption to assay tube 
Time course experiments were performed to determine the length of incubation between 
peptide and MazFSa(His)6 required for activity enhancement.  Unexpectedly, these experiments 
revealed that MazFSa activity diminished over the course of the experiment.  The addition of BSA 
or CHAPS to the buffer solution prevented the loss of activity of 100 nM MazFSa; also, higher 
concentrations of MazFSa maintained activity for a longer period of time.  The peptides were 
tested under these improved conditions and found to have no effect (Figure 4.17).  Thus, peptides 
5 and 6 did not enhance MazFSa when its activity remained stable throughout the experiment.   
 
Figure 4.17  Peptides were tested for their effect on MazFSa activity in the presence of (A) 0.01% BSA or (B) 0.1% 
CHAPS.  10 nM MazFSa was incubated for 1 hour in the absence (-) or presence (1-10) of 100 μM peptide prior to 
incubation with 100 nM RNA for 45 sec at room temperature.  RNA was separated on a denaturing polyacrylamide gel 
and stained with ethidium bromide. 
 
It was determined that in the absence of BSA or CHAPS, MazFSa adsorbed to the 
polypropylene microcentrifuge tube, causing the enzyme to lose activity over time, especially at 
the relatively low concentrations used in the peptide experiments (100 nM).  Four unrelated His6-
tagged proteins, MazFSa, MBNL, Procaspase-3 and Thi4p were shown to adsorb to the tubes and 
peptide 5 prevented adsorption of each protein to a large degree (Figure 4.18).  Thus, peptide 5 
did not actually enhance MazFSa activity; rather it kept a high percentage of MazFSa in solution 
throughout the three hour incubation that was typically employed to test the activity of the 
peptides.  Since no other peptide enhanced MazFSa activity under optimal conditions (Figure 
4.17), the MazESa peptide fragments were no longer pursued.   
1- 2 43 5 76 8 109 - 1- 2 43 5 76 8 109 -
A BMazESa peptide fragments 1-10 MazESa peptide fragments 1-10
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Figure 4.18  Peptide 5 prevents adsorption of proteins to tubes.  Four unrelated His6-tagged proteins (each ~100 μM) 
were assessed for their time-dependent adsorption to polypropylene microcentrifuge tubes.  Proteins were incubated in 
a tube for 5, 30, 60 or 180 min and at each time point, the solution (S) was transferred to another tube and SDS loading 
dye was added to keep the protein in solution.  Addition of buffer containing SDS resolubilized the protein from the 
walls of the original tube (E).  Proteins were visualized by α-His6 tag Western blot.  In the absence of peptide (top row) 
the protein is nearly all adsorbed to the tube, whereas peptide 5 (bottom row) prevents some of the adsorption.  
 
4.7 DETECTION OF MAZFSA ACTIVITY IN S. AUREUS CELL LYSATE  
 
4.7.1 Development of a radiolabeled substrate for MazFSa activity 
The next step for the assessment of the peptides was to test their effect on endogenous 
MazFSa in S. aureus cell lysate.  Thus, a radiolabeled version of the single site substrate was 
prepared.  Even though the peptides were no longer being tested, the detection of endogenous 
MazFSa activity was unprecedented but potentially had many important applications.  Primarily, a 
sensitive assay allowing the specific detection of MazFSa activity could enable studies to 
determine the effect, if any, of MazFSa activity in response to stressors such as antibiotics. 
As a prelude to experiments with endogenous MazFSa from S. aureus lysate, the activity 
of MazFSa(His)6 was assessed with a 32P-labeled version of the single site substrate in a time 
course experiment.  As shown in Figure 4.19, the sensitivity of the assay allows for clear 
differentiation in the activity of increasing concentrations of MazFSa [41].  In this experiment, 
minimal cleavage is detected by 1 nM MazFSa(His)6 after 11 min incubation, moderate processing 
is observed by 5 nM MazFSa(His)6,and significant processing by 10 nM MazFSa(His)6 (Figure 
4.19) [41]. 
 
Figure 4.19  Radiometric assay for MazFSa.  MazFSa(His)6 was incubated at room temperature with 32P- labeled single-
site substrate (100 nM) and activity visualized by phosphorimaging. 
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4.7.2 Detection of endogenous MazFSa activity in S. aureus cell lysate  
The highly sensitive and specific processing of the radiolabeled substrate allowed for 
detection of endogenous MazFSa activity in S. aureus cell lysate.  Lysate was prepared from the S. 
aureus strain NRS26, in which the mazEFSa genetic loci and transcripts were previously detected 
[39].  The radiolabeled substrate was added to the lysate 7, 15, 35 and 65 min post-lysis.  As 
shown in Figure 4.20, cleavage of the RNA substrate increased with longer post-lysis incubation 
times [41].  This result suggests that MazESa is susceptible to proteolysis in the lysate, releasing 
active MazFSa.  Addition of recombinant (His)6MazESa to lysate 65 min post-lysis inhibited 
MazFSa activity, demonstrating the specificity of the RNA cleavage by endogenous MazFSa.  This 
marks the first assessment of the activity of endogenous MazFSa [41]. 
 
Figure 4.20  Detection of endogenous MazFSa activity in S. aureus cell lysate.  Radiolabeled RNA transcript (100 nM) 
was added to of S. aureus lysate at 7, 15, 35 or 65 min post-lysis and incubated at room temperature for 2, 5 or 10 min.  
Far Right: The endogenous MazFSa present in lysate 65 min. Controls of RNA only (R) and RNA processed in vitro by 
MazFSa(His)6 (R+F) were also analyzed. post-lysis was inhibited by a 10 min incubation with (His)6MazESa prior to 
reaction with radiolabeled RNA for 10 (65+E).  Products were separated by gel electrophoresis and visualized by 
phosphorimaging.  
 
4.8 CONCLUSIONS 
 The enhancement of toxin activity by a peptide fragment based on the antitoxin is not an 
intuitive strategy, but one for which there is precedent.  As discussed in Section 1.4.4.1, the E. 
coli EDF peptide NNWNN was demonstrated to both enhance the kinetic activity of E. coli 
MazFEc, as well as allow MazFEc to remain active in the presence of MazEEc [3].  It seems 
counterintuitive that a peptide fragment that apparently competes for the most intimate interaction 
[3], between MazEEc and MazFEc would not inhibit the ribonuclease activity of MazFEc.  However, 
this observation can be explained by analysis of the MazEFEc crystal structure, which revealed 
that the binding sites for mRNA and MazEEc overlap [22].  MazE actually occupies only one of 
the possible two MazEEc binding sites within a MazFEc homodimer; furthermore, only one of the 
mRNA binding sites is ever occupied by mRNA in a MazFEc homodimer [22, 25].  Binding of 
MazEEc to one site in the MazFEc homodimer perturbs mRNA binding in the other site [20, 25].  It 
was proposed that EDF competitively inhibits the MazEEc-MazFEc interaction, while still allowing 
mRNA to bind in the second catalytic site [3, 20].  Additionally, the affinity of MazFEc for mRNA 
is reduced in the presence of EDF, which likely explains the enhancement of MazFEc 
R+F 7 15 6535 7 3515R 65 7 15 6535 65+E
2 min 5 min 10 min
Min post-lysis
Reaction time
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ribonucleolytic activity [3, 20].  Although the EDF story remains controversial [18, 21, 36], it 
provides rationale for a provocative TA system-targeting strategy. 
 Without a crystal structure of the MazEFSa complex, it is difficult to speculate why none 
of the MazESa peptide fragments enhanced MazFSa activity.  There is a structure for the B. subtilis 
MazF homologue [17], which shares both high sequence homology with MazFSa, as shown in 
Figure 4.4 (B. subtilis and B. anthracis MazF proteins are identical), and structural similarities to 
E. coli MazFEc [17].  However, the mRNA binding sites of the Gram-positive MazF proteins have 
not been extensively characterized and so it remains unknown if there are dual MazE and 
substrate binding sites in these toxins, as in E. coli MazFEc [25].  Additionally, modeling studies 
suggested that the interaction between EDF (NNWNN) and E. coli MazFEc is mediated largely by 
the tryptophan residue that competes with Trp73 of MazEEc [3], which occupies a hydrophobic 
pocket of MazFEc forming the most intimate interaction between MazEEc and MazFEc [23].  
MazESa does not contain an analagous tryptophan residue.  Additionally, the crystal structure of 
MazEFEc showed that the most extensive contact interface is mediated by conserved aromatic 
amino acids Tyr39, Tyr58 and Phe60 of MazF [23]; however, MazFSa does not have any 
analogous aromatic amino acids.  A more in depth understanding of the interaction between 
MazESa and MazFSa would be informative and highly useful.  The difficulty with this project 
further highlights the need for additional crystal structures of TA systems, as discussed in Chapter 
1.   
 Although the peptide fragment analysis did not facilitate the discovery of a toxin 
activator, it led to a set of key assays that have provided a tool to probe the effect of stress on 
toxin activation in the cell.  In S. aureus, exposure to heat or subinhibitory concentrations of 
certain antibiotics results in increased transcription of the TA genes.  However, the consequence 
of the transcriptional upregulation, if any, is unknown.  The organization of TA genes ensures 
that the toxin is only transcribed in the context of the antitoxin and that less toxin than antitoxin 
will be translated, as discussed in Section 1.3.4.  Indeed, the natural activation of the toxin is 
dependent on the specific proteolysis of the antitoxin [7].  In S. aureus, the ATP-dependent 
ClpPC protease degrades MazESa [11] and is also upregulated in response to stress, namely, heat 
shock [13].   
Many other type II TA systems have been implicated in stress management [16, 38].  E. 
coli RelBE is involved in the stringent response induced by amino acid starvation, inhibiting 
translation and causing bacteriostasis [7, 31].  MazEF in E. coli has been postulated to induce cell 
death under stressful conditions [2] or to modulate translation such that the cells become 
bacteriostatic until conditions improve [8, 31].   
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The location of the mazEFSa TA system in the sigB operon [14], transcriptional response 
to antibiotics and heat shock [10], and proteolytic regulation by a stress-induced protease [11] 
certainly implicates the role of MazFSa as a modulator of the stress response in S. aureus.  
However, an increase in MazFSa activity in response to stress has not been demonstrated.  The 
sensitive and specific assay we have developed for the detection of endogenous MazFSa activity 
in S. aureus cell lysate will allow the effect of stressors on the activation of MazFSa to be 
unambiguously measured. 
Toxin-antitoxin systems are an ingenious method to maintain a plasmid in a bacterial 
host.  Although their role on the bacterial chromosome is unclear, at the biochemical Type II TA 
systems operate via the same mechanism whether plasmid or chromosomal, that is, a stable toxin 
protein is inhibited by a proteolytically labile (and co-transcribed) antitoxin protein.  Important 
work has shown that the genes for TA systems are present in a variety of pathogenic bacteria [4, 
19, 27, 28, 33, 39].  Fewer publications have reported on the detection of TA transcripts in such 
bacteria [19, 27, 39], and fewer still on the detection of the actual TA proteins [10, 14].  While the 
presence of the DNA, mRNA, and proteins is clearly informative, it does not tell the whole story, 
especially for TA systems.  Specifically, transcription and translation does not mean that the 
protein toxin is enzymatically active, given the co-transcription and (presumably) co-translation 
of the proteic antitoxin. 
Herein described is an assay that allows, for the first time, for the detection of MazFSa 
enzymatic activity from its endogenous source.  The principles applied for the design of this 
substrate and this assay should be readily transferable to the study of other toxins from TA pairs, 
especially those that are ribonucleases.  There are many questions about the roles of TA systems 
in basic bacteriology [21, 24, 26, 35, 36, 42], their function in response to stress [16, 38] and their 
potential as novel antibacterial targets [1, 9, 12, 30, 40].  The tools described herein for the direct 
detection of endogenous toxin activity should significantly facilitate the answering of those 
questions. 
 
4.9 EXPERIMENTAL PROCEDURES 
 
4.9.1 Materials 
Primers and oligonucleotides were synthesized by IDT.  Pepstatin A, leupeptin, aprotinin, 
phenylmethanelsulfonyl fluoride (PMSF) and lysozyme were purchased from Sigma.  Restriction 
enzymes, BSA, Low-Range ssRNA Ladder, RNase Inhibitor—Human Placenta, and E. coli 
strains DH5α  and  NiCo21 were purchased from New England Biolabs (NEB).  Subcloning 
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Efficiency DH5α  Chemically  Competent E. coli was purchased from Invitrogen.  IPTG and 
kanamycin were purchased from GoldBio.  Lysing Matrix B was obtained from MP Biomedicals.  
[α-32P-UTP] was purchased from Perkin-Elmer.  Sypro RED protein stain was purchased from 
VWR.   
 
4.9.2 Cloning 
E. coli DH5α  and  NiCo21(DE3)  were  used  for  cloning  and  protein  expression,  
respectively.  The mazEFSa gene cassette was amplified by PCR using primers mazEFSa -NcoI-F 
(5’ACACCCATGGATATGTTATCTTTAGTCAAAATAG-3’)  and  mazEFSa-XhoI-R  (5’  
CACACTCGAGATTTTTCTGGTGAGCTAC-3’) (Figure 4.21) from the total DNA of the 
MRSA strain C2 [39].  The amplicon was inserted into the corresponding restriction sites of pET-
28a to create resulting in pET-28a-mazEFSa, which encodes for MazEFSa containing a C-terminal 
histidine-6 tag on MazFSa.  The mazESa antitoxin gene was amplified from the same strain using 
primers mazESa-NdeI-F  (5’ACACCATATGTTATCTTTTATCAAATAGAAG-3’)  and  mazESa-
XhoI-stop-R  (5’-ACACCTCGAGTCATTCATTCGTTGAATTAGAA-3’)  and  cloned  into  pET-
28a, resulting in pET-28a-mazESa, which encodes for an N-terminal histidine-6 tagged MazESa 
(Figure 4.22).  The correct sequence of all clones was confirmed by sequencing.  E. coli carrying 
the recombinant plasmids was cultured in LB containing 50 µg/mL kanamycin.   
 
4.9.3 Protein Expression and purification 
To express MazEFSa(His)6, an overnight culture inoculated with a single colony of E. coli 
NiCo21 freshly transformed with pET-28a-mazEFSa was diluted 100-fold into 2 L of LB+Kan.  
The culture was grown at 37°C until the OD600 reached 0.6-0.8, at which point expression was 
induced with 1 mM IPTG (final concentration) for 4 hours at 37°C.  Expression of (His)6MazESa 
was performed the same, except IPTG was added when the OD600 reached 0.4-0.6.  The 2 L 
cultures were harvested by centrifugation at 4°C (8,000 g for 500 mL bottles and 10,000 g for 50 
mL conical tubes) and stored at -20°C. 
MazFSa(His)6 was purified from the complex under denaturing conditions.  A pellet 
corresponding to 2 L culture was thawed in a room temperature water bath for 10 minutes.  The 
pellet was resuspended in 20 mL binding buffer (10 mM Tris, pH 7.9, 500 mM NaCl, 10 mM 
imidazole) containing 8 M urea and cell lysis was achieved by 30 minutes inversion at room 
temperature.  Cell debris was pelleted by centrifugation at 40,000 g at room temperature for 15 
minutes.  The clarified lysate was mixed with 1 mL 1:1 Ni-NTA resin slurry (Qiagen) and batch 
loaded for 30 min at room temperature with inversion.  The slurry was applied to a gravimetric 
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flow column and the resin was washed with 50 mL binding buffer with 8M urea to fully disrupt 
the MazESa-MazFSa complex.  On-column refolding of MazF was achieved with seven washes of 
10 mL urea/binding buffer decreasing the concentration of urea by 1 M with each wash.  Wash 
steps containing more than 4 M urea were performed at room temperature; all subsequent wash 
steps were performed at 4°C.  Refolding was followed with 10 mL washes of binding buffer 
(containing no urea) and binding buffer containing 60 mM imidazole.  MazFSa(His)6 was eluted 
with 5 mL binding buffer containing 250 mM imidazole.  To remove common contaminants 
retained on Ni-NTA resin, the eluate was diluted with 5 mL binding buffer and applied to a 5 mL 
bed volume of chitin resin (NEB) followed by washing with 8 mL binding buffer.  The flow 
through and wash fractions were combined and concentrated to ~1 mL using an Amicon Ultra-15 
3 kDa molecular-weight cutoff spin concentrator (Millipore) at 4°C.  After overnight dialysis in 
PBS, pH 6.5, the MazFSa purity and concentration was assessed by SDS-PAGE using 4-20% 
TGX Mini-Protean gels (Bio-Rad).  Concentration was determined using densitometry of the 
SDS-PAGE and by BCA Assay (Pierce) using lysozyme (molecular weight 14.3 kDa) as the 
standard for both quantification assays. 
(His)6MazESa was purified under native conditions and all steps were performed on ice or 
at 4°C.  A pellet corresponding to 2L culture was thawed for 5-10 min and resuspended in cold 
binding buffer containing protease inhibitors (2 µg/mL pepstatin A, 1 µg/mL leupeptin, 1 µg/mL 
aprotinin and 1 mM PMSF).  The cells were lysed by 5 min sonication with 1 s pulse at 50% 
amplitude.  The lysate was cleared by 15 min centrifugation at 40,000 g at 4°C and the 
supernatant was batch loaded with 0.5 mL 1:1 Ni-NTA resin slurry (Qiagen) for 30 min at 4°C 
with inversion.  Protease inhibitors were included in the wash and elution buffers.  The resin was 
washed with 20 mL binding buffer, followed with 25 mL binding buffer containing 60 mM 
imidazole.  (His)6MazESa was eluted with 5 mL binding buffer containing 250 mM imidazole, 
concentrated to ~0.5 mL and dialyzed against 50 mM sodium phosphate, pH 7.0, 150 mM NaCl, 
1 mM DTT.  Purity and concentration were assessed using the same method described for 
MazFSa(His)6.   
 
4.9.4 HPLC analysis of oligonucleotide cleavage products 
A 10 µL solution of 16 µM MazFSa(His)6 and 32 µM 5-AAGTCrUrACATCAG-3’  (“r”  
denotes RNA base) in 10 mM Tris pH 7.9, 500 mM imidazole, 20% glycerol was incubated 
overnight at 37°C.  The reaction was mixed with 20 µL 0.1 M triethylammonium acetate 
(TEAA), pH 7.0, and 10 µL was analyzed by high performance liquid chromatography using an 
Alliance HPLC System (e2965 Separations Moedule, Waters) with detection at 260 nm (2489 
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UV/Visible Detector, Waters).  The full length oligonucleotide was separated from the cleavage 
products on a YMCbasic S5 column (4.6 x 150 mm, 5 µm, Waters) with a linear gradient of 100 
mM TEAA to 50 mM TEAA/50% acetonitrile over 25 min.  Fractions were analyzed by MALDI 
mass spectrometry.   
 
4.9.5 Fluorometric oligonucleotide cleavage assay 
The  fluorogenic  substrate  5’-6FAM-AGTCrUrACATCAG-BHQ-3’  (6-FAM, 6-
carboxyfluorescein,  BHQ,  black  hole  quencher;;  “r”  denotes  RNA  base)  was  diluted  in  phosphate-
citrate (PC) buffer (71 mM phosphate, 14.5 mM citrate, pH 6.5).  Wells of a 384-well sterile 
black tissue-culture plate (ThermoFisher) were filled with 15 µL of each dilution (0.025-4 µM 
final concentration).  After substrate equilibrated for 30 min at room temperature, 15 µL of 
MazFSa(His)6 was added to the wells containing intact substrate.  The fluorescence of the plate 
was measured every 30 s for 45 min using a Criterion Analyst AD (Molecular Devices) with 485 
± 15 nm excitation and 530 ± 15 nm emission filters and a 505 nm cutoff dichroic mirror. The 
fluorophore was excited with a 1000 W continuous lamp with 10 reads per well.  The Z-height 
was set to 1 nm.   
A calibration curve of the independently synthesized substrate halves corresponding to 
the  cleavage  products,  5’-6-FAM-AGTCG and ACATCAG-BHQ-3’  [37], was constructed to 
quantify the amount of cleavage product formed based on the RFU value.  Wells containing 
0.0625-2 µM of the cleavage fragments were prepared alongside the intact oligonucleotide 
following the same protocol, except PC buffer was added instead of MazFSa(His)6.  The 
calibration curve was constructed by plotting the average RFU measured over the 45 min 
experiment against amount of oligonucleotide in the well.   
 
4.9.6 In vitro transcription of RNA substrate 
Quickchange site-directed mutagenesis was performed to modify the MazFSa cleavage 
sites in pET200-mazEF recombinant plasmid pKm6EF [37].  MazFSa optimal cleavage site 1 was 
removed by changing TACAT to GGCAT using the following primers Site1-QC-F  (5’- 
GTTTAACTTTAAGAAGGAGATAGGCATATGCGGGGTTCTCATCATC and Site1-QC-R 
GATGATGAGAACCCCGCATATGCCTATCTCCTTCTTAAAGTTAAAC-3’,  suboptimal 
cleavage site 2 was removed by changing TACGT to CACAT using Site2-QC-F  (5’-
GGATCCCGGCCACGTTAATGCAGGCGCTCAATC-3’)  and  Site2-QC-R  (5’-
GATTGAGCGCCTGCATTAACGTGGCCGGGATCC-3’)  and  the  suboptimal  cleavage  site  3  
was optimized by changing from TACGT to TACAT using Site3-QC-F  (5’- 
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GGTAATGGTAAGCCGATACATACCCGATATGG and Site3-QC-R  (5’-
CCATATCGGGTATGTATCGGCTTACCATTACC-3’).    The  quickchange  PCR  was  performed  
following the guidelines in the QuikChange manual (Stratagene) with annealing temperatures of 
58°C for Site1 and Site2 PCRs and 61°C for Site 3 PCR.  The PCR product was purified and 
digested with DpnI and transformed into Sub-cloning Efficiency CaCl2-treated E. coli following 
the  manufacturer’s  instructions  except  the  cells  were  heat  shocked  for  30  s.    The transformation 
was plated on LB containing 50 µg/mL kanamycin.  Each mutation was confirmed by sequencing 
of both strands.  The plasmid containing the optimized substrate is referred to as pET200-mazEF-
1Δ2Δ3opt.     
To prepare the RNA substrate, the pET200-1Δ2Δ3opt  plasmid  was  digested  with  HindIII 
for 3 hours at 37°C.  The digested plasmid was purified using the QiaPrep Spin Column (Qiagen) 
and eluted with 30 µL DEPC-treated water.  The digested plasmid (0.5-1 µg) served as the 
template for in vitro transcription using the T7 High Yield RNA Synthesis Kit (NEB) according 
to  the  manufacturer’s  instructions.    Each  in  vitro  transcription  reaction  was  divided  into  two  equal  
portions and purified according to the RNeasy Mini handbook (Qiagen) RNA Cleanup protocol 
using reagents from the Total RNA Kit I (Omega Bio-Tek).  RNA was eluted twice with 30 µL 
0.1 mM EDTA prepared in DEPC-treated water and all elution fractions from both columns were 
pooled, quantified by A260 and checked for integrity by gel electrophoresis on a 5% acrylamide 
8M urea 1X TBE gel post-stained for 15 min with 0.05 µg/mL ethidium bromide. 
 
4.9.7 MazFSa kinetic assays in the presence of peptide  
For  the  peptide  initial  screen,  0.8  μM  MazFSa was  incubated  alone  or  with  60  μM  each  
peptide for 3 hours at room  temperature  prior  to  addition  of  0.25  μM  fluorogenic  substrate.    
Fluorescence was monitored for 80 minutes and the rate of cleavage was determined by the 
increase in fluorescence over time.  
The effect of peptide 6 on MazFSa and RNaseA activity was determined by incubating 0.8 
μM  MazFSa (final concentration) with treated with 0, 5, 25 or 100 μM peptide 6 for 3 hours prior 
to addition of 0.05, 0.25 or 2 μM fluorogenic substrate.  Fluorescence was monitored for 1 hour.   
The effect of peptide 6 on MazFSa kinetics was determined by treating 0.8 μM MazFSa 
with 100 μM peptide 6 for 3 hours prior to adding the fluorogenic substrate at 0.025-4 μM.  
Fluorescence was monitored for 1 hour and the relative Vmax, KM and kcat/KM values were derived 
from the Lineweaver-Burk plot of the kinetic.  
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4.9.8 Effect of peptide 6 on RNase A activity in fluorogenic assay 
RNaseA was diluted to 3x10-7 U/mL, a concentration that resulted in a similar initial 
velocity as 0.8 μM MazFSa when incubated with 2 μM fluorogenic substrate, and treated with 0, 
25  or  100  μM  peptide  6  for  3  hours  prior  to  addition  of  2  μM  fluorogenic  substrate.    Fluorescence  
was monitored for 1 hour and the initial velocity was plotted. 
 
4.9.9 Effect of peptide on MazFSa activity in gel-based assay 
To screen the peptides in the gel-based assay, 100 nM MazFSa was incubated alone or in 
the  presence  of  100  μM  each  peptide  for  3  hours  prior  to  reaction  with 100 nM RNA (single-site 
substrate) for 1 min at room temperature.   
For the dose-response experiments, peptides 5, 6, LNLSL or NNWNN were tested from 
0-200 μM with 100 nM MazFSa.  After 3 hours incubation, 100 nM of the single site substrate 
was added and incubated for 1 min at room temperature.  Peptides 5 and 6 were also incubated at 
100  μM  with  100  nM  RNA in the absence of MazFSa.   
For the time-course assay 200 nM MazFSa was incubated in the absence of (-) or presence 
of 100 μM peptide 5 or 6, followed by incubation with 100 nM of the 3-site RNA substrate for 0-
8 min at 37°C.   
To test the peptide 5, 6 and LNLSLAN derivatives, the peptides were incubated at 10 or 
20 μM for 3 hours with 100 nM MazFSa prior to addition of 100 nM RNA and incubation at room 
temperature for 1 min.   
To observe increased MazFSa activity in the gel-based assay, the concentration of MazFSa 
was increased to 200 nM and the peptides were tested at 10 μM.  This mixture was reacted with 
100 nM RNA for 1 min at room temperature.  
 
4.9.10 Detection of protein adsorption to tube 
Pure solutions of three His-tagged proteins, MBNL, Procaspase-3 and Thi4p (obtained 
from lab members) were tested alongside MazFSa(His)6 at  100  μM  for  adsorption  to  the  
microcentrifuge  tube.    A  25  μL  solution  was  aliquoted  to  4  tubes  and  after  5,  30,  60  or  180  min,  
the solution was transferred to another tube.  This solution  is  referred  to  as  “S”  to  denote  the  
“soluble”  fraction,  which  was  kept  soluble  by  the  addition  of  5  μL  of  Laemmeli  SDS  loading  dye.    
The  protein  adsorbed  to  the  original  tube  was  resolubilized  using  5%  SDS.    “E”  denotes  the  
“eluted”  fraction.    This  assay  was  performed  in  this  presence  and  absence  of  100  μM  peptide  5.    
The  protein  solutions  were  detected  by  α-His Western blot. 
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4.9.11 Effect of peptides on MazFSa activity in the presence of BSA or CHAPS 
The addition of 0.01% BSA or 0.1% CHAPS to 10 nM MazFSa allowed maintained the 
activity of MazFSa over  at  least  a  3  hour  period  (data  not  shown).    Following  incubation  of  10  μM  
MazFSa for  1  hour  in  the  absence  or  presence  of  100  μM  each  of  the  MazESa peptide fragments 1-
10, 100 nM single-site RNA was incubated for 45 sec at room temperature.   
 
4.9.12 Synthesis of radiolabeled RNA transcript 
Synthesis and purification of the radiolabeled RNA substrate followed the same protocol 
as  for  the  unlabeled  transcript,  except  that  3.87  µCi  of  [α-32P-UTP] was added in addition to the 
standard amounts of unlabeled NTPs.   
 
4.9.13 Gel-based RNA cleavage assay 
To assess the cleavage of the 3-site and 1-site substrates, 50 nM MazFSa(His)6 was 
incubated with 50 nM RNA in buffer (71 mM sodium phosphate, 14.5 mM citrate, 137 mM 
NaCl, 2 mM KCl, pH 6.5) at room temperature.  To stop the reaction, a 10 µL aliquot was added 
to 10 µL SDS-formamide loading dye (87% formamide, 2.75% SDS, 16 mM EDTA, 0.025% 
bromophenol blue).  Samples were heated to 95°C for at least 5 min prior to analysis on a 3.5% 
acrylamide 8 M urea 1X TBE gel electrophoresed in 1X TBE running buffer, pH 8.3 and post-
stained  in  0.05  μg/mL  ethdium  bromide. 
For the gel-based RNA cleavage time course assay, the same conditions were followed, 
except 1 nM MazFSa(His)6 and 25 nM RNA was prepared in assay buffer containing 0.01% BSA 
and the products were separated on a 3.5% acrylamide 8 M urea 1X TBE gel.   
Activity against the radiolabeled substrate was assessed following the same conditions, 
except 1, 5 or 10 nM MazFSa(His)6 was mixed with 100 nM radiolabeled RNA substrate in assay 
buffer containing 0.05% BSA.  The products were separated on 5% acrylamide denaturing gels 
which were exposed to an Imaging Screen-K (BioRad) for 10 min prior to visualization. 
 
4.9.14 Detection of MazFSa activity in S. aureus cell lysate 
A single colony of MRSA strain NRS26 grown on tryptic-soy agar was inoculated into 
10 mL tryptic-soy broth (TSB) and grown overnight at 37°C with aeration.  A fresh 22 mL 
culture was seeded with a 1:100 dilution of the overnight culture and grown to an OD600 of ~1.3 
at which point 10 mL portions were harvested by centrifugation at 4°C, flash frozen in liquid 
nitrogen and stored at -80°C.  The pellet was resuspended in 0.3 mL assay buffer and lysed by 
vortexing for 4 min with 0.15 g Lysing Matrix B silica beads (MP Biomedical).  The lysate was 
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cleared by 30 s full speed centrifugation at room temperature and mixed with RNase inhibitor.  
After 7, 15, 35, and 65 min post-lysis, the radiolabeled RNA substrate was added to 100 nM 
(final concentration) and the samples were heated at 95°C for 1 min.  After 2, 5 or 10 min 
reaction at room temperature with the RNA, 10 µL aliquots were quenched with SDS-formamide 
loading dye, electrophoresed and imaged as described above.  To inhibit endogenous MazFSa 
activity in the most active lysate, 200 nM purified (His)6MazESa was incubated with lysate 65 min 
post-lysis for 10 min prior to addition of RNA for a 10 min reaction.  For negative and positive 
controls, 100 nM radiolabeled RNA was incubated without or with 10 nM MazFSa(His)6 in assay 
buffer with 0.01% BSA at 95°C for 1 min followed by room temperature for 1 min.   
 
4.10 FIGURES 
 
         10         20         30         40         50         60         70         80                       
AAGGAGATAT ACCATGGATA TGTTATCTTT TAGTCAAAAT AGAAGTCATA GCTTAGAACA ATCTTTAAAA GAAGGATATT   
 
         90        100        110        120        130        140        150        160                
CACAAATGGC TGATTTAAAT CTCTCCCTAG CGAACGAAGC TTTTCCGATA GAGTGTGAAG CATGCGATTG CAACGAAACA   
 
        170        180        190        200        210        220        230        240               
TATTTATCTT CTAATTCAAC GAATGAATGA TTAGACGAGG AGATGTTTAT TTAGCAGATT TATCACCAGT ACAGGGATCT   
 
        250        260        270        280        290        300        310        320               
GAACAAGGGG GAGTCAGACC TGTAGTCATA ATTCAAAATG ATACTGGTAA TAAATATAGT CCTACAGTTA TTGTTGCGGC   
 
        330        340        350        360        370        380        390        400               
AATAACTGGT AGGATTAATA AAGCGAAAAT ACCGACACAT GTAGAGATTG AAAAGAAAAA GTATAAATTG GATAAAGACT   
 
        410        420        430        440        450        460        470        480               
CAGTTATATT ATTAGAACAA ATTCGTACAC TTGATAAAAA ACGATTGAAA GAAAAACTGA CGTACTTATC CGATGATAAA   
 
        490        500        510        520        530        540        550        560               
ATGAAAGAAG TAGATAATGC ACTAATGATT AGTTTAGGGC TGAATGCAGT AGCTCACCAG AAAAATCTCG AGCACCACCA   
 
        570    
CCACCACCAC TGA  
 
 
Figure 4.21  Nucelotide sequence of clone pET-28a-mazEFSa(his)6.  The mazEFSa sequence was cloned into pET-28a 
between the NcoI and XhoI restriction enzyme sites to facilitate expression of a C-terminal His6-tag on MazFSa. 
 
 
 
         10         20         30         40         50         60         70         80  
AAGGAGATAT ACCATGATCA TCATCATCAT CACAGCAGCG GCCTGGTGCC GCGCGGCAGC CATATGTTAT CTTTTAGTCA   
 
         90        100        110        120        130        140        150        160  
AAATAGAAGT CATAGCTTAG AACAATCTTT AAAAGAAGGA TATTCACAAA TGGCTGATTT AAATCTCTCC CTAGCGAACG   
 
        170        180        190        200        210        220        230        240  
AAGCTTTTCC GATAGAGTGT GAAGCATGCG ATTGCAACGA AACATATTTA TCTTCTAATT CAACGAATGA ATGACTCGAG   
 
Figure 4.22  Nucelotide sequence of clone pET-28a-(his)6mazESa.  The mazESa sequence was cloned into pET-28a 
between the NdeI and XhoI restriction enzyme sites to facilitate expression of an N-terminal His6-tag on MazESa. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE OUTLOOK FOR TARGETING TOXIN-ANTITOXIN 
SYSTEMS 
 
5.1 CONCLUSIONS 
The occurrence of drug-resistant bacterial infections continues to rise at an alarming rate 
and remains a world health crisis.  The inability to effectively treat bacterial infections results in 
increased morbidity, mortality and healthcare costs.  As discussed in Chapter 1, the majority of 
antibiotics used in the clinic exploit one of a handful of biological targets, including DNA gyrase, 
the ribosome, or macromolecules that make up the cell wall.  Many of these antibiotics are 
derivatives of existing scaffolds that were discovered during the “Golden Age” of antibiotics.  
Thus, there is a true need for drugs with novel targets and mechanisms of action in the cell.   
One intriguing novel antibacterial strategy is the exploitation of proteic toxin-antitoxin 
(TA) systems.  The activation of TA systems as an antibacterial strategy was first proposed in 
2004 [16] and has become a highly discussed topic in the field [3, 12, 19, 30, 33, 37, 48, 49].  
Success of this strategy remains elusive, likely due to the inherent challenges associated with 
targeting TA systems.  Chapter 5 provides insights into specific challenges experienced with the 
TA targeting strategy and evaluates factors to consider when planning experiments designed to 
target TA systems as an antibacterial strategy.  Table 5.1 summarizes the general points 
discussed including the advantages and disadvantages of:  (i) performing in vitro versus cell-
based high-throughput screens, (ii) targeting ribosome-independent versus ribosome-dependent 
ribonucleases and, (iii) targeting the TA complex, antitoxin, or toxin protein.   
Perhaps the most significant challenge associated with targeting TA systems is the 
incredibly tight interaction between the toxin and antitoxin proteins.  The extensive electrostatic 
interactions between the toxin and antitoxin keep the toxin inactive in the complex.  In the 
laboratory, there appears to be little to no dissociation between the antitoxin and toxin [35, 45].  
In the cell, specific proteases that degrade the antitoxin are required for full activation of the toxin 
by freeing the toxin from the inactive complex.  As discussed in Chapter 1, the antitoxin is more 
susceptible to proteolysis than the toxin [2, 5, 10, 13], and free antitoxin is degraded at a faster 
rate than toxin-bound antitoxin [6, 34, 44].   
One major disadvantage of the two high-throughput screens reported in this thesis was 
the fact that they were performed in vitro and thus did not take advantage of the proteases that 
degrade the antitoxin.  A molecule capable of disrupting the TA complex in vitro would require 
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Table 5.1  Considerations for TA system targeting.  +, advantage; - disadvantage 
screening 
assay 
in vitro 
+ 
· simple, robust assays less likely to yield false positives 
· rapid secondary assays validate hits or false positives 
· hit compound is likely to have same effect on TA proteins in cell 
- 
· protein expression and purification may be difficult 
· requires robust, high-throughput assay; enzymatic assay is ideal 
· one step away from ultimate goal of cell death 
in cell 
+ 
· pathways up- or down-stream of TA sytem are intact 
· antitoxin-specific proteolysis and turnover 
· enables assessment of TA system without protein purification 
· most direct assay to assess end goal of cell death 
- 
· many potential off target effects of compounds 
· hit compound may have no effect on TA proteins in vitro, 
  complicating MOA studies 
ribonuclease 
selection 
ribosome-
independent 
+ 
· rapid, straightforward enzymatic assays are available 
· toxin purification, refolding and activity validation are feasible 
· full disruption not necessarily required for toxin activation 
- · toxin activity may not be sufficiently toxic to kill cell 
ribosome-
dependent 
+ · toxin activity appears to be highly toxic to cell 
- 
· toxin purification, refolding, and activity validation may be 
  challenging 
· rapid, high-throughput activity assays are lacking 
· high-throughput disruption assay is two steps away from  
  ultimate goal of cell death 
· full disruption required for toxin activation 
target protein 
selection for in 
vitro assays 
TA complex 
+ 
· more faithfully mimics natural state of proteins in cell 
· complex is straightforward to express and purify 
· assessment of complex disruption or toxin activation is feasible 
· hit compound is most likely to be effective in cell 
- · incredibly tight interaction 
antitoxin 
+ 
· binding the antitoxin would likely result in toxin activation 
· generally straightforward to express and purify antitoxin 
- 
· excess of antitoxin over toxin in cell would require higher  
  compound concentration 
· inherently unfolded nature of antitoxin complicates in vitro 
  assays 
toxin 
+ 
· tertiary structure facilitates discovery of a compound that binds  
  tightly 
· enhancement of toxin enzymatic activity can be assessed 
- 
· binding to toxin may inhibit its activity 
· expression and purification may be challenging 
· high-throughput assays do not exist for every toxin 
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an incredibly high affinity to compete for binding to either protein.  However, in the cell, a 
molecule that bound to either TA protein with a low affinity could be effective by reducing the 
affinity between the toxin and antitoxin, resulting in increased degradation of the antitoxin and 
releasing the toxin.  Furthermore, the constant turnover of the antitoxin from the complex would 
provide more opportunities for the small molecule to bind to either the toxin or antitoxin.   
Although a cell-based screen for the discovery of toxin activators seems more ideal than 
an in vitro screen, two cell based screens performed by other members of the Hergenrother lab 
failed to identify any molecules that induced TA-system dependent death.  These screens 
provided more “hits” that appeared to cause TA-dependent death; however, all the compounds 
were ruled out as false positives after performing many rigorous secondary assays [30, M. 
Rodriguez, personal communication].  This highlights one advantage of working in an in vitro 
system:  the results of the assays are generally more straightforward to interpret than cell-based 
assays.  In the high throughput screens discussed in Chapters 3 and Appendix B, elimination of 
the “hit” compounds as false positives was achieved relatively early, before spending valuable 
time characterizing the effect of the compounds.  The value of straightforward, meaningful 
secondary assays cannot be underestimated in high-throughput screening endeavors. 
Certainly, performing a cell-based screen and following up with meaningful secondary 
assays in vitro seems ideal; however, only molecules that act directly on the TA system proteins 
would be validated in this experimental set-up.  Small molecules identified in a cell-based screen 
could work by many other mechanisms, including modulating the transcription of the TA 
systems, activating proteases, or activating some physiological response mechanism that naturally 
activates the TA system.  All of these pathways could potentially be equally successful in the end 
goal of activating the toxin, but would be overlooked due to the challenge of accurately 
recapitulating complex biological systems in vitro.   
Furthermore, the in vitro follow up assays require use of straightforward and potentially 
high-throughput enzymatic assays.  Such assays are available to assess the CcdB-mediated gyrase 
inhibition using the a gel-based assay with supercoiled plasmid DNA and to assess the cleavage 
of free mRNA using the fluorogenic or gel-based assays described in Chapter 4 and Appendix B.  
However, evaluation of ribosome-dependent ribonucleases such as RelE requires reconstituting 
an actively-translating ribosome.  Although these complex systems are commercially available, 
they are potentially cost-prohibitive for many laboratories. 
An additional requirement for in vitro assays is the need for pure and active toxin protein.  
This has posed a major challenge in some endeavors to study TA systems.  Difficulty was 
experienced in expression of recombinant RelE alone, even enzymatically inactive mutants, 
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perhaps due to some residual binding of RelE in the ribosomal A site.  Although the toxicity can 
be overcome by expression of the RelBE complex, and pure toxin can be obtained by denaturing 
purification, proper refolding of denatured RelE also proved difficult.  In contrast, pure MazFEc 
and MazFSa were readily obtained by denaturing purification from their respective complexes, 
and the facile in vitro assays to assess their activity confirmed their properly folded and active 
state.   
Other members of the Hergenrother lab have experienced similar difficulties with 
obtaining pure and active toxin proteins.  One clever solution to this problem employed 
expression of a non-toxic form of the toxin YoeB, made inactive by replacement of an active-site 
tyrosine residue with a non-natural photocaged tyrosine derivative [29].  Exposure of the protein 
to light released the photocage, restoring the activity to the toxin [29].  This creative solution 
could be applied to other toxins, but also requires knowledge of the active site residues and the 
proper system to introduce the appropriate photocaged amino acids.  However, this type of 
advancement is a key step in the progress towards employing a variety of TA systems whose 
toxicity could be exploited as an antibacterial target. 
The difficulty of working with certain proteins in vitro emphasizes another advantage of 
cell-based screens, which enables the probing of TA systems for which there are not robust, high-
throughput assays available.  The fluorogenic kinetic assay developed in the Hergenrother lab 
[46] and described in Chapter 4 [50] and Appendix B is suitable for toxins that exhibit 
ribonuclease activity independent of the ribosome, but no analogous high-throughput assays have 
been described for ribosome-dependent toxins, gyrase inhibitors, or toxins that target cell wall 
biosynthesis.  Thus there is a need to expand our repertoire of facile, straightforward, robust 
assays that can be applied to high-throughput screens. 
The development of the photonic crystal (PC) biosensor technology [4, 24] was certainly 
significant to the studies with RelBE, as discussed in Chapter 3.  Prior to its development, a 
method to screen a small molecule library for the disruption of a protein complex for which there 
is no enzymatic assay did not exist.  The modulation of the PC biosensor technology to a high-
throughput platform facilitated rapid assessment of 170,000 compounds for RelBE disruption as 
well as investigation of a number of peptides for their ability to bind RelB.  This technology 
allowed for expediting the process of working through experiments and applying the knowledge 
towards the next strategy. 
The PC biosensor experiments involving RelB were expected to reveal a peptide, either 
based on a RelE fragment or discovered from phage display, which could bind RelB.  Although it 
seemed clear that interactions between RelB and the RelE fragments were indeed observed, it was 
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later determined by SPR that the interactions were likely nonspecific and possibly due to 
aggregation of the peptide.  The phage recovered from biopanning also appeared to interact with 
RelB in a manner that was dependent on the specific displayed peptide, suggesting a specific 
interaction; however, the “off-phage” peptides suffered from low affinity to RelB.  The inability 
to identify any peptides with high affinity for RelB may be due to the unstructured nature of 
RelB, which makes antitoxins less suitable targets for in vitro studies.   
The MazESa peptide fragments were never tested for their affinity to MazFSa, but rather 
for their ability to modulate the activity of MazFSa.  Although some peptides appeared to enhance 
MazFSa, their effect was nonspecific.  It was surprising that none of these peptides appeared to 
inhibit the activity of MazFSa, as other short antitoxin peptide fragments have been shown to 
inhibit their cognate toxin [1, 7].  Given the structure of the MazEFEc complex (shown in Figure 
4.2), it seems likely that one of the peptides would have some effect on MazFSa activity.  
However, it remains unknown if the peptides tested would actually bind MazFSa or were simply 
tested under conditions that precluded binding.  The effect of the peptides on MazEFSa complex 
was not pursued extensively, due in part to the fact that they did not seem to interact with MazFSa 
in any measurable way.  Given the assays established for measuring MazFSa activity, this is a 
potential avenue for future studies, but would require investigation into conditions that are more 
suitable for peptide binding.   
The feasibility of working with the MazEFEc or MazEFSa TA systems underlines their 
importance in establishing a blueprint for the identification of artificial toxin activators.  The 
antitoxin and toxin proteins can be purified in their active forms.  Their activity can be 
demonstrated in a variety of assays, such as the continuous fluorometric assay, the definitive 
HPLC assay and the gel-based assay employing a more physiologically relevant transcript 
substrate.  Development and optimization of these assays have contributed to the progress 
towards identifying activators of TA system toxins, both synthetic activators for the purpose of an 
antibacterial strategy, and natural activators that are involved in the stress response.   
The gel-based radiometric assay designed for the detection of endogenous MazFSa 
activity in S. aureus lysate could allow for the assessment of compounds or conditions that 
activate MazFSa, or similar ribonucleases, in the cell [50].  To the best of our knowledge, every 
study performed on TA systems in the cell has relied on ectopically overexpressed toxin or TA 
complex.  Although this has enabled a wealth of information regarding the biological effects of 
TA systems, there is a gap in the understanding of what TA systems do in their natural context.  
Testing a variety of stressful conditions in this assay may reveal a natural mechanism for the 
activation of the endogenous TA system, and that condition can be applied to assess the effect of 
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such endogenous toxin activation.  This may help to answer a long-standing question:  are the 
levels of endogenously-expressed artificially-activated toxin great enough to cause growth 
inhibition or cell death?   
The role of TA systems as plasmid addiction systems functioning by a post-segregational 
killing mechanism indicates that, at least when plasmid-encoded, sufficient toxin is present to kill 
the cell.  The post-segregational nature of the killing suggests that half of the toxin molecules in 
any given cell are sufficient to cause cell death.  Although their active role in plasmid 
maintenance suggests that plasmid-encoded TA proteins may be expressed to higher levels, the 
relative expression levels between plasmid- and chromosomally-encoded TA systems has not 
been studied, to our knowledge.   
Thus, answering the long-standing question of toxin levels required to kill the cell may 
reveal which TA system is in fact the most suitable for an antibacterial strategy.  Although there 
are many factors to consider when deciding which TA system to target, certainly the ability to 
activate the endogenous toxin and observe a significant toxic effect due to the activation is 
paramount.  Indeed, the strategy of artificial activation of the toxin is inspired by the evident toxic 
effect of plasmid-encoded TA systems, thus it seems obvious to target plasmid-encoded TA 
systems.  However, the heterogeneity of plasmids in important pathogens and of TA systems on 
plasmids, as demonstrated by the survey of 75 VRE isolates [32], suggests that plasmid-encoded 
TA systems may not be a reliable target.  The conservation of many chromosomally-encoded TA 
systems, as demonstrated in 78 MRSA and 42 P. aeruginosa isolates [29, 47] lends support for 
targeting of these TA systems.   
Certainly, the prevalence of the target is the most important factor when considering 
which TA system to target.  Determining that mazEFSa, higBAPa and relBEPa TA systems were 
ubiquitous in their respective hosts was satisfies at least the first requirement for targeting these 
systems for antibacterial development [47].  Furthermore, discovering that the parDEPa and 
relBE-1Ab TA systems were not present in all clinical isolates tested rules these TA systems out as 
potential targets [47].   
Once ubiquity of a TA system has been established, the success of the strategy in the 
clinic is primarily dependent on the toxicity of the toxin protein.  Some toxin proteins certainly 
seem more toxic than others, as evidenced by the inability to recover a recombinant clone of a 
vector containing the toxin gene or the inability to express the toxin on its own.  In the 
Hergenrother lab, the toxins that have given the most trouble are RelE, Txe [31] and YoeB-Sa1 
[29].  In contrast, wild-type MazFSa can be ectopically overexpressed on its own [13, 18, 52].  
This highlights the potential difference in effects based on toxin activity:  RelE, Txe and YoeB-
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Sa1 are all ribosome-dependent ribonucleases, which typically recognize conserved features of 
mRNA, such as start and stop codons [20, 38], whereas MazFSa is a ribosome-independent 
ribonuclease that cleaves at a five-nucleotide sequence, UACAU [52].  Indeed, it seems that the 
effect of ectopic overexpression of MazFSa on the cell is not as detrimental as that of RelE, Txe or 
YoeB-Sa1 [8, 9, 13, 18, 20, 29, 38, 52].  The differential toxicity of the toxins must be considered 
for the widespread, reliable application of this antibacterial strategy. 
However, it has been shown that the UACAU motif is overabundant in some transcripts 
encoding virulence factors [52], thus the activation of MazFSa may better serve as an anti-
virulence strategy as opposed to an antibacterial strategy.  Many toxins have been shown to 
cleave at more specific sequences [36, 39, 42, 43, 52], thus possibly implicating their role in a 
more specific process than other ribonucleases which cleave at more sequences, such as MazFEc, 
which cleaves at ACA [51], and has been implicated in numerous cellular pathways [2, 11, 14, 
15, 21-23, 25-28, 40, 41].  Furthermore, ectopic overexpression of MazFEc was shown to cause a 
4-log reduction in colony forming units (CFU)/mL in 1 hour [2], whereas ectopic overexpression 
of MazFSa reduced the CFU/mL by only 2 orders of magnitude [17], suggesting that MazFEc is 
more toxic than MazFSa.   
Determining the mode of action of the toxins is crucial to their development and 
application as antibacterial or antivirulence targets.  Additionally, detailed understanding of the 
interactions between the toxin and antitoxin, as determined by crystal structures or peptide 
mapping, may inform the design of, or provide insight into the types of, molecules that could 
modulate the interaction.  Testing these molecules using robust, unambiguous assays that use the 
TA system complex would likely provide the most useful results.  Specifically, assays that test for 
toxin-mediated cell death, toxin activation from the complex, or disruption of the toxin-antitoxin 
interaction more directly probe the feasibility of the strategy.  Although there is no clear blueprint 
to discover toxin activators, the work presented herein highlights major considerations for the 
strategy and will hopefully serve as a guide for future endeavors. 
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APPENDIX A 
SEQUENCE ANALYSIS OF PLASMID PS177 ISOLATED FROM VANCOMYCIN-
RESISTANT ENTEROCOCCUS FAECIUM STRAIN S177 
 
Sections from Appendix A have been published in “Txe, an endoribonuclease of the enterococcal 
Axe-Txe toxin-antitoxin system, cleaves mRNA and inhibits protein synthesis,” Halvorsen EM, 
Williams JJ, Bhimani AJ, Billings EA and Hergenrother PJ. (2011) Microbiology, 157:387-397. 
 
A.1 INTRODUCTION 
Enteroccoci such as Enterococcus faecium and E. faecalis are frequently implicated in 
nosocomial infections and are responsible for a large number of surgical site infections, 
bloodstream and urinary tract infections.  Despite their intrinsic resistance to cephalosporin and 
aminoglycoside antibiotics, enterococcal infections were once considered easily treatable.  
However, acquisition of mobile genetic elements, such as plasmids, conferring resistance to 
multiple antibiotics, particularly vancomycin, has severely limited treatment options.  Of over 
7000 enteroccocal bloodstream infections tested, approximately 28% were vancomycin resistant 
[2] and another survey revealed that up to 33% of the enterococcal isolates in hospitals were 
resistant to vancomycin [10].  Of bloodstream infections caused by E. faecium, the rate of 
vancomycin resistance increased from 57% in 2000 to 81% in 2010 [5].  Furthermore, 76% of 
597 E. faecium isolates in North America were vancomycin resistant [12].  Thus, vancomycin, 
which was once considered a last resort antibiotic, is no longer a reliable treatment option.  To 
evaluate the tractability of TA systems as an antibiotic target in VRE, the prevalence of TA 
system was determined [11]. 
The genes for TA systems were found to be ubiquitous on plasmids from 75 VRE strains 
studied [11].  It was shown that 56 of the 75 VRE isolates contained the genes for axe-txe, as 
determined by PCR analysis [11].  Of those 56 axe-txe-positive isolates, gel extractions and 
conjugative matings suggested a physical linkage between the vancomycin resistance genes and 
the axe-txe genes in 44 isolates [11].  Axe-Txe was originally discovered on the 24.8 kb 
nonconjugative plasmid pRUM and was one of the first proteic TA systems identified in Gram-
positive bacteria [6].  pRUM was isolated from a multi-drug resistant E. faecium isolate and 
confers resistance to chloramphenicol, erythromycin, streptomycin and streptothricin.  
Interestingly, a 60 kb conjugative vancomycin resistance plasmid coexisted in the same E. 
faecium strain [6].   
To further investigate the PCR results suggesting a physical linkage between axe-txe and 
the vanA resistance gene [11], we determined the DNA sequence of one plasmid, pS177, which 
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was positive by PCR for both axe-txe and vanA.  Plasmid pS177 is a 39 kb non-conjugative 
plasmid isolated from the vancomycin-resistant E. faecium clinical isolate S177.  pS177 confers 
resistance to kanamycin, streptothricin, streptomycin, erythromycin, and vancomcyin and harbors 
the genes for axe-txe and a relBE homolog, relBEEf.   
 
A.2 SEQUENCE ANALYSIS OF pS177 
The nucleotide sequence of plasmid pS177 was determined by shotgun cloning and 
sequencing, with average coverageof 12.46.  pS177 is a 39,032 bp non-conjugative plasmid 
isolated from E. faecium clinical strain S177.  Its DNA G+C content is 35.5%, consistent with  
Figure A.1  Genetic organization and mosaic structure of multidrugresistant plasmid pS177.  Coding sequences are 
indicated by arrows showing the predicted direction of transcription.  Position 1 of pS177 was assigned as the same 
nucleotide position 1 of pRUM.  The origins of the pS177 components are indicated by colored arrows:  genes from 
pRUM, red; genes from p5753cA, orange; solitary insertion elements, yellow and green; vanA-type glycopeptide 
resistance gene cassette, purple; S. intermedius resistance gene cassette, blue.  GenBank accession number HQ115078.  
 
that of other enterococcal plasmids and genomes [17].  Nucleotide BLAST analysis of pS177 
revealed that 37 358 bp (95.7 %) shared significant (99–100 %) similarity with sequences  
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deposited in the GenBank database.  Forty ORFs were identified and annotated based on these 
known sequences.  For ORFs annotated in the database as hypothetical proteins, BLASTP 
searches were performed to assign a putative function for that potential protein based on amino 
acid similarity.  pS177 has a mosaic structure comprising a pRUM backbone, two resistance gene 
cassettes and five insertion elements (Figure A.1, Table A.1).  Interestingly, pS177 has 12 748 
bp (32.6 %) and 18 930 bp (48.4 %) in common with plasmids p5753cA (GenBank accession no. 
GQ900435) and p5753cB (GenBank accession no. GQ900487), respectively, both isolated from 
E. faecium.  
Plasmid pS177 shares 12 341 bp (31.6 %) of its sequence with pRUM and contains 75% 
of the total pRUM plasmid (GenBank accession no. AF50797). It harbors a pRUM-like replicon 
consisting of the putative RepA replication protein observed in various enterococcal plasmids [6, 
13].  In addition to genes encoding stability mechanisms such as plasmid replication and 
partitioning, pS177 carries the TA system axe–txe [6].  The axe–txe genes and upstream promoter 
region share 100% homology with the pRUM sequence, suggesting that this TA system is 
functional.  Plasmid pS177 harbors a gene cassette from Staphylococcus intermedius (GenBank 
accession no. AF299292), which confers resistance to streptothricin, streptomycin, kanamycin 
and erythromycin [3].  pRUM carries a nearly identical gene cassette in which the aphA-3 gene 
encoding kanamycin resistance is truncated [6].  The full-length S. intermedius resistance gene 
cassette is also carried on the enterococcal plasmids pRE25 [15] and p5753cB.   
Additionally, vancomycin resistance is encoded by the VanA-type glycopeptide 
resistance determinant Tn1546, observed on many plasmids identified in VRE, including 
plasmids pVEF3 [16], 2008), p5753cA and pIP816 (GenBank accession no. AM932524).  
However, the Tn1546 cassette on pS177 contains the insertion element IS1251 between vanS and 
vanH.  This unusual vanA cluster type has been observed previously [4, 8, 9] and is also present 
on the enterococcal plasmid p5753cA, which carries a truncated vanA-type gene cassette with 
IS1251 in the same position as observed in pS177.   
Plasmid pS177 shares 12,748 bp (32.6 %) with p5753cA, including the putative RelBE 
TA system homologue from E. faecium, which we designate relBEEf. The ORFs encoding RelBEf 
and RelEEf were identified based on their homology with p5753cA, in which their putative gene 
products were annotated as hypothetical proteins.  A BLASTP search of the amino acids encoded 
by relEEf showed up to 100% identity with a variety of E. faecium hypothetical proteins, as well  
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Table A.1  ORFs of plasmid pS177 
      Nucleotide  position  
protein 
length     
aa 
identity  
ORF*  Gene  5'  3'   (aa)  Database match (accession no.)   (%)  
1c  prgN  1  291  97  pRUM PrgN (AAO52827)  100%  
2c  orf2  603  980  126  pRUM conserved hypothetical protein (AAO52828)  100%  
3c  uvrA  946  2271  442  pRUM UvrA, confers UV resistance (AAO52829)  100%  
4  sin  2784  3335  184  pRUM Sin recombinase (AAO52830)  100%  
5c  orf5  3500  4504  335  pRUM hypothetical protein (AAO52831)  100%  
6c  txe  4963  5220  86  pRUM Txe, toxin of TA system (AAO52832)  100%  
7c  axe  5213  5482  90  pRUM Axe, antitoxin of TA system (AAO52833)  100%  
8  orf8  5824  6126  101  pRUM conserved hypothetical protein (AAO52834)  100%  
9  orf9  6169  6387  73  pRUM conserved hypothetical protein (AAO52835)  100%  
10  tnp (IS6)  6559  7245  229  pRUM IS6 transposase  (AAO52848)  100%  
11c  corA  7536  8924  463  E. faecium Mg/Ni/Co transporter CorA (ZP_05660433)  100%  
12c  int  8989  9942  318  E. faecium integrase, catalytic region (ZP_00603158)  100%  
13c  orf13  10026  10156  43  p5753cA hypothetical protein (ADA62235)  100%  
14  res  10585  11148  188  p5753cA resolvase, N-terminal domain (ADA62236)  100%  
15  tnp (IS1678)  11336  12655  440  E. faecium transposase, IS1678 (AAW32124)  99%  
16c  relEEf  13111  13398  96  
Lactobacillus antri RelE-like toxin component of TA 
system (ZP_05745775)  53%  
17c  relBEf  13388  13717  110  
E. faecalis Abr-family antitoxin component of TA system 
(ZP_06623423)  79%  
18  cadE  14022  14351  110  
p5753cA cadmium efflux system accessory protein 
(ADA62239)  100%  
19c  vanZ  14638  15123  162  Tn1546 VanZ, teicoplanin resistance protein (AAA65959)  100%  
20c  vanY  15276  16187  304  Tn1546 VanY, truncated carboxypeptidase (AAA65958)  99%  
21c  vanX  16615  17223  203  Tn1546 VanX, D-Ala-D-Ala dipeptidase (AAA65957)  99%  
22c  vanA  17229  18260  344  Tn1546 VanA, D-Ala-D-Lac ligase (AAA65956)  99%  
23c  vanH  18253  19221  323  Tn1546 VanH, Pyruvate dehydrogenase (AAA65955)  100%  
24  tnp (IS1251)  19553  20845  431  E. faecium IS1251-like transposase  (AAF73111)  100%  
25c  vanS  20943  22097  385  Tn1546 VanS, Truncated histidine kinase (AAA65954)  100%  
26c  vanR  22075  22770  232  
Tn1546 VanR, Regulator of two-component regulatory 
system (AAA65953)  100%  
27c  res  22984  23559  192  Tn1546 resolvase (AAA65952)  100%  
28  tnp (Tn1546)  23705  25856  717  Tn1546 transposase (AAA65951)  100%  
29  tnp (IS6)  26661  27347  229  pRUM IS6 transposase (AAO52854)  100%  
30c  aph-3  28195  28980  262  
S. intermedius Aph-3, aminoglycoside phosphotransferase 
(AAG42234)  100%  
31c  sat4  29082  29612  177  
S. intermedius Sat4, streptothricin acetyltransferase 
(AAG42233)  100%  
32c  aadE  29621  30529  303  
S. intermedius AadE, streptomycin adenyltransferase 
(AAG42232)  100%  
33c  MTase  30562  31296  245  E. faecium methyltransferase (ZP_00603123)  100%  
34c  dnaP  31277  32146  290  
E. faecium DNA polymerase, beta-like region 
(ZP_00603124)  100%  
35c  tnp (IS1182)  32521  33195  225  S. intermedius transposase, IS1182 (AAG42229)  99%  
36c  orf36  33652  33783  44  S. intermedius orf3 (AAG42228)  100%  
37c  ermB  33788  34525  246  
S. intermedius ErmB, erythromycin resistance methylase 
(AAG42227)  100%  
38  tnp (IS6)  34873  35559  229  pRUM IS6 transposase (AAO52854)  100%  
39c  repA  36175  37215  347  pRUM putative RepA replication protein (AAO52855)  100%  
40c  orf40  37564  37890  109  pRUM hypothetical protein (AAO52856)  100%  
41c  soj  37877  38680  268  pRUM Soj partitioning protein (AAO52857)  100%  
*ORFs predicted to be trascribed on the complementary strand are denoted with 'c'.  
  
144 
as 53% amino acid identity with the RelE protein from Lactobacillus antri.  The BLASTP search 
of the amino acids encoded by relBEf resulted in hits sharing up to 100% homology with other E 
faecium hypothetical proteins, as well as 79% amino acid identity with the E. faecalis AbrB 
family antitoxin component. 
 
A.3 CONCLUSIONS 
The complete nucleotide sequence of the 39 kb non-conjugative plasmid pS177 was 
determined annotated.  BLAST analysis revealed extensive homology to known sequences, 
including the enterococcal plasmid pRUM, the vanA-type glycopeptide resistance determinant 
Tn1546 and the S. intermedius resistance gene cassette.  Thus, pS177 appears to have arisen from 
multiple recombination events between smaller plasmids and mobile genetic elements.  Similarly, 
sequence analysis of pRUM suggested it also arose from a variety of mobile genetic elements, 
recombination events, and smaller plasmids [6].  Thus, it seems that multiple mobile genetic 
elements commonly coexist in Gram-positive bacteria, allowing for recombination events and the 
creation of new plasmids. 
This report marked the first report, to our knowledge, of a completely sequenced VRE 
plasmid that harbors a full-length vanA cassette containing the insertion element IS1251 between 
vanS and vanH.  Additionally, plasmid pS177 confers resistance to vancomycin, kanamycin, 
streptomycin, streptothricin and erythromycin and, indeed, VRE strain S177 was resistant to 
gentamicin, erythromycin and vancomycin [11].  The presence of TA systems on pS177, 
including axe–txe and relBEEf, probably enhances plasmid stability and enables the persistence of 
this multidrug-resistant plasmid in clinical isolates of VRE.  This is also the first report of a 
completely sequenced plasmid carrying both the vanA-type resistance determinant and axe–txe.  
Additionally, it was shown here for the first time to our knowledge that the axe–txe transcript is 
produced in VRE clinical isolates, indicating that the axe-txe operon is functional [7].   
The conclusive link between the pRUM-like replicon, axe–txe, the vanA-type resistance 
determinant (as demonstrated from sequencing), the widespread prevalence of axe-txe genes and 
the presence of axe–txe transcripts in VRE clinical isolates further supports the importance of 
axe–txe in the maintenance of plasmids coding for multidrug resistance, and bolsters the notion of 
targeting Axe-Txe for antimicrobial development [7, 11, 13].   
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A.4 EXPERIMENTAL PROCEDURES 
 
A.4.1 Plasmid DNA isolation 
 Plasmid DNA was isolated from E. faecium using a modified alkaline lysis midiprep 
protocol [14].  A 50 mL bacterial culture grown in BHI broth was harvested after 12-14 hrs growth 
and the pellet resuspended in 2 mL solution I (25 mM Tris, pH 8.0, 50 mM glucose, 10 mM EDTA) 
DQGȝ/O\VR]\PHPJP/LQP07Uis, pH 8.0).  The suspension was incubated at 37°C 
for 1 hr.  Next, 3 mL solution II (0.2 N NaOH, 1% SDS) was added and the tube was inverted 
gently 6 times, followed by 4.5 min incubation on ice.  Finally, 3 mL solution III (5M potassium 
acetate, 11.5% glacial acetic acid) was added and the tube inverted 8 times, followed by 5 min 
incubation on ice.  The cell debris was collected by centrifuging for 20 min at 20,000 x g at 4°C.  
To extract the nucleic acid, 7 mL supernatant was transferred to a new tube and an equal volume of 
phenol-chloroform-isoamyl alcohol (25:24:1, w/v/v) was added and the tube shaken vigorously, 
followed by centrifuging as described previously.  Nucleic acid was precipitated from 6 mL of the 
aqueous layer by adding an equal volume of isopropanol and incubating at room temperature for 2 
min, followed by centrifuging for 30 min at 27,000 x g.  The nucleic acid pellet was washed with 5 
mL 70% ethanol and centrifuged for 10 min at 27,000 x g at 4°C.  All ethanol was removed and the 
pellet wDVDOORZHGWRDLUGU\WKHQGLVVROYHGLQȝ/P07ULVS+RYHUQLJKWDW&7KH
51$ZDVGLJHVWHGE\LQFXEDWLRQZLWKȝ/51DVH$PJP/IRUPLQDW& 
 Plasmid DNA isolated from E. faecium S177 was electrophoresed in a 0.65% agarose gel, 
FRQWDLQLQJȝJP/HWKLGLXPEURPLGH7KHGRPLQDQWVXSHUFRLOHGSODVPLGEDQGZDVH[FLVHG
from the gel and the DNA recovered by electroelution, following a modified protocol [18].  
Dialysis tubing with a 12-14 kDa nominal molecular weight cutoff (Spectra/Por) was prepared by 
boiling in 25 mM EDTA, pH 8.0, for 15 min, rinsed thoroughly in dH2O, and rinsed in 1× TAE at 
4°C.  The gel slice and approximately 2 mL 1× TAE were secured in the dialysis tubing and 
electrophoresed in 1× TAE at 70 V for 2 hrs, at which point the polarity was reversed for 2 min.  
Without removing the gel slice, the solution was subjected to dialysis against 10 mM Tris, pH 8.0, 
overnight at 4°C.  The electroeluted plasmid DNA was concentrated by centrifuging at 500 x g in a 
0.5 mL 30 kDa mROHFXODUZHLJKWFXWRIIWXEH0LFURFRQXQWLOWKHYROXPHZDVUHGXFHGWRȝ/ 
 
A.4.2 Plasmid DNA sequencing 
 The shotgun cloning, sequencing and assembly of plasmid pS177 was performed by the 
University of Illinois W.M. Keck Center for Comparative and Functional Genomics.  Briefly, DNA 
was sheared with a nebulizer, end-repaired and dephosphorylated.  The DNA was electrophoresed 
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in a 0.8% low-melting-point agarose gel, from which DNA ranging from 1.5 to 5.0 kb was purified 
and cloned into the pSMART-HCKan vector (Lucigen) according to the manufacturer’s 
instructions.  Sequencing was performed on 480 subclones from both the 5’ and 3’ ends of the 
insert using ABI Big-Dye terminator chemistry (Applied Biosystems).  Custom primers were used 
in PCRs and sequencing reactions to close gaps and to ensure at least 3x coverage at each 
nucleotide (average coverage was 12.4×).  The sequence data were assembled using the Phrap 
(http://www.phrap.org) and Sequencher (GeneCodes) software programs.  BLAST [1] analysis of 
the assembled plasmid was used to determine sequence similarity and annotations were made 
accordingly.  The nucleotide sequence of plasmid pS177 was deposited to the GenBank database 
under accession number HQ115078. 
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APPENDIX B 
HIGH-THROUGHPUT SCREEN FOR ACTIVATORS OF MAZEFEC PERFORMED IN 
COLLABORATION WITH THE NIH MLPCN 
 
B.1 INTRODUCTION 
The TA system mazEF was found in 75 out of 75 clinical VRE isolates and shown to be 
functional by stabilizing an unstable plasmid in E. faecium [7].  In E. coli, mazE and mazF are 
overlapping genes located within the rel operon, downstream of relA.  Expression is controlled by 
the P2 promoter which is regulated by the stringent response molecule 3’,-5’-bispyrophosphate 
(ppGpp) [1].  The alarmone ppGpp is synthesized by the RelA protein under amino acid 
starvation conditions [6].  The MazEEc-MazFEc complex efficiently negatively autoregulate 
expression at the transcriptional level by binding to an alternating palindrome in the promoter 
sequence [6].  MazFEc exists as a dimer and binds MazEEc in a 2:1 ratio [10]; the crystal structure 
revealed an extended heterohexamer consisting of alternating homodimers, resulting in the 
formation MazF2-MazE2-MazF2 (see Figure 4.2) [3].  The mazEFEc genes encodes the labile 
antitoxin MazEEc, which is degraded by the ClpA serine protease [1] and the stable toxin MazFEc, 
which is a ribonuclease that inhibits bacterial growth by specifically cleaving at the sequence 
ACA, thereby prohibiting protein synthesis [11].  The toxic effect of MazFEc can be recovered by 
MazEEc; however, a ‘point of no return’ exists after which cells cannot recover [2, 4, 8].  Thus, 
small molecule activation MazFEc could result in bacterial cell death.   
A fluorogenic assay was developed to detect the ribonuclease activity of MazFEc [9].  
This enzymatic assay uses a chimeric DNA-RNA oligonucleotide containing a 5’ fluoroscein (6-
FAM) and a 3’ black hole quencher (BHQ), giving the sequence 5’-6-FAM-
AAGTCRrGACATCAG-BHQ-3’.  The fluorescence of the intact substrate is dampened due to 
the proximity between the quencher and fluorophore.  Incubation of the substrate with an RNase, 
such as MazFEc, releases the fluorophore from the quencher; thus, MazFEc activity can be 
measured by monitoring the fluorescence over time [9]. 
This robust, straightforward assay was applied to a high throughput screen to identify 
small molecules that activate the MazFEc toxin from the MazEFEc complex.  The MazEFEc 
complex was incubated with compound and substrate, thus allowing for any MazFEc activity to be 
detected.  Full disruption between MazEEc and MazFEc is not necessarily required for the success 
of this strategy; a molecule that perturbs MazEEc binding or induces an allosteric change in 
MazFEc may allow access of the substrate to the active site.   
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B.2  HIGH THROUGHPUT SCREEN RESULTS 
 The NIH Molecular Libraries Probes Centers Network (MLPCN) performed the high 
throughput screen of 350,000 small molecules.  The basic protocol described previously [9] was 
IROORZHGZLWKVOLJKWPRGLILFDWLRQV:KHUHDVȝ00D])Ec(His)6 was used previously as a 
positive control in the assay, it was determined that sufficient fluorescent signal could be detected 
XVLQJȝ00D])Ec(His)6.  To increase the probability that any activation of MazFEc from the 
FRPSOH[ZDVGHWHFWHGȝ0(His)6MazEFEc was employed in the high throughput screen.  
This improvement reduced the amount of protein to perform the screen 4-fold.  The original 
protocol called for 12.5 nM substrate, and as the substrate is the most expensive reagent for the 
screen, it was not altered.  To ensure that a robust signal would be obtained by active MazFEc, the 
incubation time was increased from 2.5 hour to 5 hours.   
 From the ~350,000 compounds screened DWȝ0, 1104 were scored as initial hits, 
giving a hit rate of 0.3%.  From these, 464 were confirmed in the re-test and were tested in a 
dose-response assay, which revealed 23 compounds that showed a dose-response.  We received 
20 of these compounds and the associated EC50 data, which is summarized in Figure B.1.   
Figure B.1  EC50 of 20 lead compounds on MazFEc activity from the MazEFEc complex.  Dose-response assays for the 
activation of MazFEc resulted in EC50 values ranging from 1.8-21 ȝM.  
 
B.3 INVESTIGATION OF HITS 
 The HPLC assay developed for the detection of MazFEc activity [9] was employed to 
definitively assess the effect of the compounds on MazFEc activity.  (His)6MazEFEc was incubated 
IRUKRXUVZLWKȝ0FRPSRXQGDQGWKHQRQ-fluorogenic substrate 5’-
AAGTCRrGACATCAG-3’.  A portion of this reaction was analyzed by HPLC for each of the 20 
compounds.  Figure B.2 shows HPLC traces of intact and cleaved substrate and the two overlaid 
for direct comparison.  Cleaved substrate was not observed from any of the reactions containing 
(His)6MazEFEc and compound; thus the compounds were ruled as false positives.  Some of the 
compounds had intrinsic fluorescence and others demonstrated MazFEc- and oligo-dependent 
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increases in fluorescence.  The cause of the false positive result was not determined for every 
compound, given the definitive result of no effect on MazFEc activity. 
 
Figure B.2  HPLC assay.  HPLC corresponding to intact oligo (A), cleavage products (B) and the two overlaid (C) 
demonstrate the definitive assessment of MazF activity using this assay.   
 
B.4 CONCLUSIONS 
 The failure to identify small molecule activators of the MazEFEc TA system emphasizes 
the inherent challenges associated with the TA-system targeting strategy, namely, overcoming the 
incredibly tight interaction between the two proteins.  The affinity of the MazEFEc complex has 
been estimated at below 100 nM [5].  Testing compound in approximately 30-fold excess over the 
MazEFEc complex provided conditions that would likely identify even a weak modulator of the 
MazEFEc interaction.  The facile nature of the screen enabled the examination of ~350,000 
compounds, and we were fortunate to take advantage of the collaboration with the MLPCN.  
Although the hits initially seemed promising, they were all deemed as false positives using the 
definitive HPLC assay.  Some of the hit compounds resembled fluorophores and were not 
expected to perform well in the HPLC assay.  Other compounds were shown to increase 
fluorescence in a MazFEc- and fluorophore-dependent manner but did not induce cleavage of the 
non-fluorogenic substrate.  The explanation for this phenomenon remains elusive; however, these 
compounds were ruled as false positives as well.  The definitive nature of the HPLC assay serves 
as a highly useful secondary assay to evaluate potential hit compounds. 
 
B.5 EXPERIMENTAL PROCEDURES 
 
B.5.1 Protein expression and purification  
 Expression of (His)6MazEFEc or MazEFEc(His)6 was achieved by inducing cultures of E. 
coli BL21(DE3) carrying the plasmid pKm6EF or pKmEF6 with IPTG, as previously described 
[9].  (His)6MazEFEc was purified under native conditions as previously described [9].  
5.00 6.00
AAGTCrGACATCAG
AAGTCrG
ACATCAG
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AAGTCrGACATCAG
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A B C
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MazFEc(His)6 was obtained by denaturing purification from MazEFEc(His)6.  A pellet 
corresponding to 1 L culture was thawed in a room temperature water bath for 10 minutes.  The 
pellet was resuspended in 5 mL binding buffer (10 mM Tris, pH 7.9, 500 mM NaCl, 10 mM 
imidazole) containing 8 M urea and cell lysis was achieved by 1 hour incubation at room 
temperature with inversion.  Cell debris was pelleted by centrifugation at 35,000 g at 4°C for 30 
minutes.  The clarified lysate was mixed with 1.5 mL 1:1 Ni2+-NTA resin slurry (Qiagen) and 
batch loaded for 60 min at room temperature with inversion.  The slurry was applied to a 
gravimetric flow column and the resin was washed with 20 mL binding buffer with 8 M urea to 
fully disrupt the MazEEc-MazFEc complex.  On-column refolding of MazFEc was performed with 
seven washes of 10 mL urea/binding buffer decreasing the concentration of urea by 1 M with 
each wash.  Wash steps containing more than 4 M urea were performed at room temperature; all 
subsequent wash steps were performed at 4°C.  Refolding was followed with 10 mL washes of 
binding buffer (containing no urea) and binding buffer containing 60 mM imidazole.  MazFEc was 
eluted with 5 mL binding buffer containing 250 mM imidazole.   
 
B.5.2 Fluorometric assay for MazF activity 
The fluorogenic substrate 5’-6FAM-AGTCTrACATCAG-BHQ-3’ (6-FAM, 6-
carboxyfluorescein, BHQ, black hole quencher; “r” denotes RNA base, synthesized by IDT) was 
diluted in TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0).  Wells of a 384-well sterile black 
tissue-culture plate (ThermoFisher) were filled with ȝ/ of ȝ00D])+LV6, (final 
concentration) diluted in assay buffer (10 mM Tris, pH 7.9, 500 mM NaCl) and 12.5 nM substrate 
(final concentration).  The fluorescence of the plate was measured immediately and after 5 hours 
using Criterion Analyst AD (Molecular Devices) with 485 ± 15 nm excitation and 530 ± 15 nm 
emission filters and a 505 nm cutoff dichroic mirror.  The fluorophore was excited with a 1000 W 
continuous lamp with 10 reads per well.  The Z-height was set to 1 nm.   
 
B.5.3 High throughput screen 
 The screen followed the same general conditions for the MazFEc fluorometric assay.  A 
ȝ/YROXPHRIȝ0+LV6MazEFEc ZLWKQ0IOXRURJHQLFVXEVWUDWHDQGȝ0 of each 
compound were incubated at room temperature for 5 hours.  Buffer alone and substrate alone 
were used as negative and positive controls, respectively.  The fluorescence was read 
immediately after adding all components and after 5 hours incubation.   
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B.5.4 HPLC assay 
 The HPLC assay was performed using the non-fluorogenic substrate 5’-
AAGTCRrGACATCAG-3’ (IDT).  %ULHIO\ȝ0+LV6MazEFEc ZDVLQFXEDWHGZLWKȝ0
FRPRXQGDQGȝ0VXEVWUDWHIRUKRXUVDWURRPWHPSHUDWXUH51DVH,ZDVXVHGDVDSositive 
FRQWUROIRUFOHDYDJH$ȝ/SRUWLRQRIWKHUHDFWLRQZDVDQDO\]HGE\+3/&DVGHVFULEHG
previously [9].   
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